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IAbstract
Large bone defects constitute a challenge for the clinical field, because they
cannot be repaired by the body itself, but require the implantation of suit-
able bone grafts. To overcome the drawbacks of grafts from autologous or
allogous sources, modern bone tissue engineering aims to replace lost tis-
sue by cultivating cells in vitro on porous biomaterials. The cell culture on
large porous scaffolds has shown to be difficult, requiring bioreactors, which
are used for tissue culture and the study of cell behaviour in 3D scaffolds.
Of special interest is the mechanical conditioning of the cultured tissue for
bioreactor-based bone tissue engineering, which is able to enhance the os-
teogenic potential of the synthetic grafts.
In this work two bioreactor systems were developed to allow insight into
bioactive properties of different scaffold materials and the mechanoregula-
tion of cell or tissue behaviour. An in vitro perfusion bioreactor system was
developed for the cell seeding and culture on porous biomaterial cylinders.
Several studies for the determination of applicable cell seeding parameters
were conducted, as well as experiments of cell culture under steady fluid
flow with additional mechanical stimulation by alternating fluid flow. A
bone chamber system was developed as an in vivo bioreactor. The system
produced a large bone defect in dog tibia and allowed the repeated im-
plantation of large porous scaffolds of different material compositions. The
ingrowing tissue was observed to allow conclusions about osteoconductive or
osteinductive properties of the scaffolds. Additionally a compression device
was developed to apply cyclic loading on the scaffolds in vivo to study the
effect of mechanical stimulation on tissue development.
The studies with the developed in vitro perfusion bioreactor system have
shown that it is possible to seed cells throughout large porous scaffolds, which
II
is deemed crucial for the further cell culture. The long time cell culture
showed the proliferation of mesenchymal stem cells up to two weeks. The
stimulation pattern used in the study enhanced the expression of osteocalcin,
indicating an enhanced cell activity, but the absence of RunX2 and collagen
I expression rendered the determination of differentiation inconclusive.
The developed bone chamber system proved to be functional in the sur-
gical environment during the in vivo experiments. Occurring complications
during the experiments did not allow the application of the cyclic loading of
implanted scaffolds. Delayed bone formation due to created bone defect and
remaining scaffold material did not allow final conclusions about the scaf-
fold material properties. Nevertheless the study provides input for further
development of the device and clinical protocol.
The conducted studies constitute a novelty regarding the creation of
bioreactors for the study of synthetic porous scaffolds of large dimensions in
vitro and in vivo. The developed systems form the basis for further studies
in mechanobiology of bone cells and tissue.
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Scope
Advances in biomaterial sciences in the last decades have given new possi-
bilities for tissue engineering. The successful combination of living cells with
specially designed materials can form functional living tissue, a controlable
source for implantable tissue substitutes. The demand for remedy of tissue
failure in the clinical field as well as the need for scientific research towards a
deeper understanding of tissue-material interaction, lead to the development
of bioreactors as tissue engineering tools.
Regarding the role of mechanotransduction in the formation, mainte-
nance and repair of bone, the objective of this thesis was the development
of bioreactors for the study of mechanical stimuli application in the field
of bone tissue engineering. The development included an in vitro perfusion
bioreactor and a device for compressive loading of implanted scaffolds in vivo
to give an insight into the interaction of cells and tissue to biomaterials. The
emphasis in this studies lies in the use of porous scaffolds of large dimensions,
a property which constitutes a major challenge in tissue culture.
The developed perfusion bioreactor system is used to seed and culture cells
on large porous scaffolds. The scaffold has to be characterized by technical
relevant properties, such as permeability and porosity which are crucial for
the determination of the applicability of the specific scaffold type. Cell
seeding is accomplished by perfusion of the scaffolds with cells suspended in
medium and filtration of the cells into the scaffold. A high seeding efficiency
and heterogeneous cell distribution is highly important for the further cell
culture with the aim of obtaining a structure similar to premature bone. For
cell culture, the cell-loaded scaffold is perfused with medium during long
periods. The bioreactor system is used to establish conditions favourable
for cell survival and proliferation. Different fluid flow shear stress patterns
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stimulate undifferentiated mesenchymal to differentiate into the osteoblastic
cell type. The objectives of the in vitro experiments consist in finding the
optimal parameters to achieve a high cell seeding prior to culture and the
most applicable fluid flow pattern during culture to produce bone-like tissue
in the scaffold.
A bone chamber system is developed for the application of compressive
loads on implanted scaffolds. This system is a reusable bone chamber, allow-
ing the in vivo test of different materials consecutively in the same animal.
The bone chamber is used to implant different scaffolds materials into dog
tibia with and without application of cyclic loading. The objective is to
investigate the role of material properties and mechanical stimulation for
tissue ingrowth and the development of a procedure that allows to test ma-
terials in as few as possible animals and reduce the inter-animal variability.
The technical objectives lie in the development of a repeatable implanting
system, including tools for implantation and sample extraction which is us-
able in the surgical environment. An actuator has to be developed which
features a sufficient resolution in linear displacement and force measurement
to control and monitor the compression of the samples in situ.
One of the possible approaches for scientific investigation in the field of
tissue engineering consists in the use of numerical models for simulation
of tissue development. Even if not in the scope of the presented thesis
it is important to mention that the obtained results from the conducted
experiments can be used as feedback in the development of numerical models.
This data input might serve as a further step towards the interconnection of
experiment and simulation in tissue engineering.
1Chapter 1
Introduction
When large amounts of bone are lost due to trauma, pathologies (such as
osteosarcoma) or is needed for joint fusion, a suitable bone substitute must
be provided for implantation into the defect. A common practice is the
implantation of allografts or autografts, which consist of bone tissue taken
respectively from another patient or from a harvesting site in the same pa-
tient. Every year about 450,000 bone grafts are needed by doctors in the
USA alone [1]. To relieve patients from harvesting of suitable grafts, bone
tissue engineering aims at generating grafts by combining synthetic mate-
rials and cells. The generation of in vitro cultured bone on such synthetic
materials has shown to be difficult, because bone is a complex, living tissue
with a need for the right signalling for adequate development.
1.1 Bone tissue
Bone is an essential tissue in the body, which serves as support, protection,
leverage, storage of minerals and lipids and blood cell production [2]. About
65 % of bone is mineral matrix, which consists of small crystals of largely
impure hydroxyapatite situated between collagen fibres. The mineral content
gives bone the strength to support large loads. 35 % of bone consists of
organic matrix, cells and water. The organic matrix itself contains 90 %
collagen (mostly type I with traces of types III, V and X) and 10 % other
proteins (mostly osteocalcin, osteopontin, osteonectin, bone sialoprotein) [3].
Initially bone is laid down as immature (or woven) bone. It consists of a
matrix of interwoven coarse collagen fibres and randomly distributed osteo-
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Figure 1.1: Structure of compact and cancellous bone. Modified from [2].
cytes. Woven bone can be found in the developing embryo, fracture healing
or under pathological conditions (e.g. osteosarcoma or ectopic ossification).
The immature woven bone is replaced by mature (or lamellar) bone which
is built up from layers (lamellae) of 3 to 7 µm thickness. The lamellae occur
in three major patterns: Circular rings as part of the osteons, circumferen-
tial lamellae which cover the whole bone shaft uninterrupted and interstitial
lamellae which fill gaps in the haversian system [3].
All bones consist of spongy bone on the inside, covered by compact bone
[2]. Compact (or cortical) bone constitutes 80 % of the total bone mass. Its
main units are osteons (or Haversian systems) which are cylindrical struc-
tures composed of lamellae surrounding blood vessels (see Figure 1.1). The
remaining 20 % of bone mass consists of cancellous (or spongy or trabecular)
bone, which is made of struts (or trabeculae) of lamellar structure [2].
Bones are lined on the exterior (except in joints and tendon anchorage)
with the periosteum, a membrane that isolates the bone, routes the the
circulatory and nervous supply and participates in bone growth and repair.
The interior surfaces of bones are lined with a flat layer of osteoprogenitor
cells, the endosteum. This cell layer lines marrow cavities, trabeculae and
the inner surfaces of the central channels and is active in bone growth, repair
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and remodelling [2].
Four types of cells are active in the bone formation, resorption and main-
tenance, which are bone-lining cells, osteoblasts, osteocytes and osteoclasts.
Bone-lining cells are flattened elongated cells which line the majority of
adult bone surface. They are in-active osteoblasts and play a role in bone
formation, stress/strain sensing and serve as an ion barrier. Osteoblasts are
cuboidal cells (15 to 30 µm thick) with large nucleus, endoplasmatic reticu-
lum, Golgi apparatus and collagen vesicles which produce the unmineralized
bone matrix (osteoid). They are derived from osteoprogenitor cells from pe-
riosteum, endosteum and bone marrow. When embedding themselves in the
osteoid, osteoblasts become osteocytes. In the human adult there are about
10 times more osteocyctes than osteoblasts. Osteocytes are embedded in
the lacunar-canalicular system where they connect through small channels
(canaliculi) the other osteocytes and bone-lining cells over gap junctions.
The functions of osteocytes are strain sensing, information transduction to
surface cells, bone mineral stabilization by maintenance of a ionic milieu and
microdamage detection. The resorption of bone is effectuated by osteoclasts,
which are multinucleated (1 to 50 nuclei) large cells (20 to 100 µm). Os-
teoclasts are located in cavities on the bone surface, the so called Howship’s
lacunae, where they produce an acidic environment (pH 3.5) to solubilise
mineral and organic components of the bone matrix. The osteoclasts are
derived from the mononuclear phagocygotic lineage of the hematopoeitic
marrow [3].
Bone is remodelled over time by formation and absorption of the bone
matrix. Osteoblasts and osteoclasts form the ‘basic multicellular unit’ or
BMU’s (or ‘bone remodeling units’) which remove microdamages, replace
dead and hypermineralized bone to adapt to local stress. During bone re-
generation only 19 of 20 parts of bone are replaced by the basic multicel-
lular units, creating a negative bone balance, called the ‘bone remodelling-
dependent bone loss’ [3, 4]. To achieve an adaption of bone mass to mechan-
ical requirements, bone can translate mechanical signals into bone formation
or resorption. This process is called mechanotransduction.
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1.2 Mechanotransduction
The structure of load bearing bone is guided by biological regulatory pro-
cesses, as is known since the 19th century [5, 6], where it was stated that
bone structure and density is oriented to applied loads (see Figure 1.2).
Figure 1.2: A cut through a proximal femur. The trabecular structure is oriented
in the main lines of stress. Modified from [7].
It has been shown in humans that load bearing increases bone mass in rel-
evant bones, as in weightlifters’ femur [8], tennis players’ radii [9], whereas
the absence of loading, as in astronauts [10] or during prolonged bed rest [11]
decreases the bone mass significantly. The correlation between bone mass
and loading was described by Frost in the mechanostat model (see Figure
1.3). The model shows that during the absence of loading, an increased
activity of the bone remodelling units (BMUs) causes an decrease in bone
mass. When load is applied, BMUs remodel bone with a minimal bone loss.
At a mild overload, the bone mass is increasing with the formation of mature
bone. If bone is overloaded, mainly woven bone is deposited accompanied
by microdamage, constituting a pathological situation.
Analogue to the control of the bone remodelling by loading, mechanical
stimulation is important for fracture healing. When fixating bone fractures,
it was observed that a stiff fixation can suppress the callus formation and
delay the fracture healing process considerably. When a certain mechanical
loading is permitted, especially in a low-magnitude high-frequency range,
fracture healing can be enhanced. Too much strain however causes the for-
mation of fibrous tissue, leading to an unsuccessful fracture healing [13–17].
The influence of mechanical loading on fracture healing can be explained
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Figure 1.3: Frost’s mechanostat theorem shows the dependency of bone mass on
loading conditions in load bearing bones [12].
by the influence of mechanical signals on the differentiation of mesenchymal
stem cells (MSCs), where a certain magnitude of strain is needed to generate
bone, but excessive signals lead to fibrous tissue (see Figure 1.4). The the-
oretical model of fracture healing based on mechanical stimulation of tissue
differentiation was implemented successfully into numerical models which
were able to show the applicability of the theory [18]. The differentiation of
MSCs, directed by mechanical stimulation, has been successfully conducted
in in vitro experiments, which shows the applicability of numerical models
[19–22].
The alteration in bone structure and bone mass by mechanical loading
is governed on cellular level. The path from mechanical signal to changes in
gene expression includes the signal, a correspondent sensor and a pathway
to the DNA transcription in the cell nucleus. Even though it is not clear how
this pathway works, certain details emerged by thorough studies (see Figure
1.5). It has been shown that the appropriate mechanical stimuli for bone
cells are mechanical strain as well as fluid flow shear stress [25, 26]. During
loading, bone cells are stretched due to the strain of the matrix and a fluid
6 Introduction
Figure 1.4: Tissue strain and fluid flow are influencing the mesenchymal stem cell
differentiation over time as represented by this model [18].
flow is induced through the pericellular matrix in the lacunar-canalicular
network, deforming the processes of the osteocytes [27, 28]. As second theory
on the mechanosensation of bone the microdamage model has been proposed
[29]. This theory states that the increase of bone mass in certain locations
is guided by accumulating microcracks due to a overloading of bone. In
experiment it has been shown that regions of accumulated microdamages
also showed an increased BMU activity [30, 31] and the applicability of this
theory has been implemented successfully in computational models [32, 33].
It is estimated that 30 % of bone remodelling is initiated by microdamage
[34].
The mechanical stimulus is received by a sensor and passed over the cell
membrane to the cell interior. Different cell components have been proposed
to take part in this process of mechanosensation:
• Integrins, connecting the cytoskeleton with the extracellular matrix,
transmitting extracellular signals to the interior [35, 36].
• G proteins, forming part of focal adhesion points, are activated by
conformational changes by shear stress and stretching [37, 38].
• Membrane molecules taking part in the mechanosensations (receptor
tyrosine kinasis (RTK) and mitogen-activated protein kinasis (MAPK))
[39, 40].
• Stretch-activated ion channels, whose permeability for specific ions
(e.g. Na+, K+, Ca2+) is influenced by mechanical strain [41].
• Tensegrity of the cytoskeleton, containing semi-flexible microfilaments
Bone tissue engineering 7
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Figure 1.5: The sensation and transduction pathways of mechanical loading on
cellular level. Modified from [23] and [24].
and rod-like microtubules, connects the cell membrane with the nucleus
membrane and transmits movements [42].
Recently the primary cilia, microtubule-based antenna-like structures that
emanates from the surface of cells [43], have been proposed as suitable
mechanoreceptors [44]. Even though the pathways for mechanotransduction
are not known entirely, it has been shown that mechanical strains influence
those different cell components. The sensors transduce the signal to the cell
interior via the cytoskeleton or intracellular signaling molecules (e.g. Rho,
Raf, ERK1/2, JNK, p38), which alter the gene transcription in the cell nu-
cleus either directly or via transcription factors (e.g. AP-1, Egr-1, NFκB)
[24].
1.3 Bone tissue engineering
One of the most promising approaches of bone tissue engineering consists
of the in vitro cultivation of cells on a biocompatible matrix or scaffold to
achieve an implantable tissue (see Figure 1.6) [45, 46]. The most challeng-
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Figure 1.6: Schematic of a promising bone tissue engineering approach. Mesenchy-
mal stem cells are harvested from the patient, expanded and cultured on bioma-
terials. The achieved engineered tissue is implanted into the bone defect. From
[45].
ing step of this approach lies in the culture of expanded cells on scaffolds
to obtain applicable differentiated tissue, which can sustain loads after im-
plantation in defects, accelerates healing of large bone defects and can be
integrated into the healthy tissue.
The scaffolds used for the tissue culture can either be synthetic porous
materials or decellularized extracellular matrix (ECM) of bone grafts (see
Figure 1.7). Other common methods include the stacking of cell-ECM sheets
or inclusion of cells in hydrogels.
Synthetic scaffold materials provide control over composition and struc-
ture, which cannot be obtained with decellularised bone explant. With this
approach it is possible to provide spatial alignment and chemical clues to
cells, to achieve the adequate differentiation and bone cell activity. The most
commonly used scaffold materials for bone tissue engineering are synthetic
polymers, bioceramics, composites and metal alloys. The advantage of syn-
thetic polymers lies in the control of physiochemical properties and delivery
kinetics for specific molecules. They have the disadvantage of a possible
induction of immune inflammatory response after implantation [48]. Bioce-
ramics consisting of hydroxyapatite (HA), tricalcium phosphate (TCP) or a
combination of both are widely studied and used for bone repair because of
their osteoconductive and osteointegrative properties [48]. Porous scaffolds
of bioceramics can have similar internal architectures as natural trabecular
bone, which provides a large surface for tissue development and cell attach-
ment [48]. The major benefit of porous metal alloys compared to other bone
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Figure 1.7: Different approaches of tissue engineering, using different scaffold-cell
combinations. From [47].
graft substitutes consists in its mechanical strength for weight-bearing ap-
plications with an elastic modulus closer to that of bone than any other
material [49, 50]. These unique properties combined with good biocompat-
ibility, open-pore structure and shape memory characteristics make porous
nickel-titanium a very promising candidate material for a bone graft sub-
stitute [51], even though a possible release of nickel is considered a major
drawback, leading to the development of nickel-free shape memory titanium
alloys [52]. Nevertheless the lack of biodegradability of metal alloys is highly
unfavourable, because it is intended to leave as few foreign material in the
patient’s body to minimize the risk of adverse effects. Composites are mate-
rials that consist of a material that gives the composite its structural strength
and a matrix material that binds the strong material and distributes load in
the composite. Combining generally weak polymer materials with particles
(e.g. calcium phosphate glass) can yield strong constructs, manufactured at
low temperatures and incorporating organic molecules (e.g. growth factors)
which are not neutralised by the manufacturing process [53].
The cultivation of cells on those scaffold types is challenging, because the
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Figure 1.8: The pathways a multipotent mesenchymal stem cell can follow in its
differentiation (from [55]). The stem cells differentiate depending on the external
stimulus into different types of musculoskeletal cells.
cells have to be accessed by signalling molecules, growth factors and nutrients
and metabolism products have to be removed from the cells in order to obtain
a viable environment [54]. In bone tissue engineering a special interest exists
in mesenchymal stem cells, because these multipotent cells have the ability
to differentiate in the cell types of the muskoskeletal system (see Figure 1.8).
To achieve the appropriate culture conditions, bioreactors are used, including
culture under dynamic conditions [56], in perfusion bioreactors [57] and in
bioreactors applying strains [58]. Bioreactors are not solely used to sustain
a viable environment for cells, but also to apply stimuli which can enhance
cell activity or guide cell differentiation [59, 60] or even as tissue model in
cancer research [61]. Therefore the use of bioreactors is of high importance
for bone tissue engineering, because it provides insights into tissue-material
interaction and cell response on different culture environments.
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Chapter 2
Scaffold Characterisation for
the Perfusion Bioreactor
System
2.1 Introduction
The use of perfusion bioreactors is a promising approach to the culture of
tissues on biomaterials for the purpose of tissue engineering. The success
of bone cell culture under fluid flow is highly influenced by the scaffold
properties, including porosity and permeability of the scaffold. The porosity
of a scaffold is highly important, because it determines the surface area for
cell attachment. Consequently high porosity can enhance cell proliferation
in cell culture [1]. Permeability represents the accessibility of the pores
in the scaffold. If the scaffold is highly porous, but the pores cannot be
accessed, cells cannot be seeded throughout the scaffold homogeneously and
the transport of nutrients and waste products is limited to the accessible
areas. Pore interconnection (or permeability) is of high importance for the
applied shear stress stimulus on the cells by perfusion, because it determines
the number of flow pathways through the scaffolds and hence the fluid flow
velocities occurring in those pathways (see Figure 2.1). One limitation is
that a permeability value does not give any conclusion about its effects on
individual cells. So the measured permeability mostly serves as a global
parameter. It gives a rough idea, if the material geometry is in an applicable
18 Scaffold Characterisation for the Perfusion Bioreactor System
 
Figure 2.1: A schematic representation of porous and permeable materials. Dark
grey represents the material walls, white the accessible pores and light grey the
porosity isolated from the scaffold exterior. Even though both examples ((a)+(b))
have a similar porosity, the higher permeability of (b) provides more pathways
through the sample and opens up a larger part of the porous area.
range and if the pressure build-up in the perfusion system is small enough
to run the perfusion system.
In the present study the porosity and permeability of polymer/glass com-
posite scaffolds, consisting of a poly lactic acid matrix and titanium stabilised
calcium phosphate glass particles as reinforcement, were characterized for the
use in a perfusion bioreactor. The material used was characterized for me-
chanical properties and biocompatibility by Navarro [2] and Charles-Harris
[3] previously.
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2.2 Objectives
The objectives of this Chapter were the fabrication of polymer/glass com-
posite scaffolds for perfusion culture bioreactor and the determination of the
applicability of the scaffolds for this type of bioreactor by measuring porosity
and permeability.
2.3 Materials and methods
2.3.1 Scaffold fabrication
The following characterization was conducted on porous composite scaffolds
consisting of poly lactic acid (poly(95L/5DL) lactic acid) and titanium sta-
bilised calcium phosphate glass (44.5P2O5-44.5CaO-6Na2O-5TiO2 glass mo-
lar composition, particle size < 40 µm). The porosity was obtained by
solvent casting and particle leaching method (NaCl particle size 80 µm -
210 µm). It was intended to fabricate scaffolds with dimensions of 6 mm in
diameter and 12 mm in length (see Figure 2.2). The dimensions were the
same as used in previous mechanical testing [2, 3]. By using the same fab-
rication technique and hence the same moulds and materials, it was assured
to achieve scaffolds of the same structure as in previous studies.
Figure 2.2: PLA/glass scaffolds used for the material characterization and later cell
culture.
The scaffolds were fabricated by dissolving poly lactic acid (PLA) in
trichloromethane (CHCl3 or chloroform) in 5 % weight/volume ratio over two
days. Glass and salt particles (NaCl) were added to this solution, whereas the
amount of glass was 50:50 in relation to the weight of PLA and the amount
of salt was 94 % in relation to the total weight of solid components. The used
quantities for production were 250 ml trichloromethane, 12.5 g PLA, 12.5 g
glass particles and 391.67 g salt particles. The paste was then pressed into
20 Scaffold Characterisation for the Perfusion Bioreactor System

(a) 15 times magnification showing the
whole diameter of the scaffold.

(b) 150 times magnification showing the
highly interconnected cube-like pores left
behind after NaCl extraction.

(c) 800 times magnification showing glass
particles adhered to the polymer material.
Figure 2.3: Scanning electron microscopy images of the PLA/glass composite scaf-
folds.
Teflon moulds. During two days of rest the solvent vaporized and the samples
were extracted from the moulds. The samples were washed in distilled water
for two more days to extract the salt particles from the scaffolds and they
were dried at 37 ◦C for storage and further processing. The dimensions of
the produced scaffolds were measured with a slide calliper (TESA ShopCal,
serial number 1K375806). Figure 2.3 shows scanning electron microscopy
(SEM) images of the produced scaffolds. For the SEM images, scaffolds were
frozen in liquid nitrogen and broken in two. The fragments were mounted
on a copper plate and sputtered with gold. The cube-like pores can be
clearly seen under 150 times magnification (see Figure 2.3b). In even higher
magnification the glass particles can be seen (see Figure 2.3c). The glass is
not totally embedded into the polymer, making its surface available for cell
attachment.
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2.3.2 Permeability measurement
The permeability measurement method used was based on Darcy’s law which
is stated in 2.1, where Q is the fluid flow in m3/s, k is the intrinsic perme-
ability coefficient in m2, A the cross-sectional area of the sample in m2, η
the dynamic viscosity of water in Pa·s (0.001002 Pa·s [4]), P the pressure
gradient in Pa and x is the length of the sample in m [5].
Q = k ×
A×∆P
η ×∆x
(2.1)
The pressure gradient to which the sample was subjected can be calculated
by Pascal’s law (Equation 2.2).
∆P = ρ× g × (∆h) (2.2)
By inserting in Equation 2.2 the density of water ρ (1000 kg/m3), the gravi-
tational acceleration g (9.81 m/s2) and the height of the water column given
by the height of the water basin of the permeameter h (0.255 m) the pressure
gradient of 2.5 kPa was calculated. This pressure was held constant during
the experiments by adding water to the basin while the water was running
through the sample.
The Darcy equation shows that the fluid flow through a porous sample
depends on the dimensions of the sample (length and cross-section area), the
viscosity of the used fluid and the applied pressure gradient (see Equation
2.1). Additionally the flow depends on the intrinsic factor k, the perme-
ability factor. In this experiment it was intended to measure this material-
specific factor for the PLA/glass scaffolds. The samples were wetted prior
measurement to establish a defined condition. Prewetting was conducted
by immersion of the scaffold in a 30 % vol. ethanol solution for 1 minute.
Using higher concentrations of ethanol have shown to shrink the scaffolds in
previous tests. This effect may be caused by damage of the PLA polymer
chains by the ethanol. After the immersion in ethanol, scaffolds were washed
three times in distilled water. The scaffolds were kept for at least 1 day in
distilled water before measurement.
It was assumed that swelling of the scaffolds took place by immersion
in water and might affect the permeability of the material. The scaffolds
22 Scaffold Characterisation for the Perfusion Bioreactor System
used in these experiments were grouped into four groups of different prewet-
ting periods (1, 3, 6 and 9 days). The effect of the prewetting period was
evaluated by measuring the permeability for two hours. The permeability
measurement itself was conducted with an in-house developed constant head
permeameter (see Figure 2.4) [6].
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Figure 2.4: Constant head permeameter used for the material characterization. (A)
water basin, (B) water outlet, (C) fixation, (D) sample holder, (E) disk securing
sample from slipping out.
The scaffolds were taken out of the prewetting bath and measured (diameter
and length) with a slide calliper. The scaffolds were then inserted in the
sample holder as shown in Figure 2.5 by pushing them with an insertion
bolt through a Teflon guide, which assured the perpendicular insertion into
the sample holder’s sealings.
After fixating the sample holder to the water basin, distilled water was
poured into the basin, establishing a water column of 255 mm height over
the sample. A timer was started and the water level was kept constant by
pouring water into the basin. After a certain time (first two measurements
after 1 and 3 minutes, from 5 to 120 min in 5 minutes steps) the out-flowing
water was collected for 40 seconds and weighed. The measured water weight
in combination with the fluid density and the measurement time were used
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Figure 2.5: Scaffold insertion in the permeameter’s sample holder. The scaffold is
pushed through a Teflon guide into the sample holder, using a bolt.
to calculate the fluid flow Q. Using the Darcy equation the permeability
constant k was calculated for every measured point of time.
2.3.3 Porosity measurement
Mercury immersion The porosity of the scaffolds was measured by mer-
cury immersion. Following the Archimedes principle, the buoyancy force
occuring by immersing a body in a liquid equals the weight of the displaced
liquid volume. Because the mercury does not penetrate the immersed scaf-
fold’s pores, the volume of the scaffold with its air containing compartment
is replaced and reflected in the measured buoyancy force.
The measurement was conducted by positioning a container with mercury
on a precision scale (Cobos Precision, M-150-SX, Serial No. B06291). A
mechanical apparatus was used to hold the scaffold under the mercury level.
The arm of this apparatus was put in the mercury to a defined depth and
the scale was set to zero, so the buoyancy force of the arm did not influence
the measurements. The scaffold was put on the scale and the weight was
measured (mscaffold). After this, the scaffold was immersed by use of the
mechanical apparatus in the mercury down to the beforementioned defined
depth. The weight indicated on the scale was registered (mHg).
With the weight of substituted mercury mscaffold the volume of the scaf-
fold V was calculated considering the mercury density (ρHg = 13.546 g/ml
[7]):
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Figure 2.6: Experimental setup for porosity measurement by mercury immersion.
V =
mHg
ρHg
(2.3)
Knowing the weight mscaffold and the volume of the scaffold V the apparent
density ρscaffold was calculated:
ρscaffold =
mscaffold
V
(2.4)
With the apparent density ρscaffold and the density of the material (ρPLA/glass
= 1.705 g/cm3 [2]) it is possible to calculate the porosity P of the material
[8]:
P [%] =
(
1−
ρscaffold
ρPLA/glass
)
× 100 (2.5)
For validation of the measured porosity the theoretical porosity of the scaf-
folds was calculated. This was done by calculating the volume ratio of ingre-
dients that are extracted from the sample to the total amount of ingredients
(see Equation 2.6).
P =
VNaCl + VCHCl3
VNaCl + VPLA/glass + VCHCl3
= 96.7% (2.6)
Mercury porosimeter For the measurement of scaffold pore size distri-
bution a mercury porosimeter type AutoPore IV 9500 (Micromeretics Instru-
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ment Corp.) was used. The automated porosimetry is based on the intrusion
of mercury into the porous structure. The pressure needed to press mercury
into a pore corresponds to the pore size, assuming a cylindrical dimension
of the pore. The relationship between applied pressure P and the pore di-
ameter D is defined by Equation 2.7 with the mercury surface tension γ and
the mercury contact angle Θ [9].
D =
−4× γ × cosΘ
P
(2.7)
By inserting the surface tension constants used by the AutoPore porosimeter
for surface tension γ (485 dynes/cm or 0.485 N/m) and the mercury contact
angle Θ (130◦) in Equation 2.7, the pore sizes measurable at the low and
high pressure used by the AutoPore can be determined at 0.50 psi (3.4 kPa)
with 360 µm and at 30,000 psi (206.8 MPa) with 6 nm. For the assessment
of the pore size distribution three measurements were conducted. In every
measurement three scaffolds were inserted into the sample holder to minimize
the amount of mercury used in every measurement. The mean of the three
pore size distribution curves and the total porosity was then calculated.
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2.4 Results
2.4.1 Scaffold fabrication
By measuring the dimensions of the produced scaffolds before the perme-
ability measurement it was observed that the mean length of 20 samples
was 11.4 mm ± 0.1 mm and the mean diameter was 5.7 mm ± 0.1 mm.
The results for the scaffold dimension showed that the scaffolds were 5 % in
length and 5.3 % in diameter smaller than the mould dimensions of 12 mm
length and 6 mm diameter.
2.4.2 Permeability measurement
The fluid flow Q was measured over two hours for 20 scaffolds and the per-
meability coefficient k was calculated. Preliminary test had shown that the
permeability of the soft PLA/glass scaffold dropped during two hours of con-
tinuous perfusion to a stable value. Hence the measurement of fluid flow on
the scaffold was conducted over two hours, measuring after 1, 3, 6 and 9 days
prewetting, five samples for each group (Figure 2.7). The resulting perme-








  	 
   
 
























 
Figure 2.7: Permeability measured after different prewetting periods for PLA/glass
scaffolds (n=5 per group).
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Figure 2.8: Average permeability graph measured over time for PLA/glass com-
posite scaffolds.
abilities had high standard deviations with up to 36 % for 1 day prewetting,
48 % for 3 days, 35 % for 6 days and 34 % for 9 days. All scaffolds showed a
drop of permeability over the two hours of measurement. The graphs for dif-
ferent prewetting times depicted similar trends and amplitudes, suggesting
that the prewetting time had no effect on the permeability. By conducting
an ANOVA analysis to compare each group at every recorded time point,
no statistically significant differences were observed (p < 0.05) between the
four prewetting groups.
After validation of the independence of the prewetting period on the
permeability, the mean of all 20 scaffolds measured over time was calculated
(see Figure 2.8). It was observed that the mean values dropped from 1.7 ×
10−10 m2 ± 3.6 × 10−11 m2 more than 50 % over 2 hours showing a standard
deviation of about 30 %. After the permeability decrease the coefficient was
determined at the nearly stable state with 8.1 × 10−11 m2 ± 2.4 × 10−11 m2.
In the perfusion bioreactor system, which was developed as part of this
thesis, fluid flow velocities v in ranges of 1 mm/s to 10 mm/s [8] were used.
The found permeability coefficient signifies for this fluid flow velocities a
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pressure build-up calculated by the converted Darcy equation (Equation
2.8).
∆P =
Q× ηH2O ×∆x
k ×A
=
v ×∆x× ηH2O
k
(2.8)
By inserting values for scaffold length x (12 mm), dynamic viscosity of water
ηH2O (0.001002 Pa·s) and permeability coefficient k (8.1 × 10
−11 m2) into
Equation 2.8, pressure gradients over the scaffold were calculated as 150 Pa
for 1 mm/s and 1.5 kPa for 10 mm/s.
2.4.3 Porosity measurement
Mercury immersion Scaffold porosity was measured for 5 samples by
mercury immersion. For the calculation of porosity based on Equation 2.5
the constants for PLA/glass density ρsample (1.705 g/cm
3 [2] and mercury
density ρHg (13.546 g/cm
3 [7]) were taken from the literature. The measured
values for sample weight msample and displaced mercury weight mHg as well
as the calculated volume VHg and porosity P are listed in Table 2.1. The
calculated porosity resulted in a mean porosity of 95.7 % with a standard
deviation of 0.3 % for the five samples.
msample [g] mHg [g] VHg [cm
3] ρapparent [g/cm
3] P [%]
0.014 2.364 0.17 0.080 95.3
0.013 2.443 0.18 0.072 95.8
0.017 3.091 0.23 0.075 95.6
0.020 3.980 0.29 0.068 96.0
0.021 4.101 0.30 0.069 95.9
Table 2.1: Porosity of PLA/glass samples assessed by mercury immersion.
Mercury porosimeter The total porosity of the PLA/glass was deter-
mined with 95.4 % ± 0.2 % which differs only 0.3 % from the porosity
measurement method used beforehand. The pore size distribution presented
in Figure 2.9 shows a peak, where 90.7 µm ± 0.1 µm pore diameters occupy
25.5 % ± 1.1 % of the total pore space (see Figure 2.9).
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Figure 2.9: Pore size distribution of the PLA/ glass composite samples measured
by the Autopore IV porosimeter (n=3).
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2.5 Discussion
The measurement of the produced PLA/glass composite dimensions sug-
gested that the scaffolds shrank after salt extraction 5 % in length and 5.3 %
in diameter compared to the mould dimensions of 12 mm length and 6 mm
diameter. This does not influence the permeability measurements theoreti-
cally, because the dimensions are considered in the used equation. However
for the further use in a perfusion bioreactor it is recommended to make new
moulds for scaffold production, which account for the shrink factor of 5 %
(12.6 mm length and 6.3 mm diameter) to assure the scaffolds fit into the
perfusion chambers of the bioreactor system.
By conducting the described measurements it was possible to obtain the
porosity and permeability of the manufactured PLA/glass composite scaf-
folds. The presented values for permeability were obtained by measurement
with a constant head permeameter. A time-dependency of the measurement
was observed, an appropriate pre-treatment (wetting of the samples) was
established and evaluated. The time-dependent drop in permeability is as-
sumed to be based on the influence of internal fluid flow and pressure on the
thin-walled soft composite material. The large standard deviations between
different samples (about 30 %) are attributed to the measurement method
and material heterogeneity. The long measurement time required to keep
the water steady manually over two hours, which introduces sources of er-
ror. The used constant head permeameter has the advantage of subjecting
the sample to constant conditions (i.e. constant pressure gradient), which
minimizes changes in the sample during the measurement and facilitates the
data acquisition. The disadvantage of this system is the possible deformation
of the sample caused by the insertion method. Furthermore it is impossible
to know the state of the sample inside the sample holder, because the sample
is not visible during the experiment. Due to the scaffold extraction method
after the experiment, it is not possible to distinguish deformations of the
scaffold caused by insertion, water pressure or sample extraction.
The measured porosity of 95.7 % was 1 % smaller than the theoretical
value of 96.7 % as calculated in Equation 2.6. The small standard deviation
of 0.3 % shows the high reproducibility of the measurement which points to
a consistent scaffold quality. The pore distribution assessed by mercury in-
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trusion porosimetry showed that the pore diameters are distributed around
about 100 µmwhich is similar to the salt particle size of 80 µm to 210 µm. An
ideal pore size for materials used in tissue engineering is stated as 100 µm
to 400 µm [10, 11] to allow enhanced bone ingrowth. Regarding this re-
quirement the produced scaffolds are applicable for the use in bone tissue
engineering.
Comparable studies showed permeability for polymer scaffolds (Polyvinyl
alcohol, 150 µm pore size, porosity 60 %), lying in the same magnitude as
the scaffolds measured here (2 × 10−10 m2) [12]. Better permeability may
be achieved by other scaffold production methods. Barry et al. [13] for
example achieved methacrylate scaffolds with a permeability of 2 × 10−8
m2 with about 90 % porosity by venting from polymer discs saturated with
CO2. Avoiding the random distribution of pores, Lee et al. [14] used rapid
prototyping methods to make Poly(Propylene Fumarate) scaffolds. The re-
sult were scaffolds with 100 % open pores (size 300 µm) which reached even
with a small porosity of 19 % a permeability of 2 × 10−11 m2.
Even though it is not intended to culture a mature trabecular bone on
the scaffolds, it is interesting to compare the scaffold characteristics with
bone, to have an understanding of the structural similarity of both materials.
The measured permeability coefficient of the porous PLA/glass composite
corresponded to physiological values of trabecular bone in the magnitude of
10−8 to 10−14 m2 [15–17]. The measured porosity was at the maximum of
the physiological range found in trabecular bone with 30 % - 90 % [18].
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2.6 Conclusions
• The produced cylindrical PLA/glass composite scaffolds resulted in
dimensions 5% smaller than intended. This does not play a crucial role
for the presented measurements, but it is recommended to use moulds,
which take in account the shrink factor of 5% (12.6 mm length and
6.3 mm diameter) to produce scaffolds applicable for the bioreactor
system.
• The high standard deviation observed for the permeability coefficient
of the PLA/glass material may result from systemic error of the mea-
surement method or heterogeneity of the scaffolds. It is suggested that
the permeability measurement is much more sensitive to pore structure
than the porosity measurement. Because the permeability measure-
ment gives only a clue for the technical applicability of the material
for the perfusion system, the high deviation of the permeability is re-
garded as tolerable.
• The porosity measurements conducted in this study showed high repro-
ducibility and reasonable results compared to the theoretical porosity.
Hence the used method of mercury immersion is deemed as appropri-
ate for the characterization of the material. The porosity distribution
assessed by mercury porosimetry showed that the scaffolds had pores
big enough for intrusion by cells, which makes them applicable for bone
tissue engineering.
• The similar porosity of PLA/glass composite and similar porous scaf-
fold materials does not correlate with their differences in permeability,
showing that porosity and pore interconnection depend on material
and manufacturing method. It is recommended to include permeabil-
ity as an essential property in scaffold characterization.
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Chapter 3
Development of a Perfusion
Bioreactor System
3.1 Introduction
The goal of bone tissue engineering is the combination of cells and bioma-
terials to achieve in vitro cultured tissue substitutes used to bridge critical
tissue defects in patients. One of the main approaches consists in the culture
of cells on porous scaffolds, where the cells provide the active biological func-
tion for the integration, while the material provides support for the cells. It
has been shown that cell culture on scaffolds can be enhanced by the use of
bioreactor systems [1–3]. Bioreactor systems have to provide an uniform cell
seeding in 3D scaffolds, a control of nutrients and gases in culture medium,
an efficient mass transfer to the growing tissue and allow the application
of physiological stimuli to developing tissues [2]. One particular bioreactor
design which gained high interest in bone tissue engineering is the one of
perfusion bioreactor systems. By pushing fluid through porous scaffolds,
cells can be seeded on scaffolds and nutrients transported to the cells. It
has been shown that static culture leaves large porous scaffolds with regions
of insufficient nutrient concentration to sustain cell viability [3]. Perfusion
culture overcomes this shortcoming by enhancing cell viability and hence
improving the generated tissue structure [4, 5].
Different research groups have developed and used perfusion bioreactor
systems for tissue engineering research [4, 6–12, 12–15]. In general the de-
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(a) Perfusion chamber design realised by
Jaasma et al. [11].
(b) Perfusion chamber design used for lon-
gitudinal perfusion by Bancroft et al. [17].
Figure 3.1: Perfusion chamber designs for perfusion bioreactor systems.
signs of the systems are quite similar, only distinguished by the different
sample holder dimensions, the type of propulsion of the fluid through the
scaffold and the level of complexity of the system. Perfusion bioreactor sys-
tems are used for different materials ranging from polymers [6] over calcium
phosphate ceramics [7] to titanium meshes [8, 9]. Usually the scaffolds used
are flat discs, with diameters larger than their heights [10–13], rather than
diameters smaller than their heights [14]. The distance of perfusion through
those scaffolds was usually in the range of a few millimetres (e.g. 6 mm as
in [12]). Different propulsion systems were used for perfusion bioreactors.
By moving a membrane to push fluid through scaffolds, small volumes of
medium could be moved for the cell seeding and stimulation during cell cul-
ture [15], whereas peristaltic pumps were used to transport large amounts
of fluids with the advantage of an easier control of fluid flow velocity [4, 16].
Some of the used perfusion bioreactor designs were modular systems,
in which one perfusion chamber contains an individual scaffold (see Figure
3.1) [11, 12]. Other designs use blocks of sample holders for simultaneous
perfusion of several scaffolds [6, 13]. Either way every scaffold is connected
to its own channel of the perfusion system to allow control over the perfu-
sion of the individual scaffolds. The modular perfusion chambers have the
disadvantage of the large amount of system parts needed for larger sam-
ple numbers. But the individual design allows the replacement of damaged
components and facilitates the reconfiguration of the system for different
perfusion arrangements.
Furthermore the perfusion bioreactor systems used in research span a
wide range of complexity. One of the more simple systems used was the
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perfusion bioreactor developed by Olivier et al. [14], where a large scaffold
was attached on a nozzle and immersed in cell suspension or medium. The
medium was then pushed or pulled through the nozzle and hence through
the scaffold. This design is very convenient, because it unified sample holder
and medium reservoir, reducing the components of the system. More com-
plex systems were developed for example by Wendt et al. [4] containing
different tubing systems for cell seeding and cell culture and incorporating
an oxygen sensor (see Fig. 3.2). Another sample for more complex systems
was the modular perfusion bioreactor developed by Orr and Burg which not
only served for perfusion cell culture, but also incorporated a mechanism
for hydrostatic compression of the sample. Simple systems have the advan-
Figure 3.2: Complex perfusion bioreactor system developed by Wendt et al. [4] with
configuration for cell seeding (a) and cell culture (b). The scaffolds were placed in
perfusion chambers (c).
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tage of consisting of as few as necessary components, keeping assembly and
installation straightforward. The disadvantage consists in the limitation of
control parameters, whereas more advanced systems have the possibilities
of controlling perfusion parameters as well as culture parameters. With-
out any doubt increasing complexity brings in more factors for errors and
contamination, which should be decreased as much as possible.
Based on those designs it was intended to develop a perfusion bioreactor
system for cell seeding and cell culture by longitudinal perfusion of porous
scaffolds. The system had to be applicable for large scaffold sizes, which up
to day constitute a difficulty in bone tissue engineering. It should incorporate
a direct fluid propulsion system to ensure perfusion of large medium volumes
over long terms in cell culture. To allow the assembly in different experiment
setups it had a modular structure and the system was held simple to reduce
risks of contamination during assembly and mounting.
3.2 Objectives
The objective of the work presented in this chapter consisted in the develop-
ment of a perfusion bioreactor system. The requirements for the development
were:
• The perfusion bioreactor system should be adequate for cell seeding
and cell culture over long periods with programmable perfusion fluid
flow velocity profiles.
• Ideally the system incorporated mechanisms for cell seeding and cell
culture in one assembly, to avoid the contamination risk of transferring
seeded scaffolds to a culture system.
• A main component of the perfusion system was the perfusion chamber
which held the scaffolds for perfusion. The perfusion chamber had to
be applicable for scaffold dimensions of 6 mm diameter and 12 mm
length and different material types, ranging from soft porous polymers
to brittle glass ceramics.
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3.3 Materials and methods
3.3.1 Scaffold material
The validation experiments for the perfusion bioreactor system were con-
ducted with porous PLA/glass composite scaffolds fabricated as presented
in Chapter 2.3.1. Scaffolds were fabricated by solvent casting particle leach-
ing technique in polytetrafluoroethylene (PTFE) moulds. For this PTFE
moulds with dimensions of 6.3 mm diameter and 13 mm depth were used to
compensate the shrinking of the scaffold material previously observed in the
scaffold characterisation (see Chapter 2). To confirm the sample dimensions,
six fabricated scaffolds were measured with a calliper (TESA ShopCal, serial
number 1K375806).
3.3.2 The perfusion bioreactor system
3.3.2.1 Perfusion bioreactor system assembly
System for cell seeding experiments The perfusion system for the
cell seeding experiments presented in Chapter 4 consisted of system tubing
and perfusion chambers, a peristaltic pump and a laptop computer (Acer
Travelmate 372TCi) running custom software to control the pump. The
pump dedicated for this perfusion bioreactor system was a commercially
available pump peristaltic with 8 channels (type IPC, Ismatec, Art. No.
ISM 931). The pump could support pressures of up to 1 bar (105 Pa) and its
rotational speed could be adjusted in steps of 0.1 %. In this assembly, pump
tubing of 2.79 mm inner diameter was used, which allowed fluid flow ranging
from 0.35 ml/min to 35 ml/min. The pump had a RS-232 connection which
allowed the control of the pump movements by commands sent from the
connected laptop computer. The accuracy of the pump was stated by the
manufacturer as < ±1 % per channel, where the accuracy between channels
was stated with ±5 %. The overall accuracy depended on different factors
(e.g. type of the tube material, tube life time, temperatures and viscosity),
so the deviation could amount up to 10 %. The main reason for inaccuracy
is the tubing rather than the pump itself.
A USB-to-serial adapter (Prolific 2303) was used to connect the laptop
to the peristaltic pump. For this, a RS-232 cross-linked cable was used as
40 Development of a Perfusion Bioreactor System
an extension cable and modified to match the necessary connections for the
peristaltic pump (see Table 3.1). For use of the connector with the laptop the
USB-to-serial adapter was installed as COM port 2 using the driver version
2.0.2.8 provided by the adapter manufacturer.
Sub-D 9 (female) Sub-D 9 (male) Signal Function
2 2 Tx Transmit Data
3 3 Rx Receive Data
5 5 GND Electric ground
Table 3.1: Pin assignment on both Sub-D connectors for connection of pump to
computer.
The tubing used for the perfusion system was chosen considering the ap-
plication for cell culture and for pneumatically driving the cell suspension
level for cell seeding. The tubing connected to the perfusion chambers was
Tygon LFL (i.D. 6.4 mm, o.D. 9.6 mm) for the cell seeding experiments. Ty-
gon LFL features a broad chemical resistance and non-ageing characteristics
[18]. Tubing for the connection to the pump was stiff fluorinated ethylene
propylene (FEP) tube (i.D. 3.2 mm, o.D. 4.8 mm) to prevent the buffer-
ing of the driving pneumatic force by the elasticity of the tube. FEP is
characterized by its chemical inertness, toughness, flexibility, low coefficient
of friction and non-stick characteristics [19]. All tubing materials were au-
toclavable or sterilisable by gamma-ray. The tubing was connected with
polypropylene Luer-Lok connectors [20] which guaranteed the connectabil-
ity to other commercially available standard components, like polycarbonate
three way stopcocks, syringes and syringe filters.
The pump and the computer were located outside of the incubator (Ther-
mo Forma Scientific Series II CO2 Water Jacketed Incubator 3110) used to
keep the perfusion chambers under continuous conditions, because they could
not withstand the atmosphere in the incubator. Off-the-shelf pump tubing
(Tygon LFL, 400 mm, i.D. 2.79 mm, o.D. 4.72 mm) was inserted into the
pump cassette and connected via a three way stopcock to stiff FEP tubing
(i.D. 3.2 mm, o.D. 4.8 mm, length 150 cm). The free connection on the valve
was connected to syringe filters (0.22 µm, PES membrane), which allowed
the escape of air during the injection of cell suspension into the system at
the beginning of cell seeding. The stiff tubes were guided through a plastic
disc with 5 mm diameter holes which was fixated with a threaded outlet
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(i.D. 20 mm, o.D. 26 mm, length 85 mm). This outlet combined with the
plastic disc ensured the sealing of the incubator interior, preventing leakage
of the atmosphere to the outside. The stiff tubes were then connected inside
the incubator to bigger diameter tubing (i.D. 6.4mm, o.D. 9.6 mm, length
15.5 cm, Tygon LFL), representing the tubing above the perfusion chambers.
The perfusion chambers were connected to these tubes and held vertically
in a custom-made rack. Between each other the perfusion chambers were
connected with two pieces of tubing (length 8 cm each) and a three way
stopcock representing the tubing under the perfusion chambers. All tubing
was connected by attached Luer-Lok connectors (male or female) tightened
with zip ties. Figure 3.3 and Figure 3.4 show the assembly of the seeding
perfusion system.
The intended use of the cell seeding system began with the connection of
the components with the scaffolds situated in the perfusion chambers. The
valves on the top of the system (near the peristaltic pump) were opened to
permit air to exit from the system. Then the cells were injected suspended
in 10 ml of medium. This set the fluid on the start level on both sides of the
system. All valves were closed and the alternating perfusion was conducted
by initiating the control software. After the cell seeding, the top valves were
opened again and the remaining medium was extracted (see Figure 3.5).
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Figure 3.3: Graphic representation of the component assembly for the cell seeding
experiments.
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(a) Perfusion chambers mounted vertically in
the incubator.
(b) FEP tubing exiting the
incubator on the inside.
(c) FEP tubing exiting the
incubator on the outside.
(d) Laptop and peristaltic pump situated on
top of the incubator.
Figure 3.4: Setup of the perfusion system in the cell culture facilities.
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(c) Fluid levels in tubing oscillates be-
tween minimum and maximum level.
(d) After cell seeding the suspension is ex-
tracted through bottom valve. Air can
enter through the top valves.
Figure 3.5: Use of the perfusion bioreactor system for cell seeding.
Materials and methods 45
System for cell culture experiments For the cell culture experiments
(as described in Chapter 5) the seeding and culture were conducted in the
same perfusion system. Compared to the system used in the seeding experi-
ments presented before, some system components were changed. Two three
way stopcocks were added above the perfusion chambers and the valve be-
tween the chambers eliminated (see Figure 3.6). The assembly of the system
used in the cell seeding experiments was changed to allow the incorporation
of a medium reservoir and the elimination of tubing to minimize the medium
volume needed to fill the system. The tubing material was exchanged for
silicone peroxide (Masterflex L/S 17, Cole-Parmer), because of the better
properties regarding its use in cell culture and maintenance. Silicone per-
oxide is transparent, non-toxic, has broad resistance against chemicals and
high temperatures [21]. Pump and controlling computer were left untouched
from those changes.
As described in the system for cell seeding experiments a pump and
computer were located outside of the incubator. The pump tube (Tygon
LFL, 400 mm, i.D. 2.79 mm, o.D. 4.72 mm) was connected on both ends
with three way stopcocks which connected to syringe filters on one end and to
FEP tubing (i.D. 3.2 mm, o.D. 4.8 mm, length 150 cm) at the other end. The
FEP tubing was led into the incubator through the door and clamped into
place by the elastic door sealing. The FEP tubing was connected to silicone
peroxide tubing (15.5 cm, i.D. 6.4 mm, o.D. 9.6 mm). Those large diameter
tubes were connected over three way stopcocks to the perfusion chambers,
which were joined by silicone peroxide tubing (10 cm, i.D. 6.4 mm, o.D.
9.6 mm) on the bottom (see Figure 3.6).
After the cell seeding the system was converted for the cell culture (see
Figure 3.7). A 250 ml bottle (opening diameter 30 mm) was used as a
reservoir. Three FEP tubes (i.D. 3.2 mm, o.D. 4.8 mm) were inserted into
the reservoir through a rubber stopper which was used to close the reservoir.
One tube connected the reservoir interior with the exterior to allow gas
exchange through a filter. The two other tubes reached into the medium for
the fluid transport through the system. Both tubes were connected to three
way stopcocks, one connecting directly to the FEP tubing leading to the
outside of the incubator, the other connected over a silicone peroxide tube
(40 cm length, i.D. 2.79 mm) to the three way stopcock over one chamber.
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The second FEP tube coming from the pump was connected to the other
three way stopcock ion top of the second perfusion chamber, closing the
circulatory system. The assembly for cell seeding and culture in an incubator
is depicted in Figure 3.8.
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Figure 3.6: Schematic of the tubing connection for the cell culture experiments in
the seeding phase.
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Figure 3.7: Schematic of the tubing connection for the cell culture experiments in
the culture phase.
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(a) Cell seeding phase includ-
ing tubing for cell suspension
level oscillation.
(b) Cell culture phase including the medium
reservoir.
Figure 3.8: Mounting of tubing for the cell culture experiments in an incubator.
To use the system, the empty tubing was connected with the perfusion
chambers which contained the scaffolds. For cell seeding the cell suspension
was injected into the system through one of the three way stopcocks located
on top of the perfusion chambers. Air was permitted to escape during the
suspension injection through the filters situated near the pump. When the
suspension was filled in and the suspension had the same level on both sides
of the system, the pump was used to oscillate the levels, pushing the suspen-
sion through the scaffolds repeatedly. After cell seeding, the cell suspension
was extracted through the valve above the perfusion chambers. To prevent
a vacuum formation, the air inlets near the pump were opened to let air
into the system. For cell culture, the two large diameter tubes above the
perfusion chambers were taken off and the medium reservoir was connected
to the system. By running the pump in either direction at low fluid flow
rate the system was filled with medium. The pump was the used to apply
the programmed perfusion pattern over a long period. After cell culture, the
system was drained by letting air through the filter connected at the reser-
voir. See Figures 3.9 and 3.10 for a schematic of the perfusion bioreactor
system use.
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(a) The empty system before cell seeding.
Perfusion chambers contain scaffolds.
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(b) Cell suspension is inserted in side
valve. Air escapes through filter on top
valves.
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(c) Fluid levels in tubing oscillates be-
tween minimum and maximum level.
(d) After cell seeding the suspension is ex-
tracted through side valve. Air can enter
through the top valves.
Figure 3.9: Use of the perfusion bioreactor system for cell culture (1 of 2).
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(a) Tubing pump is connected directly to
the chambers and the medium reservoir.
The entire tubing is perfused constantly
with medium during culture.
(b) At the end of culture the tubing are
emptied by letting air into the system at
the reservoir.
Figure 3.10: Use of the perfusion bioreactor system for cell culture (2 of 2).
3.3.2.2 The perfusion chamber
The perfusion chamber for the bioreactor system was designed using CA-
TIA Version 5 (Dassault Systemes) as 3D computer assisted design (CAD)
program and fabricated in the workshop of the School of Industrial Engineer-
ing of Barcelona (ETSEIB). The design process for the perfusion chamber
started from scratch, no previous model had been taken as a basis for the
design. The presented design was the final product after three development
iterations as presented in Figure 3.11. The idea for the first version was to
inject the scaffold material directly into the polytetrafluoroethylene (PTFE)
sample holder before polymerization to guarantee the sealing of the scaffold
against the sample holder wall and prevent a compression of the scaffold.
This had to be discarded, because the material adhered to the walls dur-
ing fabrication and the scaffolds could not be extracted without destroying
them in the process. Additionally the first version featured a bonding of
the tubing to the chamber by silicone adhesive, which proofed not to be a
good measure to attach the tubing (see Figures 3.11a and 3.11b). The sec-
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(a) Version 1 assembled. (b) Version 1 parts.
(c) Version 2 assembled. (d) Version 2 parts.
(e) Version 3 assembled. (f) Version 3 parts.
Figure 3.11: The three development stages of the perfusion chamber.
ond version of the perfusion chamber added the half-shell sample holder and
tube connections (see Figures 3.11c and 3.11d). This version was identical in
the inner dimensions to the final version, only the exterior dimensions were
changed to make assembly easier.
The final version of the perfusion chamber was designed to hold scaffolds
of 6 mm diameter and 12 mm length and allow a longitudinal perfusion of
the scaffolds. PTFE was chosen for the half-shells of the sample holder to
prevent the adhesion of the tissue developing in the scaffold to the chamber
walls and to facilitate the scaffold extraction after the experiments. Stain-
less steel (ASTM A176 [22]) was selected as material for sample holder shell
and housing, because of its long service life, which allows a prolonged use,
especially of the threading. Furthermore stainless steel withstands the high
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temperatures of the autoclaving process. In this design, a scaffold was situ-
ated between two PTFE half-shells which were then pushed into a stainless
steel shell. The PTFE half-shells and the stainless steel shell constituted the
sample holder. The sample holder was sealed against two lids with nitrile
sealings (O-ring, i.D. 10.1 mm, o.D. 13.3 mm). Those sealings ensured that
the fluid perfused the scaffold and did not escape along the outside of the
sample holder. To prevent fluid from leaking out of the chamber, a nitrile
sealing (O-ring, i.D. 14.1 mm, o.D. 17.3 mm) was placed between the two
lids, sealing of the space containing the holder. The sealings had a diam-
eter of 1.6 mm and lay in 1 mm deep grooves. The design was made to
compress the sealings about 0.6 mm for sealing of the chamber. The two
lids positioned over the holder were equipped with hose connectors which
connected to elastic tubing with an inner diameter of 6.4 mm. One of the
lids was threaded (Lid A), while the other had a smooth cylindrical exterior
(Lid B). This allowed a nut to be slid over lid B and threaded onto lid A.
This design prevented torsion of the O-rings when assembling the chamber,
because the two lids were not forced to turn in respect to each other around
the longitudinal axis. In Figure 3.12 a cross-sectional view of the chamber
design is presented. A full set of the technical drawings of the perfusion
chamber is provided in Appendix A.
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Figure 3.12: Cross-section of the perfusion chamber design.
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Perfusion chambers were assembled as depicted in Figure 3.13. One
scaffold was placed between the PTFE half-shells and the half-shells were
inserted into the stainless steel shell (see Figures 3.13a and 3.13b). One
O-ring was inserted in the groove at the bottom of lid A (see Figure 3.13c)
and the sample holder was inserted into lid A (see Figure 3.13d). Another
O-ring was slipped over the sample holder (see Figure 3.13e). The last O-
ring was inserted into lid B (see Figure 3.13f) and the lid was slid over the
sample holder (see Figure 3.13g). The fixation nut was then put over lid B
and tightened with lid A (see Figure 3.13h).
(a) Sample holder parts and
scaffold.
(b) Scaffold in-
serted in sample
holder.
(c) O-ring placed in
Lid A.
(d) Sample holder in-
serted in Lid A.
(e) O-ring slid over the
sample holder.
(f) O-ring placed in
Lid B.
(g) Lid B mounted on sample
holder.
(h) Fixation nut threaded
on Lid A.
Figure 3.13: Assembly of the final perfusion chamber design.
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3.3.3 Software development
The software for the perfusion bioreactor system was written in BASIC and
developed using iterative validation by testing small functional routines be-
fore incorporation into the main program. The software was written and
compiled in Microsoft Visual Basic (Version 1.00) to obtain an executable
file which was copied to the laptop used in the experiments. The syntax
used to control the pump was provided by the manufacturer of the peri-
staltic pump. Table 3.2 lists the ASCII commands used in the developed
software.
Command Function
1J Set pump clockwise
1K Set pump counter-clockwise
1H Start pump
1I Stop pump
1S00999 Set pump to 99.9 % of max. Flow
Table 3.2: ASCII commands used to control the peristaltic pump and their corre-
sponding functions.
3.3.3.1 Cell seeding software
The cell seeding software was developed to control the peristaltic pump to
generate an oscillating movement of cell suspension through the scaffolds.
During the preparation of the system for the cell seeding, cell suspension
was injected at the bottom of the system. During each oscillation cycle,
the entire volume of the bottom part of the system (4.5 ml) was to be
moved through the scaffolds in both directions. It was defined that half
of the bottom volume had to be moved in every half cycle through the
scaffold to minimize the length of ascending tubes on top of the perfusion
chambers. The bottom volume combined with the selected fluid flow velocity
determined the time needed to move the volume in one cycle and hence the
frequency of the oscillation. Equation 3.1 shows the relation between the
frequency f , the constants cross-sectional area A at the scaffold entry and
volume V and the variable velocity v.
f =
1
t
=
Q
V
=
A× v
V
(3.1)
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Table 3.3 shows the four fluid flow velocities for the cell seeding experiments
and their corresponding frequencies. Hence high perfusion velocities lead to
high perfusion frequencies.
v [mm/s] f [Hz]
1 0.006
5 0.03
10 0.06
15 0.09
Table 3.3: Fluid flow velocities used in the cell seeding experiments and their cor-
responding theoretical frequencies.
The oscillating velocity profile was chosen as a square wave form which
signified that the software had to invert the direction of the fluid flow after
every half-cycle. It is important to notice that lower perfusion velocities
decrease the perfusion frequency and hence increase the total seeding time
for a constant perfusion cycle number.
Function of the cell seeding software The parameters determined by
the user were the velocity of the fluid flow v and the number of cycles ncycles.
The fluid flow velocity was converted by the software to volume velocity
Q based on the convention that the entrance area A of the scaffold was
28.27 mm2 according to its diameter of 6 mm (see Equation 3.2). It is
important to notice that the velocities occurring in the pathways through
the scaffolds are not equal to the overall velocity.
Q = A× v (3.2)
The peristaltic pump had to be calibrated before the experiment. The cal-
ibration determined the maximal fluid flow Qmax which could be pumped
by the peristaltic pump. The maximal flow value was necessary to calculate
the percentage of pump velocity needed to achieve the intended fluid flow.
The function of the cell seeding software was sequentially:
1. Convert the input velocity v [mm/s] to a pump-readable signal [%].
(a) Input the maximum flow of the pump Qmax (e.g. 34.0 ml/min).
(b) Input the desired velocity v (e.g. 10 mm/s).
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(c) Calculate for the diameter of 6 mm the fluid flowQ (e.g. 16.96 ml/min).
(d) Calculate the percentage Qproz of the max. flow (e.g. 48.2 %).
(e) Translate to a compatible signal for the IPC pump (e.g. 48.2 %→
1S00482).
2. Calculate time thalf for a half-cycle.
(a) Divide volume V (2.25 ml) by the fluid flow Q to get V/Q = thalf
(e.g. 8 s).
3. Start the perfusion cycles.
(a) Set the pump counter-clockwise.
(b) Start pump with Qproz for thalf/2; This drives the medium levels
to start position.
(c) Stop pump and set it clockwise.
(d) Start pump with Qproz for thalf .
(e) Stop pump and set it counter-clockwise.
(f) Start the pump with Qproz for thalf .
(g) Repeat (c) - (f) for desired cycle number ncycle.
(h) Stop pump.
4. End program.
During the perfusion cycles every signal sent to the pump was written to a
text file as a measure for later control. One limitation encountered during the
programming in connection with the pump was that the pump had a latency
period of approximately 0.5 s which prohibited to send commands non-stop.
This limited the perfusion alternating frequency to 1 Hz. The functions of
the software are depicted in more detail in the flowcharts presented in Figure
3.14, 3.15 and 3.16.
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Figure 3.14: Cell seeding software flowchart (1 of 3).
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Figure 3.15: Cell seeding software flowchart (2 of 3).
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Figure 3.16: Cell seeding software flowchart, subroutine “tmchg” (3 of 3).
The main functions of the software were the establishment of the COM2
connection, the conversion of fluid flow to pump signal and the control of
the timer status. The connection to the pump was established by opening
the COM2 port by use of the following code.
OPEN "COM2:9600,n,8,1,CS,DS,RS" FOR RANDOM AS #1
The COM2 port was opened with a baud rate of 9600, no parity bit, 8 data
bits, 1 stop bit and assigned it the directory number #1.
The conversion of the desired fluid flow velocity to the pump command
was managed by calculating first the percentage of the maximum fluid flow.
The percentage fluid flow was rounded to one decimal place and converted
to a string. This string was then added to a prefix depending on the size
of the percentage. The following excerpt from the source code shows this
function.
...
y! = INT(Qproz * 10 ^ 1 + .5)
speed$ = STR$(y!)
speed$ = LTRIM$(speed$)
IF y! < 10 THEN GOTO 111
IF y! < 100 THEN GOTO 112
IF y! < 1000 THEN GOTO 113
IF y! < 10000 THEN GOTO 114
111
speed$ = "1S0000" + speed$
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GOTO 115
112
speed$ = "1S000" + speed$
GOTO 115
113
speed$ = "1S00" + speed$
GOTO 115
114
speed$ = "1S0" + speed$
GOTO 115
115
...
One problem encountered in the development of the cell seeding soft-
ware was caused by the use of the TIMER function. All timing in the pro-
gram is achieved by comparing the actual TIMER to the time value desired.
This caused a problem every time the day changed, because the TIMER
value counts seconds from 0 (for 00:00:00 in hours:minutes:seconds) to 86399
(23:59:59), representing the number of seconds of the day. After a change
from 23:59:59 to 00:00:00 the TIMER value changes from 86399 to 0. The
overcome this problem, the variable Start was set to the actual timer value,
the amount of time to wait was added and, in case the sum was bigger or
equal to 86399, the program went to the tmchg subroutine. In the subrou-
tine, the 86400 was subtracted from the Start value followed by a loop until
the TIMER value changed from 86399 to 0 (see Figure 3.16). The following
code illustrates the function:
...
Start = TIMER
...
Start = Start + t
IF Start >= 86399 THEN GOSUB tmchg
...
tmchg:
Start = Start - 86400
DO
LOOP UNTIL TIMER <= 10
RETURN
...
LOOP UNTIL TIMER >= Start
...
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After returning from the subroutine the main routine waited for the re-
mainder of the waiting period. The complete source code of the software is
provided in Appendix C.
Use of the cell seeding software The first screen appearing when run-
ning the software was the start screen, showing the name of the program
(see Figure 3.17). By pressing the ‘x’ key the program could be stopped or
by pressing any key the program could be continued.
The next screen served to enter the name of the experimenter, the fluid
flow velocity and the number of cycles desired. Pressing the ‘x’ key stopped
the program. After pressing any key the entered data as well as calculated
parameters were displayed as a summary (see Figures 3.18 and 3.19). Again,
pressing the ‘x’ key stopped the program, pressing any key continued the
program.
The user was presented in the next screen with a warning that the pump
cycles were going to start. At this point the user was reminded that the
pump had to be connected at COM2 of the computer, that the pump was
turned on, the power supply should be guaranteed over the duration of the
experiment and that the cell suspension levels should have two equal medium
levels in the tubing with at least 3.5 cm over the perfusion chambers (see
Figure 3.20). Pressing the ‘x’ key stopped the program, pressing any key
started the cell seeding cycles.
The program started then to write commands to the peristaltic pump
and to a log file (see Figure 3.21). In this phase the program could not be
stopped until all cycles were complete. After ending all cycles the program
stopped and asked the user to press any key to close the application.
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Figure 3.17: Screenshots of the cell seeding program; Start screen.
Figure 3.18: Screenshots of the cell seeding program; Parameter input.
Figure 3.19: Screenshots of the cell seeding program; Summary.
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Figure 3.20: Screenshots of the cell seeding program; Warning message.
Figure 3.21: Screenshots of the cell seeding program; Writing to IPC pump.
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3.3.3.2 Cell culture software
Function of the cell culture software The software developed for cell
culture had to take into account the cell culture perfusion profile. The culture
profile consisted of recurring cycles with a duration of 24 hours divided into
two periods. The first period was the period for cell stimulation in which
medium oscillated through the scaffolds at a high velocity with the intention
to stimulate the cells. The second period provided a constant low perfusion
velocity to transport nutrients to the cells and eliminate metabolism waste
products.
For the stimulation period with oscillating fluid flow the user entered
in the program the velocity v1, the time for every flow direction t1, which
determined the frequency of the stimulation, and the total time for the stim-
ulation period ttotal, which determined the number of oscillations performed.
For the second period the velocity v2 for the medium transport to the cells
was provided by the user (see Figure 3.22). The cell culture software had
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Figure 3.22: Cell culture profile and variables.
the following sequential function:
1. Convert the input velocity to a pump-readable flow.
(a) Input the maximum flow of the pump Qmax (e.g. 34.0 ml/min).
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(b) Input velocity v1 and v2 (e.g. 10 mm/s and 1 mm/s).
(c) Calculate for the diameter of 6 mm the fluid flow Q1 = A × v1
and Q2 = A× v2(e.g. 17.0 ml/min and 1.7 ml/min).
(d) Calculate the percentage of the max. flow Qproz1 and Qproz2 (e.g.
48.2 % and 4.8 %).
(e) Translate to compatible signal for the IPC pump (e.g. 48.2 %→ 1S00482,
4.8 % → 1S00048).
2. Calculate number of stimulation cycles.
(a) Get input for t1 and ttotal.
(b) Calculate the rounded number of cycles by |ncycle| =
ttotal
2× t1
.
3. Conduct stimulation period perfusion cycles.
(a) Stop pump, set pump clockwise.
(b) Start pump with Qproz1 for thalf .
(c) Stop pump, set pump counter-clockwise.
(d) Start pump with Qproz1 for thalf .
(e) Repeat (a) - (d) for desired cycle number ncycle.
4. Conduct continuous nutrition period.
(a) Stop pump, set pump clockwise.
(b) Start pump with Qproz2 for 24h − ttotal.
(c) Begin new “Stimulation period” (go to point 3).
During the perfusion cycles every signal sent to the pump was written
to a text file as a measure for later control. These 24 hour cycles run until
the system was stopped by pressing the ‘x’ key or paused by pressing the
‘p’ key for ending or pausing the program. The software for cell culture was
written according to the previously defined requirements. The user entered
the values for the stimulation period (v1, t1 and ttotal) and the nutrition
period (v2). Figures 3.23, 3.24, and 3.25 depict the detailed flowcharts of
the main program function, while Figure 3.26 shows the subroutines for day
change and pause mode. The routine for the day change (the change of
the Timer from 86400 to 0 at midnight) has been described earlier as a
subroutine for the cell seeding software. The whole source code is provided
in Appendix D.
One of the new key functions in this software was the pause function.
This function halted the pump activity until any key is pressed. To achieve
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this the remaining waiting period was calculated by subtracting the current
TIMER value from the Start value and the pump was stopped. When resum-
ing the pump process, the remaining time was added to the TIMER value to
determine the new Start parameter. The pump profile was hence shifted
by the pause function by the amount of time spent in pause mode.
...
Start = TIMER
...
Start = Start + 2
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
char$ = INKEY$
SELECT CASE char$
CASE "x"
GOTO 999
CASE "p"
GOSUB pause
...
pause:
PRINT #1, "1I" ’stop perfusion
PRINT
pt = Start - TIMER
PRINT "You are in pause mode!"
PRINT #2, TIME$, TIMER, "*** Perfusion paused ***"
PRINT
PRINT "Hit any key to proceed!"
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
Start = TIMER + pt
PRINT "Returned from Pause mode..."
PRINT #2, TIME$, TIMER, "*** Returned from pause ***"
PRINT #1, "1K" ’start perfusion again
RETURN
...
The pause subroutine is illustrated in Figure 3.26.
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Figure 3.23: Cell culture software flowchart (1 of 4)
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Figure 3.24: Cell culture software flowchart (2 of 4)
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Figure 3.25: Cell culture software flowchart (3 of 4)
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Figure 3.26: Cell culture software flowchart (4 of 4)
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Use of the cell culture software When executed, the software showed
a start screen as presented in Figure 3.27 with the name of the program. By
pressing ‘x’ the software could be stopped, pressing any other key led the
user to the next screen. The input screen showed a graphic representation
of the variables for the cell culture (see Figure 3.28). The user was asked
to enter values for the variables v1, t1, ttotal and v2 as explained previously.
After entering the values, the program proceeded to show a summary of all
entered and calculated parameters (see Figure 3.29). The program could
again be cancelled by pressing ‘x’ or proceeded by pressing any other key.
The user was presented with a warning that the pump has to be connected to
the COM2 port and that power supply should be guaranteed for the duration
of the experiment (see Figure3.30). Pressing ‘x’ stopped the program at this
point, any other key did start the perfusion profile. During the perfusion
profile the commands were printed on screen and to a log file (see Figure
3.31). By pressing the ‘p’ key, the software went into pause mode (see Figure
3.32). The pause mode was left by pressing any key and the perfusion profile
was resumed. By pressing the ‘x’ key the program could be ended (see Figure
3.33).
Figure 3.27: Screenshots of the cell culture program; Start screen.
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Figure 3.28: Screenshots of the cell culture program; Parameter input.
Figure 3.29: Screenshots of the cell culture program; Summary.
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Figure 3.30: Screenshots of the cell culture program; Warning.
Figure 3.31: Screenshots of the cell culture program; Writing to peristaltic pump.
Figure 3.32: Screenshots of the cell culture program; Pause mode.
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Figure 3.33: Screenshots of the cell culture program; End of the program.
3.3.4 Fluid flow velocity validation
The fluid flow profiles applied with the perfusion bioreactor system were
validated by determination of the pump accuracy. This included the fluid
displacement control by software, as well as the accuracy of the pneumatic
displacement of fluid through the scaffolds.
3.3.4.1 Verification of the pump control on the displaced volume
The volume transfer at different pumping velocities was measured to assess
the accuracy of the used peristaltic pump in combination with the developed
software. For this, a pump tube (Tygon LFL) of 40 cm length and internal
diameter of 2.79 mm was inserted into the peristaltic pump cassette. After
calibrating the pump according to the manual, the pump tube was immersed
in distilled (MilliQ) water on one end, the transported volume was collected
on the other end with a beaker. The laptop for control of the pump was
connected to the pump via the RS-232 interface and the software for flow
control executed. The pump was controlled by the software to pump 2.25 ml
at velocities of 1 mm/s, 5 mm/s, 10 mm/s and 15 mm/s. The velocities
referred to the 6 mm diameter of the scaffold the fluid would have to pass in
the perfusion bioreactor. Before and after each transport the recipient was
weighed and the volume of added water calculated (Equation 3.3).
∆mH2O = ρH2O ×∆V (3.3)
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This test was repeated six times for the four velocities. The four groups
were then compared using the Mann-Whitney U test to determine statistical
significant differences. This comparison was made to ensure that the volume
displacement was not dependent directly on the velocity.
The software used the same algorithm for the calculation of the pump
signal and the pumping time for different velocities as in the cell seeding and
cell culture software, which calculaed the time of volume transport ∆t.
∆t =
∆V
A× v
=
2.25ml
pi × 9mm2 × v
(3.4)
The software provided following functions:
1. Convert the input velocity [mm/s] to a pump-readable flow [%].
(a) Input the maximum flow of the pump Qmax (e.g. 34.0 ml/min).
(b) Input velocity v (e.g. 1 mm/s).
(c) Calculate for the diameter of 6 mm the fluid flowQ (e.g. 1.7 ml/min).
(d) Calculate the percentage of the max. flow Qproz (e.g. 4.8 %).
(e) Translate to compatible signal for the IPC pump (e.g. 4.8 % →
1S00048).
2. Transport 2.25 ml.
(a) Stop pump.
(b) Set pump counter-clockwise.
(c) Start pump with Qproz for t.
(d) Stop pump.
3. End program.
The function of the software in detail is presented in flowcharts in Figure
3.34 and 3.35, the source code is provided in Appendix B.
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Figure 3.34: Software for volume transport flowchart (1 of 2)
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Figure 3.35: Software for volume transport flowchart (2 of 2)
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3.3.4.2 Influence of the tubing system on the fluid flow velocity
To verify the fluid flow velocity controlled by the software, one channel of
the perfusion system was mounted on a laboratory bench. On one side of
the flexible tubing a section of a polystyrene 10 ml pipette (Rubilabor, Ref.
221.1010) was added to determine the displaced volume during the perfusion
cycles.
Evaluation of the measurement device For the determination of fluid
flow during several perfusion cycles by use of a 10 ml pipette section, the
tolerance of the measurements had to be determined. The pipette section
used for the readings was sealed shut on one end and was located vertically
on a precision balance (Sartorius CP622, tolerance 0.01 g).
Random volumes between 0.2 ml to 1.2 ml of distilled water were filled
into the pipette. The volume on the pipette scale and the weight indicated
by the balance were read off before and after adding the water. The scale
of the pipette had marks in 0.1 ml steps. A distinction could be made in
the pipette reading between volume steps of about 0.05 ml. The weight of
added volume was then compared to the measured weight using Equation
3.3 with a water density of ρH2O of 0.998 g/cm
3 [23].
Fluid movement profiles in the perfusion system channel One
channel of the perfusion system was assembled to verify the fluid flow veloc-
ity controlled by the software. One side of the flexible tubing was expanded
with a piece of a polystyrene 10 ml pipette to measure the transported vol-
ume (see Figure 3.36). The total length of the tubing remained the same to
maintain the elastic properties of the system. The channel was filled with
10 ml of distilled water. Before conducting the experiments the peristaltic
pump was calibrated according to its manual. The previously developed cell
seeding software was used to apply velocities of 1 mm/s, 5 mm/s, 10 mm/s
and 15 mm/s for 5 cycles each. To determine the effect of the tubing assembly
on the fluid flow velocity, experiments were conducted with empty perfusion
chambers. For the determination of the influence of the PLA/glass com-
posite scaffolds on the fluid flow velocity, three different pairs of pre-wetted
scaffolds were inserted into the chambers. The maximum and minimum level
of the water in the pipette was read off the scale for every cycle conducted in
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Figure 3.36: Setup for measurement of transported volume per half-cycle. Left side
of the tubing wass replaced by a 10 ml polystyrene pipette section.
these experiments and used to calculate the transported volume per cycle.
Additionally the water level in the pipette section was filmed with a digital
camera (Panasonic Lumix DMC-FZ28). The movies in format ‘.mov’ were
converted using VLC media player (Version 0.8.6i) using the ‘stream/save’
feature (output ‘.avi’ file extension, encapsulation method ‘MPEG 1’, video
codec ‘mp1v’, bitrate 1024 kb/s). The converted movie files were opened
with VirtualDub (Version 1.8.1) to observe the movies frame by frame. By
advancing frames, the movies were examined to determine the frame number
at specific fluid levels. This provided information over form and amplitude
of the perfusion cycles.
Results 81
3.4 Results
3.4.1 Scaffold material
As presented in Chapter 2, scaffold dimensions were subjected to shrinkage
during fabrication. By using PTFE moulds of 6.3 mm diameter and 13 mm
depth it was expected to compensate this effect on the scaffolds to obtain the
desired dimensions. Six scaffolds were measured with a slide calliper (TESA
ShopCal, serial number 1K375806) after fabrication, resulting in a mean
diameter of 6.2 mm ± 0.1 mm and a mean length of 12.5 mm ± 0.2 mm.
3.4.2 Perfusion bioreactor system
A perfusion bioreactor system for cell seeding and cell culture under fluid
flow was developed as presented previously. The design requirements stated
in the objectives were accomplished in the development of the perfusion
bioreactor system. The only component of this system which could not be
obtained commercially were the perfusion chambers, used to contain the
scaffolds. The perfusion chambers were applicable to autoclaving, whereas
tubing and connectors could be sterilised by gamma rays. The chambers
could be mounted by hand without the need of further tools. As could be
observed in all conducted experiments the chambers were sealed off tight,
ensuring the perfusion of the scaffolds. The sample holder of the chambers
showed to be applicable in preliminary tests for scaffolds made of PLA/glass
composite and calcium phosphate cement samples.
3.4.3 Software development
As a result of the software development three executable files were obtained,
for cell seeding, cell culture and for the volume transport experiments. The
executables were tested successfully for their function on the laptop dedi-
cated for the system with the pump connected prior to the validation exper-
iments.
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3.4.4 Fluid flow velocity validation
3.4.4.1 Verification of the pump control on the displaced volume
Using the developed software for volume transports of 2.25 ml at different
fluid flow velocities, the volume displacement at 1 mm/s, 5 mm/s, 10 mm/s
and 15 mm/s was measured to verify the pump algorithm and pump accu-
racy. The volume was determined by weighing the displaced water and using
Equation 3.3 for the volume calculation. The experiments were conducted
six times for each velocity. The averages of fluid transport for different fluid
flow velocities are listed in Table 3.4.
Comparing the groups using a Mann-Whitney U test, it was found that
only the 1 mm/s group was significantly different from the 10 mm/s group
(P < 0.01, two-tailed test). This showed that the displaced volume did
not depend directly on the pump velocity. The average of all values was
determined as 2.27 ml ± 0.04 ml. This was a deviation of about 1 % of the
intended volume.
Velocities Volume [ml]
1 mm/s 2.25 ± 0.03
5 mm/s 2.26 ± 0.02
10 mm/s 2.29 ± 0.01
15 mm/s 2.28 ± 0.04
Table 3.4: Displaced volumes in the fluid transport validation at different velocities.
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3.4.4.2 Influence of tubing and samples on the cell seeding per-
fusion pattern
Accuracy of the measurement device To determine the reading tol-
erances of the used pipette section, different water volumes were added to
the pipette and compared to the weight readings. The differences of read
values before and after adding water are shown in Table 3.5 as well as the
differences in measured volume for the 10 conducted measurements.
Deviations of up to 0.04 ml from the measured weight were obtained
by this measurement. The determined values and tolerances of volumetric
and weight measurements are plotted in Figure 3.37. As can be seen from
the graph, the measured volume had a linear relationship to the measured
weight as was expected.
calculated V [ml] measured V [ml] Difference
from weight from pipette scale ∆V [ml]
0.75 0.75 0.00
1.11 1.15 0.04
0.27 0.30 0.03
0.47 0.45 -0.02
0.38 0.40 0.02
0.40 0.41 -0.01
0.47 0.50 0.03
0.34 0.35 0.01
0.27 0.25 -0.02
0.67 0.70 0.03
Table 3.5: The weight added to the pipette section converted to water volume, vol-
ume readings and deviation of the volume for the measurement of the measurement
tolerance.
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Figure 3.37: Error in volume measurement with a pipette section. The tolerance of
measured volume was determined to be 0.04 ml, the tolerance of measured weight
was given by the manufacturer with 0.01 g. The dotted line shows the theoretical
relationship between weight and volume.
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Fluid flow and flow profile validation The developed cell seeding soft-
ware was used to apply 5 cycles with the velocities of 1 mm/s, 5 mm/s,
10 mm/s and 15 mm/s to an assembled cell seeding channel. Experi-
ments were conducted with empty perfusion chambers and with pre-wetted
PLA/glass composite scaffolds in both chambers. Measurements with scaf-
folds were conducted with three different sample pairs to eliminate the effect
of sample heterogeneity. The measured volumes were calculated for every
cycle and averaged over five cycles (see Table 3.6). The velocities calculated
from those measurements are depicted in Figure 3.38. For the experiments
with empty chambers the volume displacement showed to be stable over the
whole range of applied velocities, but was decreased in comparison to the
intended volume about 8.4 %. When scaffolds were present in the chambers,
the displaced volume was decreased about 9.0 %, 13.4 %, 19.6 % and 25.3 %
for 1 mm/s, 5 mm/s, 10 mm/s and 15 mm/s respectively.
When the volume displacement in the pipette section was recorded in
a movie, the patterns of the fluid level movement could be extracted from
the frames. The patterns for experiments with and without scaffolds are
depicted in Figure 3.39. In the experiments without scaffolds, a drift of
about 0.03 ml/cycle to one side of the channel was observed for all four
velocities. This drift occurred in all tested velocities. The triangular pattern
of volume displacement was not altered by the channel assembly. Inserting
the PLA/glass scaffolds in the perfusion chambers resulted in a higher drift
of the fluid to one channel side. During the experiments with scaffolds
with 5 cycles with 1 mm/s, 5 mm/s, 10 mm/s and 15 mm/s the drift was
0.025 ml/cycle, 0.035 ml/cycle, 0.04 ml/cycle and 0.08 ml/cycle respectively.
The triangular pattern of displacement was kept true for velocities of 1 mm/s
and 5 mm/s, whereas the peaks of the pattern were rounded off at high
velocities of 10 mm/s and 15 mm/s.
Pump
velocity
Volume measured V [ml] Velocity calculated v [mm/s]
no scaffolds with scaffolds no scaffolds with scaffolds
1 mm/s 4.13 ± 0.06 4.09 ± 0.06 0.92 ± 0.01 0.91 ± 0.01
5 mm/s 4.16 ± 0.05 3.89 ± 0.08 4.62 ± 0.06 4.33 ± 0.09
10 mm/s 4.13 ± 0.08 3.61 ± 0.10 9.2 ± 0.2 8.04 ± 0.2
15 mm/s 4.04 ± 0.05 3.37 ± 0.04 13.5 ± 0.2 11.2 ± 0.5
Table 3.6: Transported volumes and calculated velocities with and without
PLA/glass composite scaffolds in the velocity validation experiments (n=5).
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Figure 3.38: Velocity validation of the set fluid flow velocity to the real velocity.
Measurements were conducted with and without scaffolds in the perfusion chambers.
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Figure 3.39: Volume drift during alternating perfusion with and without scaffolds.
During perfusion without scaffolds, the fluid level drifted to one side of the channel.
This effect was enhanced by inserting scaffolds into the perfusion chambers.
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3.5 Discussion
PLA/glass composite scaffolds were fabricated for the perfusion bioreactor
system validation experiments in PTFE moulds. The porous cylinders were
6.2 mm in diameter and 12.5 mm in length and hence larger than the in-
tended dimensions. This discrepancy did not constitute a disadvantage for
the use in the perfusion bioreactor system, because the soft material was
pressed against the sample holder walls and hence ensuring the perfusion of
the scaffold. Because it is difficult to produce scaffolds which meet exactly
the 6.0 mm in diameter and 12.0 mm in length as well as to fabricate scaffold
holders with the same dimensions, for samples of harder material it should
be considered for further development to incorporate a scaffold holder which
adapts to to the actual dimensions of the sample.
A perfusion bioreactor system, including tubing, perfusion chambers,
peristaltic pump and computer was developed. As a main component, per-
fusion chambers for the bioreactor system were developed and tested.
The perfusion pattern of the cell seeding process was validated. This
part of use is considered most problematic considering that the fluid levels
are driven pneumatically against the resistance of the porous scaffolds in-
serted. It could be shown that the pump did work with an accuracy of about
1 %, which was considered sufficient for the intended use. The form and am-
plitude of the cell seeding perfusion was observed, showing that the tubing
with empty perfusion chambers diminishes the velocity set to the pump by
8.4 %. This diminishing effect could be determined with a reading tolerance
of 0.04 ml as was determined for the measurement device. The lowered fluid
flow velocity was most likely caused by compression of air as the driving
medium and by tubing elasticity which was buffering the driving pressure.
Driving the cell suspension levels pneumatically did imply a loss in fluid flow
velocity. Putting PLA/glass composite scaffolds into the chambers lowered
the fluid flow velocity up to 25 % depending on the applied velocity in a
range up to 15 mm/s. Darcy’s law (Equation 2.8) which relates pressure
to flow, shows that a higher fluid flow causes a higher pressure difference
through the sample. It was suggested that higher pressure enhanced the
buffering of transported volume due to tubing elasticity and air compress-
ibility. For cell culture the observed effects of diminished fluid flow velocities
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was considered not as severe as in the cell seeding process, because the driv-
ing medium in cell culture is the less compressible medium fluid, the amount
of elastic tubing is smaller and the applied fluid flow velocities are lower.
Additionally it has to be taken into account that after a long term culture
the changes in the scaffolds (material adsorption and tissue development)
influence the permeability and hence affect the occurring pressures and per-
fusion velocities. The impact of this development on the fluid flow velocity
cannot be estimated sufficiently. This signifies that tissue development can
only be related to the fluid flow set on the pump, not the fluid flow actually
occurring in the system.
From these results it can be seen that the main inconvenience of the de-
veloped system consists in the missing feedback of actual fluid flow velocity
to the pump control. Such feedback allows to measure the actual velocity
and correcting the velocity set at the pump. This would have to be moni-
tored very carefully, because the feedback might cause an up-regulation of
pump speed which leads to a high pressure in the system which cannot be
handled by the pump. So an additional monitoring of the systemic pressure
would be appropriate. Implementation of such a feedback loop has not been
undertaken in the current system, because of the technical changes implied.
These changes would not only consist of adding sensors and changing the
software, but also need appropriate electronic for the sensors and a new type
of interface connecting the pump and sensors to the laptop. Another type of
interface, preferable for parallel data acquisition, implies the change of the
programming language. Without any doubt those technical changes in the
system can be undertaken in the future and might enhance the function of
the perfusion bioreactor system.
Additionally the developed perfusion bioreactor system did not contain
measurement mechanisms for cell activity. As Volkmer et al. [24] stated,
even in perfusion bioreactor systems it is important to monitor the oxygen
gradient in the scaffold. In a future redesign the integration of sensors should
be considered to monitor the biological activity of the cultured cells.
The software for controlling perfusion profiles was developed given the
required function for cell seeding and cell culture. The user interface was very
basic and the input was minimized to the necessary parameters. For further
changes, the software can be expanded using the software tools mentioned in
90 Development of a Perfusion Bioreactor System
the development description. One major limitation of the software was the
command latency of the pump, which did not allow to send two consecutive
commands in direct succession, but needed a period between commands. In
the case of alternating velocities for the purpose of mechanical stimulation
of the cells, this signifies a maximum frequency of 1 Hz.
The selection of BASIC as language limited the application when expand-
ing the systems complexity in the future development. A better combination
for further progress would be the use of a hardware interface controlled by
software written in a language which supports the interface driver.
3.6 Conclusions
• A perfusion bioreactor system was developed for cell seeding and cell
culture experiments including control software. The presence of scaf-
folds in the perfusion chambers did diminish the fluid flow velocity
through the tubing.
• As one of the crucial parts of the bioreactor system a perfusion chamber
was developed. The chambers used for the initial tests proved to be
usable for the system.
• During cell seeding, the resistance constituted by the scaffolds was
diminishing the perfusion velocity and caused a drift to one of the sides.
Sensors for control of the fluid flow parameters were not incorporated
in the perfusion bioreactor system, but should be considered for further
development.
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Chapter 4
Cell Seeding in the Perfusion
Bioreactor System
4.1 Introduction
One approach in tissue engineering of bone tissue substitutes is the in vitro
culture on 3D biomaterial matrices or scaffolds. For the development of
tissue in the scaffolds it is beneficial to provide a high number of cells and
an even cell distribution throughout scaffolds at the start of cell culture. A
high cell number can increase bone mineralization in the scaffolds [1] and an
even cell distribution is linked to uniform tissue generation during culture
in a bioreactor [1, 2]. Additionally a high cell number seeded on scaffolds
shortens the time of culture necessary to achieve a sufficiently developed
tissue. A high cell seeding efficiency, i.e. the ratio of cells adhered to the
scaffold to the total number of cells seeded, can reduce the extent of cell
harvesting and in vitro cell expansion. Different cell seeding techniques
are applied to achieve tissue engineered construct on 3D substrates. Most
commonly used methods are static, dynamic and perfusion seeding.
The most applied cell seeding method is static seeding. By pipetting
cell suspension on top of a scaffold, cells sink into the pores of the scaffolds
by gravity [3]. Even though this is an easy method which does not need
special equipment, the number of cells that adhered to the porous scaffolds
is relatively small. A cell seeding efficiency between 18 % to 85 % can be
obtained by static seeding. The cell seeding densities for this lay in the
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magnitude of 104 to 107 cells/cm3 [1, 4–11] . It has been shown that most
of the cells adhered on the outside of the scaffold, so that only few or no
cells were located on the inside [1, 4–6]. This is considered unfavourable for
further cell culture.
The most common method for cell seeding under dynamic conditions is
the use of spinner flasks. Scaffolds fixated on skewers are immersed into cell
suspension [20]. The cell suspension is then agitated by an electromagnetic
stirrer and the cells accumulate in the pores of the scaffolds. Seeding in
spinner flasks under dynamic conditions yields efficiencies of a wide range,
from 17.5 % to 55 %. By rearranging the scaffold placement and changing
the wall symmetry of the spinner flask Bueno et al. [12] even achieved
seeding efficiencies of 100 %. Cell density in the scaffolds was in the order
of 104 to 108 cells/cm3 [6, 7, 12] which was in the same range as the static
seeding method (see Table 4.1). The cell distribution throughout scaffolds
after spinner flask seeding was reported to be non-uniform. While some
regions contained aggregations of cells, other regions were found void of cells
[6]. Nevertheless dynamic seeding in a spinner flask resulted in better cell
distribution compared to static seeding [21, 22].
Perfusion of the scaffolds with cell suspension aims to overcome the short-
coming of cell distribution. By deposition of cells throughout the scaffold
by repeated filtering of the suspension through the scaffold the cell number
and cell distribution can be enhanced. As presented in the introduction of
Chapter 3, different perfusion systems were developed by different research
groups. All systems have in common that they allow to push cell suspension
through scaffolds, seeding cells throughout the porosity. It has been shown
that perfusion seeding results in a high seeding efficiency. The cell seeding
efficiencies achieved by this method were 70 to 90 % with cell densities in
magnitudes of 105 to 107 cells/cm3 [5, 6, 8–10, 13–19] (see Table 4.1). This is
comparable to the efficiencies with the dynamic seeding method. But in con-
trary to the downside of heterogeneous cell distribution, using the perfusion
cell seeding method it was possible to distribute cells evenly throughout the
scaffold [4–6, 8, 22]. In another form of the perfusion seeding, where scaf-
folds move through cell suspension instead of the suspension through the
scaffolds, Timmins et al.[19] obtained with their T-CUP system a seeding
efficiency of 75 % and a high seeding uniformity. Overall perfusion seeding
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Type Reference Cells Material Dimensions (diam-
eter(d) length(l))
Porosity Ncells
initial
Efficiency
[%]
Efficiency⋆
[cells/cm3]
static Holy et al. [1] BMSC PLGA 75/25 5×7×7mm3 NA 1.5×106 25 1.5×106
static Li et al. [4] Trophoblast-
like ED27
non-woven PET Matrices d:1.8mm, l:1mm 85-93% 1×107 NA 5.0×106
static
Godbey et al. [7] HBSMC PGA 40×8×2.5mm3 95% 2×105
17.5 4.4×104
dynamic 15 3.8×104
dynamic Bueno et al. [12] Chondrocytes PGA d:5mm, l:2mm 97% 1.0×107 100 2.5×108
static
Wendt et al. [6] Chondrocytes
Polyactive foam d:8mm, l:4.3mm 75% 1.3×107 85 5.1×107
Hyaff-11 mesh d:5mm, l:4mm 73% 5.0×106 71 4.5×107
dynamic
Polyactive foam d:8mm, l:4.3mm 75% 1.3×107 71 4.3×107
Hyaff-11 mesh d:5mm, l:4mm 73% 5.0×106 66 4.2×107
perfusion
Polyactive foam d:8mm, l:4.3mm 75% 1.3×107 87 5.2×107
Hyaff-11 mesh d:8mm, l:4mm 73% 5.0×106 71 2.0×107
perfusion Janssen et al. [13] BMSC biphasic calcium phosphate
(BCP)
2-6mm granules in
10cm3 volume
59% 16×106 14 2.8×105
static
Zhao et al. [8] MSC non-woven PET Matrices
d:12mm, l:1.2mm
89%
7.5×105 34 1.9×106
perfusion d:16mm, l:1.2mm 1.2×105 68 3.4×105
perfusion Radisic et al. [14] C2C12, car-
diomyocytes
UltrafoamR© collagen hemo-
stat sheet
d:11mm, l:1.5mm NA 12×106 76 6.4×107
perfusion Radisic et al. [15] C2C12 PGS d:10mm, l:3mm 90% 12.0×106 72.9 3.7×107
static Alvarez-Barreto et
al. [5]
MC3T3-E1
PLLA foams, non-woven
polystyrene
d:8mm, l:3mm 95% 2.5×105
46 7.7×105
perfusion 87 1.5×106
static Alvarez-Barreto et
al. [9]
MSC RGD-modified PLA d:8mm, l:3mm 90% 1×106
22 1.5×106
perfusion 64 4.2×106
perfusion Grayson et al. [16] MSC decellularized bovine bone d:4mm, l:4mm 70-80% 3×106 24.7 1.5×107
perfusion Chen et al. [17] Hepatocytes vegetable sponge d:8mm, l:112.5mm 90% 7.0×107 54 6.7×106
static Kitagawa et al.
[10]
NIH/3T3 PLLA
i.d.:1mm, o.d.:
95.5% 2.0×106
50 8.0×105
perfusion 3mm, l:20mm 100 1.6×106
static
Lee et al. [11] RAEC poly glycerol sebacate d:4mm, l:1mm NA
5.0×105 59 2.4×107
perfusion NA 66.4 NA
perfusion Shvartsman et al.
[18]
C3A hepato-
cyte
Alginate d:5mm, l:2mm 90% 6.6×105 98 1.6×107
perfusion Timmins et al. [19]
Articular
chondrocytes
Polyactive foam
d:8mm, l:4mm
75%
1.0×107
86 4.3×107
Hyaff 11 93% 75 3.7×107
ChronOS ceramic foam 60% 84 4.2×107
BMSC Hyaff 11 93% 80 4.0×107
⋆Cell density was calculated from the reached cell number and scaffold volume which was deduced from the dimensions given by the referenced publications.
Figure 4.1: Cell seeding efficiencies achieved by the three main methods used in tissue engineering.
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is attractive, because it allows to perform the cell seeding in the same biore-
actor system used for the later perfusion cell culture. Additionally it has
been shown that fluid flow movement can enhance the osteogenic potential
of the scaffold [22].
The main problem of the cell seeding in perfusion bioreactor systems is
the selection of the right fluid flow velocity. As Wendt et al. [6] commented,
high velocities do not give to the cells enough time to adhere to the material,
whereas low velocities do not move the cells fast enough, so they adhere
to the tubing of the perfusion system or sink to the lowest point of the
system by the effect of gravity. They found that a fluid flow velocity of
1 mm/s is appropriate for cell seeding in their system. It must be pointed
out that the optimal velocity depends highly on the scaffold microstructure.
The tortuosity and diameter of the fluid flow pathways in the scaffold affect
directly the velocity and hence the occurring forces on the cells in suspension.
Without any doubt more approaches for cell seeding are developed re-
cently, using different principles like centrifugation [7, 23], acoustic waves
[24] or vacuum [25]. Other approaches are progressions of the perfusion
principle [19, 26], based on the promising results of perfusion bioreactors.
In general, the comparison between different studies is problematic, be-
cause cell seeding depends highly on dimensions and structure of the scaf-
folds, such as porosity, tortuosity, pore size and pore form, the cell density
in the suspension used for seeding and the fluid flow fields induced by the
perfusion system. The scaffolds used in perfusion seeding and culture studies
had diameters ranging from 3 mm to 18 mm and a thickness from 1 mm to
4.3 mm [4–6, 8, 14, 22]. However it is desirable to achieve bigger tissue sub-
stitutes if tissue engineering wishes to make a clinical impact. The promising
results of previous studies with the perfusion cell seeding approach and the
need for larger scaffold culture constitute the basis of the here presented
study.
4.2 Objective
The objective of this study was the determination of suitable fluid flow condi-
tions for the perfusion seeding of MG63 cells on porous PLA/glass scaffolds.
The cell seeding was conducted using the perfusion bioreactor system as
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described in Chapter 3. In this study, the effect of fluid flow velocity and
perfusion cycles of the oscillating seeding method on the resulting seeding
efficiency and cell distribution had to be determined. The hypothesis of this
study was, that it is possible to seed cells throughout a large porous scaffold,
with a high length to diameter ratio, by the perfusion seeding approach.
4.3 Materials and methods
4.3.1 Scaffold preparation
The PLA/glass composite scaffolds for this study were fabricated as de-
scribed in Chapter 2 by solvent cast particle leaching technique. The scaf-
folds were of 6 mm diameter and 12 mm length with pore diameters of
80-210 µm, porosity of 95.7% and permeability of 1.7 × 10−10 m2. The
scaffolds were then packed in transparent microcentrifuge tubes which were
sealed in sterilization bags. The packed scaffolds were sterilized by gamma
radiation with a dose of 8 kGy. One day before the seeding experiments
the needed number of scaffolds was taken out of the packing under sterile
conditions and immersed in 30 % ethanol for less than one minute. The
scaffolds were then transferred to a Petri dish with complete medium (high
glucose Dulbecco’s Modified Eagle Medium (DMEM), 10 % foetal bovine
serum (FBS), 1 % penicillin-streptomycin, 1 % sodium pyruvate and 1 %
L-glutamine) and incubated overnight. At the beginning of the experiments
the scaffolds and the medium were observed under the light microscope to
exclude a possible bacterial contamination.
4.3.2 Preliminary test
One of the encountered challenges for this study was to determine the
methodology used to obtain an imaging of the cells located in the porous
scaffolds. Even though the preliminary tests presented here were not all
applicable for the treatment of the samples, those efforts did produce im-
ages which show cell morphology and scaffold structure at a more detailed
manner than in the cell seeding imagines used in the final experiments.
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4.3.2.1 Cell culture on scaffolds
For the preliminary test, cells were seeded into scaffolds. For this, MG63
human osteoblast-like cells were suspended to 500,000 cells per 300 µl com-
plete medium (DMEM, 10 % FBS, 1 % penicillin-streptomycin, 1 % sodium
pyruvate and 1 % L-glutamine) and 300 µl injected with a syringe into the
scaffolds. The scaffolds were then incubated for 24 hours before preparation
for histology.
Preparation of object slides The object slides used for mounting of the
cut samples were silanized to enhance the adhesion of the sample cuts. For
this purpose the glass slides were left in soap solution overnight and washed
thoroughly with deionized water. The slides were dried and washed with
acetone for three minutes. The slides were then immersed in TESPA (3-
aminopropiltrietoxysilane) dissolved in acetone in a concentration of 2 % for
five minutes. The so treated slides were briefly flushed with distilled water
and left for drying overnight protected from dust.
Sample preparation The scaffolds were taken out of culture and im-
mersed for one hour in formalin and passed into phosphate buffer (PB, 0.1 M
at pH 7.4). The samples were then included by immersion in increasing con-
centrations of ethanol followed by xylol and inclusion in paraffin. Consecu-
tively the samples were transferred for one hour each in 70 % ethanol, two
times in 96 % ethanol, two times in 100 % ethanol, two times in xylol, two
hours in paraffin at 57 ◦C and then left in paraffin at 57 ◦C over night. The
prepared samples were put on a metal tray and paraffin poured over them
and an embedding cassette was placed over the sample. The samples were
left to cool off in a refrigerator at 4 ◦C until the paraffin was totally hard-
ened. The cassettes were fixed in a rotary microtome (Leica RM2125) and
the samples were cut in transverse plane with a thickness of 20 µm under
frequent change of the used blade. The best cuts were laid out on silanized
object slides and stored overnight at 37 ◦C.
The sections of the samples were then stained with methylene blue after
extraction of the paraffin to make the cell nuclei more visible. To extract the
paraffin from the sample sections, the slides were immersed for five minutes
in xylol, five minutes in 100 % ethanol, five minutes in 70 % ethanol and
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one minute in deionized water. For the methylene blue staining the slides
were immersed for 30 to 60 seconds in methylene blue solution. To remove
excess dye from the samples, the slides were immersed in deionized water for
three minutes, one minute in 95 % ethanol, one minute in 100 % ethanol and
lastly for five minutes in xylol. After evaporation of the xylol the samples
were mounted with DPX (Di-N-Butyle Phthalate in Xylene). The sections
were inspected under light microscope (Nikon Eclipse E-600) and images
were taken for documentation.
4.3.3 Perfusion cell seeding
4.3.3.1 Perfusion system
The perfusion bioreactor system was assembled as presented in Section
3.3.2.1. For the experiments three parallel channels where assembled which
allowed the use of six perfusion chambers simultaneously. The components
of the perfusion chamber were sterilized by autoclave, tubes and plastic con-
nectors were washed thoroughly with ethanol and distilled water and located
for 20 minutes under ultraviolet light for sterilization prior to the seeding
experiments. At the beginning of the experiment the tubing leading from
the pump to the perfusion chambers was assembled under sterile conditions
and the connectors closed with sterile caps. The tubing was then transferred
to the incubator, guided through an inlet tube on the back of the incubator.
The computer and pump were connected and the tubing inserted into the
pump. The perfusion chambers were assembled with inserted scaffolds and
connected via the large diameter tubing which was closed on top with sterile
caps. The perfusion chambers were then transferred to the support rack in
the incubator and connected to the previously installed tubing.
4.3.3.2 Cell preparation
The medium used for the cell culture was complete medium (DMEM, 10 %
FBS, 1 % penicillin-streptomycin, 1 % sodium pyruvate and 1 % L-glutamine).
MG63 human osteoblast-like cells were used for the cell seeding experiments.
The cells were cultured in 75 cm2 culture flasks and trypsinized when reach-
ing confluency. For trypsinization the medium was extracted from the cul-
ture flasks, the cells were washed twice with sterile phosphate buffered saline
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(PBS). Three millilitre of trypsin (TrypLE Express, Gibco 12605) were added
to the cells and the flask incubated over five minutes at 37 ◦C. Seven millil-
itre of medium were added to stop the enzymatic activity and the detached
cells were extracted from the flask and transferred into a centrifuge tube.
The 10 ml suspension was centrifuged at 1000 rpm for five minutes. The
supernatant was removed and the cell pellet resuspended in 10 ml medium.
The cell number in the suspension was counted in a Neubauer chamber. The
suspension was again centrifuged at 1000 rpm for five minutes, the super-
natant removed and the cells resuspended in 10 ml medium. Cell density was
determined by counting again in the Neubauer chamber to verify the first
measurement. The cells were then either transferred to a new culture flask
or if used for the experiment diluted to a density of 2 × 106 cells per 10 ml
medium. Ten millilitre cell suspension was then injected into the bottom
valve of the perfusion bioreactor channels. For the cell seeding experiments
MG-63 osteoblast-like cells from pass 8 to 13 were used.
4.3.3.3 Static cell seeding
As a comparison to the perfusion seeding, 106 MG63 cells per scaffold sus-
pended in 300 µl complete medium were injected with a syringe (0.9 mm
needle) into the composite material. With this method it was intended to
bring cells into the interior of the scaffolds. After the injection, the samples
were left in complete medium at 37 ◦C four hours to allow cell adhesion. Four
samples were washed with PBS and frozen in serum-reduced medium and
used for the determination of the cell number. Two samples were used for
the determination of the cell distribution in the interior by acridine orange
staining.
4.3.3.4 Perfusion cell seeding
Cell seeding was conducted under oscillating suspension perfusion with vary-
ing values for cycle number and fluid flow velocity. The cycle numbers used
were 50, 100 and 500 cycles, whereas fluid flow velocities were 1 mm/s,
5 mm/s, 10 mm/s and 15 mm/s. Consequently twelve single experiments
were conducted. The combinations of fluid flow velocities and cycle num-
bers resulted in seeding times from 9 minutes up to 23 hours (see Table 4.1).
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Velocity [mm/s] Cycle number Cell seeding time
50 2h19min
1 100 4h36min
500 23h09min
50 28min
5 100 55min
500 4h36min
50 14min
10 100 28min
500 2h19min
50 9min
15 100 19min
500 1h33min
Table 4.1: Total seeding time for the different perfusion velocities and perfusion
cycle numbers.
After completion of the seeding cycles, the system was left undisturbed for
four hours to facilitate cell adhesion to the scaffolds. It was ensured that
unattached or dead cells were removed from the samples by extraction of the
cell suspension supernatant with a syringe and by washing the samples with
PBS twice. Two of the six scaffolds were used to determine cell distribution.
Four scaffolds were frozen for later determination of the cell number in the
scaffolds.
4.3.3.5 Cell distribution
Cell distribution in the scaffolds was assessed directly after four hours of
cell adhesion time. The scaffolds were cut longitudinally with a scalpel.
All scaffolds were stained with acridine orange to identify living cells. The
samples for 50 cycles and 100 cycles were additionally stained with ethidium
bromide. Acridine orange (AO) and ethidium bromide (EB) were prepared
by diluting a 1 mM stock solution to 10 µM solution which equals a solution
of 2.6 µg/ml of acridine orange and 3.9 µg/ml of ethidium bromide. AO
and EB were added to the scaffolds and incubated over 5 minutes at 37 ◦C.
The scaffolds were then washed twice with sterile PBS and observed under
fluorescence stereoscope (Leica MZ16F) with DSR filter for EB and GFP-3
filter for AO. Pictures were taken of the fluorescence for documentation.
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4.3.3.6 Cell number
The cell number present in the scaffolds was measured using a cytotoxi-
city detection kit (Roche Applied Science) for detection of lactate dehy-
drogenase (LDH). For the quantification, four scaffolds per experiment were
washed twice with serum-reduced medium (DMEM, 1 % FBS, 1 % penicillin-
streptomycin, 1 % sodium pyruvate and 1 % L-glutamine), destroyed with
tweezers and frozen in 1 ml of serum-reduced medium at -20 ◦C. The samples
were then thawed and frozen three times to destroy all cell membranes. The
use of a LDH detection kit for the determination of cell number after cell
lysis is an established method [27] and freeze-thawing is an effective method
for cell lysis [28]. The samples were prepared in 96 well plates in triplicate.
Per well 50 µl of resuspended samples were diluted with 50 µl of serum-
reduced medium before adding the test liquid as described in the kit’s user
manual. The controls were 100 µl of serum-reduced medium. The samples
were incubated for 30 minutes at room temperature and kept protected from
light. The absorbance of the samples was then measured at 450 nm with
a reference wavelength of > 690 nm in a microplate-reader (Biotek Pow-
erwave XS). The cell concentration in the samples was calculated using a
standard curve measured on the same 96 well plate. The found seeding effi-
ciencies were compared using the Student’s t-test to determine statistically
significant differences.
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4.4 Results
4.4.1 Preliminary test
The samples used for the preliminary tests were included in paraffin, cut with
a rotary microtome and cells were stained with methylene blue. During the
preparation it was found that only a few good sections could be preserved,
because by cutting, glass particles were dragged by the microtome blade
through the sample, slicing the sections into thin strips. Additionally it
was found that parts from the usable sections were lost during the various
immersions necessary for the staining procedure. The sections treated by
the described method were inspected under light microscope and showed
the location of MG63 cells inside of the porous material (see Figure 4.2).
The cells were lining the pore walls of the composite material and it was
observed that cells were adhering preferably to the calcium phosphate glass
particles rather than to the PLA polymer.
(a) (b)
Figure 4.2: Light microscopy images of histological cuts performed with a rotary
microtome after methylene blue staining of adhered MG63 cells (thickness 20 µm).
(a) In lower magnification the cells can be seen distributed in the material. Arrow
shows rectangular pores achieved by embedding salt crystals. (b) At higher mag-
nifications the morphology of the cells show that cells do adhere preferably to the
glass particles (arrow).
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4.4.2 Cell seeding
4.4.2.1 Static cell seeding
The measurement of cell seeding efficiency of the cell injection used a quasi-
static method resulted in an efficiency of 51.9 % ± 14.3 %.
For the assessment of cell distribution, the scaffolds were cut longitudi-
nally and stained with acridine orange. The fluorescence images taken were
converted and stitched together to represent a map of cell distribution over
the whole scaffold interior and exterior (see Figure 4.3). The imaging sug-
gested that on the exterior only few cells were located, while in the interior
one region contained a high cell density.
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Figure 4.3: Cell staining with acridine orange allowed to observe the distribution
of living cells in the scaffold seeded by the static method. The cells are represented
as green areas.
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4.4.2.2 Perfusion cell seeding
Estimation of shear stress on cells To estimate the shear stress applied
by the fluid flow on adhered cells in the scaffold, a calculation was conducted.
Similar to Grayson et al. [16] it was assumed that the pathways through
the scaffold were straight tubes of uniform diameter. The diameters were
assumed here with 80 and 210 µm according to the size of the pore generating
agent. The fluid induced wall shear stress τw can be calculated using the
culture medium viscosity µ (0.77 cP) and density ρ (1.004 g/ml) [29], the
linear fluid flow velocity v and the conduct diameter d. The equation used
was derived from the Hagen-Poiseuille relation for laminar flow through a
round conduit [16, 30].
τw =
4×Q× µ
pi × r3
=
8× v × µ
d
(4.1)
The occurring velocities of 1 mm/s, 5 mm/s, 10 mm/s and 15 mm/s were
adjusted to the sample porosity 95.7 % (1.0 mm/s, 5.1 mm/s, 10.3 mm/s
and 15.4 mm/s respectively). Additionally for all velocities and diameters,
the Reynolds number was calculated to ensure that the flow was laminar
[31], which was a prerequisite for the use of the Hagen-Poiseuille relation.
Re =
ρ× v × d
µ
(4.2)
The shear stresses for the four velocities were calculated and are depicted
in Figure 4.4. For the diameters of the porosity from 80 to 210 µm shear
stresses of up to 1.2 Pa were estimated. Comparing the estimated stresses
with the physiological fluid induced shear stresses on bone cells between 0.8
and 3.8 Pa [32, 33], suggested that all fluid flow velocities applied provided
a viable stress.
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Figure 4.4: The wall shear stresses in tubular conduits was calculated to estimate
the shear stresses occurring in the porosity of the PLA/glass composite scaffolds.
Results 109
Cell distribution After seeding cells in the PLA/glass composite scaf-
folds using the perfusion bioreactor system with an initial cell number of 106
MG63 cells per scaffold, the cells which were present in the scaffolds were
stained with acridine orange to determine their distribution on the interior.
The staining was observed under fluorescence using a stereoscopic micro-
scope. It was observed that the limited focus plane under the microscope
reduced the sharp reproduction of the 3D structure, hence not depicting
all stained cells in the images. Additionally, the cutting of the scaffolds
affected their structural integrity, because the soft material was partially
compressed during preparation. Even though the scaffolds were pulled open
with tweezers, the internal structure showed alterations. The images taken
under fluorescence were treated by desaturation and adjustment of contrast
and brightness to make the cells better visible in print. Single images were
stitched together to give a better impression of the overall distribution. De-
tail images of the perfusion entrance areas and the middle of the samples (see
Figure 4.5, 4.6, 4.7 and 4.8) were used to compare the cell distribution at the
different perfusion parameters, where the cells can be distinguished as black
dots on the lighter background. The images suggested that the cell number
inside of the scaffolds did increase with cycle number, showing more cells at
100 and 500 cycle seedings. Likewise an increasing cycle number seemed to
improve the distribution throughout the scaffolds providing a more uniform
cell distribution inside the scaffold (see Figures 4.5 and 4.6). In a similar
way the increasing fluid flow velocity improved cell number and cell distri-
bution up to 10 mm/s. The 15 mm/s experiments showed low cell number
present despite the homogeneous cell distribution. Qualitatively the imaging
showed that a minimum fluid flow velocity and cycle number had to be used
to reach the aim of the perfusion cell seeding, uniform cell distribution and
high cell density. The exterior of the scaffolds showed a similar pattern to
the uniformity of cell distribution shown in Figures 4.7 and 4.8.
By staining the cut scaffolds with ethidium bromide it was possible to dis-
tinguish apoptotic cells from living cells. The obtained images were treated
by desaturation and colour inversion and finally coloured red. The images
were then overlaid with the green coloured acridine orange staining pictures
to achieve maps of cell distributions on the exterior and interior of the scaf-
folds (see Figures 4.9 and 4.10). The images suggested that the ratio of
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apoptotic cells to living cells is low in all cases. With higher cell seeding
cycle numbers and higher perfusion flow velocities the amount of apoptotic
cells increased. It was observed that one end of every sample bore more
apaptotic cells than the other.
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Scaffold interior
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Figure 4.5: Scaffold interior: Cell staining with acridine orange allowed to observe
the distribution of living cells on the inside of the scaffold. Shown are sections of
both ends and the middle of the scaffolds’ insides for 1 mm/s and 5 mm/s fluid flow
velocities and 50, 100 and 500 cycles. The cells are represented as green points.
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Scaffold interior
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Figure 4.6: Scaffold interior: Cell staining with acridine orange allowed to observe
the distribution of living cells on the inside of the scaffold. Shown are sections of
both ends and the middle of the scaffolds’ insides for 10 mm/s and 15 mm/s fluid
flow velocities and 50, 100 and 500 cycles. The cells are represented as green points.
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Scaffold exterior
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Figure 4.7: Scaffold exterior: Cell staining with acridine orange allowed to observe
the distribution of living cells on the exterior of the scaffold. Shown are sections of
both ends and the middle of the scaffolds’ outsides for 1 mm/s and 5 mm/s fluid
flow velocities and 50, 100 and 500 cycles. The cells are represented as black points.
114 Cell Seeding in the Perfusion Bioreactor System
Scaffold exterior
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Figure 4.8: Scaffold exterior: Cell staining with acridine orange allowed to observe
the distribution of living cells on the exterior of the scaffold. Shown are sections of
both ends and the middle of the scaffolds’ outsides for 10 mm/s and 15 mm/s fluid
flow velocities and 50, 100 and 500 cycles. The cells are represented as black points.
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Figure 4.9: Scaffold interior: Cell staining with ethidium bromide and acridine
orange allowed to observe the distribution of living and apoptotic cells on the inside
of the scaffolds. Shown are longitudinal sections of scaffolds insides for 1 mm/s,
5 mm/s, 10 mm/s and 15 mm/s fluid flow velocities and 50 and 100 cycles. The
living cells are represented as green areas, apoptotic cells are coloured red.
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Figure 4.10: Scaffold exterior: Cell staining with ethidium bromide and acridine
orange allowed to observe the distribution of living and apoptotic cells on the exte-
rior of the scaffolds. Shown are scaffold outsides for 1 mm/s, 5 mm/s, 10 mm/s and
15 mm/s fluid flow velocities and 50 and 100 cycles. The living cells are represented
as green areas, apoptotic cells are coloured red.
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Cell seeding efficiency After seeding cells with 106 MG63 cells initially
per scaffold using the perfusion bioreactor system, scaffolds were frozen three
times to free all incorporated LDH. The samples were diluted 50:50 and the
absorbance of the samples was measured at 450 nm wavelength for four sam-
ples per perfusion seeding condition. The total cell number was calculated
by the use of the standard curves, taking into account the dilution and the
total volume of the samples. The cell seeding efficiency was then calculated
as ratio of the found cell number to the initial cell number. Figure 4.11
shows the average efficiencies and standard deviations of the samples.
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Fluid flow velocity
Perfusion cycle number
50 cycles 100 cycles 500 cycles
1 mm/s 48.3±30.5 40.1±22.0 22.0±4.4
5 mm/s 43.0±21.7 27.2±21.7 19.9±1.9
10 mm/s 42.6±32.4 27.4±11.8 22.6±4.4
15 mm/s 51.5±16.0 23.7±6.0 36.5±1.8
Figure 4.11: Cell seeding efficiencies achieved with different fluid flow velocities
and varying cycle number with initially 106 MG63 cells per scaffold in the perfusion
bioreactor system (n=4). Marked groups (*) are statistically significantly different
(Student’s t-test, p<0.05).
As can be observed in Figure 4.11, the uniformity of seeding between
samples increased with the increasing number of perfusion seeding oscilla-
tions which can be observed by the narrowing standard deviations. At the
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same time higher numbers of seeding cycles did lower the efficiency of the
seeding from about 50 % to about 20 %. The changes of fluid flow velocity
did not influence the cell seeding efficiency significantly at constant perfusion
cycle numbers. An exception to this finding is the case of the 15 mm/s per-
fusion fluid flow velocity at 500 cycles, which was significantly higher than
the efficiencies found at the same cycle number and varying velocity, as was
confirmed by Student’s t-test (p < 0.05).
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4.5 Discussion
As was observed during the preliminary test conducted to determine the
feasibility of methodology, the sectioning of the microtome sectioning of the
samples was not applicable, because only thick partial cuts could be pre-
served. This was not sufficient to obtain a representation of cell distribution
in the interior of the scaffold as was intended. Nevertheless it was possible
to examine the structure of the scaffold porosity and the morphology of the
cells in the scaffold. It was found that cells adhere better to glass than poly-
mer which is in accordance with the findings of Charles-Harris et al. [34]
using the same material and cell type. This behaviour is attributed to the
differences in hydrophobicity of both phases. The calcium phosphate glass
is more hydrophilic than the PLA [35], which is the most likely cause for a
better cell adhesion on the glass particles.
Cell distribution after perfusion cell seeding was observed by cutting
open the seeded scaffolds and observing stained cells under fluorescence.
This method was found feasible although the structure of the sample was
affected by the cutting of the sample. Nevertheless it was possible to observe
the distribution of cells throughout the scaffolds. One of the most critical
requirements of the perfusion seeding method is the location of cells into
the deep porosity of large scaffolds. In this study it was found that for the
porous PLA/calcium phosphate glass composite material, velocities over 1
mm/s were needed to press the cells inside of the scaffolds. This is similar
to the finding of Wendt et al. [6] which showed that a minimum velocity
was needed for a successful cell seeding. It was found that a more uniform
distribution of living cells was achieved at 5 mm/s, 10 mm/s and 15 mm/s
of fluid flow velocity. The increase in the cell seeding perfusion cycle number
did improve the cell distribution throughout the scaffolds. The staining of
apoptotic cells suggested that high perfusion cycle numbers had a negative
effect on the cell viability, resulting in bigger regions of fluorescence. Higher
intensities of the staining were found always on one extreme of the samples.
Even though it was not recorded which side of the sample, bottom or top,
showed this phenomenon, it was suspected to be on the bottom, being the
entry of cells during cell suspension injection and hence the place of high
cell densities at the beginning seeding cycles. More apoptotic cells were also
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found at high velocities, which also indicated higher stresses on the cells.
Hence lower cell seeding fluid flow velocities are better as well as few seeding
cycles. The results from this part of the study suggested that a fluid flow
velocity of 5 mm/s and 100 cycles of perfusion is sufficient to provide an
uniform cell distribution and keeps stress on the cells limited.
To estimate the shear stress on the cells in the scaffolds porosities a calcu-
lation was performed based on Hagen-Poisseuille relation. This calculation
did not take into account the tortuosities of the fluid flow pathways and
the non-uniform structure of the fluid pathways. A computational model
realised by Milan et al. [36] for the same PLA/glass composite material
showed stresses of 1-8 mPa at 100 µm/s. The estimation applied here gave
for this inlet velocity stresses of 3-8 mPa, showing that the estimation was in
the same magnitude of the more sophisticated method. The shear stresses
estimated for the different fluid flow velocities were in the physiological range
of bone cells. This was not consistent with the increasing regions of dying
cells at velocities of 10-15 mm/s. It was suggested that the high velocities
combined with the numerous direction changes of the fluid flow caused the
elevated stress on cells.
The static seeding performed by injecting cells into scaffolds yielded a
efficiency comparable to the perfusion seeding. The cell distribution however
showed that the cells were concentrated in one area of the scaffold interior,
which was less homogeneous than the distribution achieved by perfusion
seeding. A region of high cell density was observed at the place of injection
of the cell suspension.
The results of the cell seeding efficiencies at different fluid flow velocities
and cycle numbers cannot be compared directly, because of the high standard
deviations. However a trend can be observed that suggested that the velocity
of cell seeding cycles did not have an influence on the number of cells located
in the scaffolds. The distribution of cells between samples in the same seeding
channel was improved by higher cell seeding cycle numbers as shown by the
decreasing standard deviations, whereas at the same time the efficiencies
decreased.
Overall the cell seeding was relatively low compared to research men-
tioned in the introduction [5, 6] with a maximum of about 50 % and high
standard deviations. The high standard deviations showed that at low seed-
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ing cycles the cells were distributed unevenly between the two scaffolds in
one channel. It is important to mention that for this study the efficiency
was determined per scaffold instead per channel. A lower deviation might
be found when comparing the overall efficiency per channel, but this would
exclude information about individual scaffolds. The low efficiency obtained
may be caused by the low cell suspension density of 2 ×105 cells/ml. An-
other parameter possibly responsible for the low cell seeding efficiency can be
the volume of moved cell suspension in every cell seeding cycle. This volume
was predefined as 4.5 ml in the development of the perfusion bioreactor sys-
tem.Implementing a higher volume transport would imply the use of longer
ascension tubes (or the implementation of a large diameter container above
the perfusion chambers) and the further dilution of the cell suspension, which
is unfavourable for achieving high cell seeding densities. Even though the
cell seeding efficiency was found to be low, when calculating the cell density
over the scaffold volume, the magnitude of 106 cells/cm3 was in the range of
105 cells/cm3 [8] to 108 cells/cm3 [6, 14] found in comparable studies. With-
out any doubt the comparison of different studies is complicated, because of
the different materials, perfusion systems and cell suspension densities used.
This study has shown that cell seeding in the developed perfusion bioreactor
system is feasible and comparable to other existing systems. It was further
shown that the cell seeding on scaffolds of large volume and high length to
diameter ratio can be achieved by the perfusion approach, which is a very
important step towards the cell culture in large scaffolds. Of further interest
is the development of cell viability and distribution over longer times after
the perfusion cell seeding.
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4.6 Conclusions
• It was concluded that the perfusion cell seeding experiments showed
the functionality of the developed perfusion bioreactor system. It was
possible to bring MG63 cells into the deep pores of the scaffolds, which
is essential for the further cell culture. Furthermore the cell seeding
of large scaffolds was achieved successfully, opening the way for the
culture of large tissue engineered bone substitutes.
• It was determined that a minimum perfusion velocity was needed to
push cells into the scaffolds and the most uniform cell distribution was
observed at 5 mm/s, 10 mm/s and 15 mm/s and 100 to 500 perfusion
cycles.
• Cell viability was determined to be higher at low perfusion velocities,
as could be observed in the staining of apoptotic cells, which indicated
that high velocities and seeding cycles signified high stress on cells.
• The cell seeding efficiency achieved by the described method was about
50 %. The results suggested that cell seeding efficiency was not influ-
enced by the perfusion seeding velocities, but rather by the perfusion
seeding cycle number.
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Chapter 5
Cell Culture in the Perfusion
Bioreactor System
5.1 Introduction
It has been demonstrated that cell culture under fluid flow is a promising
approach for the conditioning of bone tissues cultured in vitro and the pro-
duction of clinically relevant engineered tissue volumes [1]. A seeded scaffold
can be cultured in perfusion bioreactors over long periods of time, achieving
highly cellularised tissue substitutes, containing the tissue specific extracel-
lular matrix. Studies have shown in 2D and 3D culture that a steady flow
as well as an alternating fluid flow profile can guide cell differentiation and
enhance cell activity [2–18].
The patterns used for perfusion cell culture in scaffolds can be divided
into a steady flow, which provides viable conditions, and an alternating
flow as a stimulus for cell activity (see Table 5.1). Steady fluid flow rates
in the range of 5 µm/s to 400 µm/s [2–12, 19] enhance the distribution,
proliferation and osteoblastic differentiation of cells [11, 12, 20, 21], show-
ing the osteoblastic differentiation by enhanced production of alkaline phos-
phatase (ALP) [7, 8, 13, 22–24], osteopontin [22] and osteocalcin [7, 19] and
an increased calcium deposition [10, 13, 18, 22]. Alternating or oscillating
fluid flow was studied predominantly in 2D experiments. It was found that
alternating fluid flow alters cell activity [17], enhancing prostaglandin E2
(PGE2) and intracellular calcium release in comparison to continuous flow
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[14–16]. Also pulsatile fluid flow has shown to enhance cell proliferation
over longterm treatment [14]. When the cell culture under fluid flow was
studied in 3D scaffolds, it was observed that analogue to the 2D experi-
ments, pulsatile perfusion caused enhancement of prostaglandin E2 (PGE2)
release [4]. Alternating fluid flow through porous scaffolds maintained cell
viability and stimulated osteoblast differentiation [6, 25, 26] and resulted in
constructs capable of inducing bone formation upon implantation [27]. Also
did the application of dynamic fluid flows enhance cellular distribution and
osteogenic responses of the scaffold [28].
The alternating fluid flow for cell stimulation for the perfusion culture of
bone cells had a frequency of 1-2 Hz with fluid flow velocities of up to 8.5
mm/s and a stimulation duration of 30 minutes daily up to three times 1
hour per day [4, 6, 26, 28] (see Table 5.1).
The flow rate applied to cells in scaffolds is highly important for the cell
culture, because even though lower rates increase the proportion of viable
cells in the scaffold, high flow rates can result in cell death [5]. As stated
for the cell seeding, the scaffold microstructure has an important role on the
fluid flow velocities in the fluid pathways and hence on the stimulation of
cells.
The beneficial role of fluid flow on the development of engineered tissue
in perfusion bioreactors give the basis for the presented study, which aims at
the culture of mesenchymal cells on large porous composite scaffolds using
the developed perfusion bioreactor system.
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Flow Reference Cell type Continuous
velocity∗
Alternating
velocity∗
Repetitions Stimulation duration Total
duration
steady
Volkmer et al.[29] MC3T3-E1 5 µm/s - - - 1 week
Glaum et al. [30] osteoblast-like cells 6 µm/s - - - 2 weeks
Zhao et al. [21] hMSC 10 µm/s - - - 35 days
Hosseinkhani et al. [31] rMSC 20 µm/s - - - 3 weeks
Wang et al. [7] BMSC 20 µm/s - - - 4 weeks
Bo¨gel et al. [24] MG63 30 µm/s - - - 17 days
Meinel et al. [13] hMSC 35 µm/s - - - 5 weeks
Hosseinkhani et al. [19] rMSC 40 µm/s - - - 2 days
Li et al. [23] osteoblast 50 µm/s - - - 16 days
Freyria et al. [32] primary chondrocytes 20-60 µm/s - - - 3 weeks
Zhao et al. [33] hMSC 10-150 µm/s - - - 20 days
Yang et al. [20] hMSC 0.1 mm/s - - - 12 days
Wendt et al. [2] articular chondrocytes 0.1 mm/s - - - 2 weeks
Du et al. [25] MC3T3-E1 0.2 mm/s - - - 6 days
Goldstein et al. [8] osteoblasts 0.2 mm/s - - - 2 weeks
Holtorf et al. [22] rMSC 0.3 mm/s - - - 16 days
Holtorf et al. [11] rMSC 0.3 mm/s - - - 16 days
Gomes et al. [10] rMSC 0.3 mm/s - - - 15 days
Fassina et al. [12] SAOS-2 0.3 mm/s - - - 16 days
Grayson et al. [3] hMSC 0.1-0.4 mm/s - - - 5 weeks
alternating
Du et al. [34] MC3T3-E1 - 0.1 mm/s cont. 1/60 Hz 6 days
Du et al. [25, 35] MC3T3-E1 - 0.1-0.2 mm/s cont. 1/120 Hz 6 days
Timmins et al. [27] BMSC - 0.4-1 mm/s cont. NA 19 days
Plunkett et al. [28] MC3T3-E1 0 mm/s 0.2 mm/s 3× daily 1h, ∼0.04-0.07Hz 14 days
Plunkett et al. [28] MC3T3-E1 10 µm/s 0.2 mm/s 3× daily 1h, ∼0.04-0.07Hz 2 days
Jaasma et al. [6, 26] MC3T3-E1 20 µm/s 0.2 mm/s 3× daily 1h at 1Hz 1 day
Vance et al. [4] MC3T3-E1 5 µm/s 8.5 mm/s daily 30 min at 1 Hz 2 days
Figure 5.1: Long term cell culture patterns used in cell culture in 3D scaffolds for bone and cartilage tissue engineering.
∗Fluid flow velocities were calculated from the fluid flow and scaffold cross-section area given in the respective publications.
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5.2 Objectives
The objective of this study was to determine the applicability of the devel-
oped perfusion bioreactor system for the long term culture of rat mesenchy-
mal cells (rMSC) on large porous PLA/glass scaffolds. The cell culture was
conducted with a steady fluid flow for maintenance of viable cell culture
conditions and a daily stimulation by oscillating fluid flow. In this study the
cell activity after long culture periods was determined by the resulting cell
proliferation, distribution and differentiation. The hypothesis of this study
was, that it is possible to maintain viable cells in large porous scaffold using
the perfusion bioreactor and influence the differentiation of mesenchymal
stem cells by oscillating fluid flow stimulation.
5.3 Materials and methods
5.3.1 Scaffold preparation
For the cell culture experiments the same scaffold type was used as for the cell
seeding presented in Chapter 4. The PLA/glass scaffolds were sterilised with
gamma rays at 8 kGy prior to the experiments. One day before cell seeding
the needed number of scaffolds was taken out of the packing under sterile
conditions and immersed in 30 % ethanol for prewetting. The scaffolds were
then transferred to a Petri dish with complete advanced medium (Advanced
DMEM, 15 % FBS, 1 % penicillin-streptomycin and 1 % L-glutamine) and
incubated overnight. At the beginning of the experiments the scaffolds and
the medium were observed under a light microscope to exclude possible
bacterial contamination.
5.3.2 Cell preparation
Mesenchymal stem cells were isolated from rat bone marrow. For this, Lewis
rats (Charles-River) were sacrificed and femora and tibiae were surgically re-
moved. Bone marrow was obtained by flushing the inside of the bones with
advanced DMEM (15 % FBS, 1 % penicillin-streptomycin, 1 % L-glutamine,
1 % sodium pyruvate) and 22.5 µg/ml heparin. The obtained cell fraction
was transferred to 6-well plates and allowed to adhere. After 24 hours, su-
pernatant was removed and fresh medium was added. 2-3 days after the
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initial plating a population of small, elongated, spindle-shaped cells rapidly
proliferating could be observed. Cells were trypsinised at subconfluence and
passaged 1:3. Cells from passages 3 to 6 were frozen in liquid nitrogen for
later cell culture. The cell line for experiments was cultured with com-
plete advanced DMEM (15 % FBS, 1 % penicillin-streptomycin and 1 %
L-glutamine) and trypsinised according to protocol described in Chapter 4.
rMSC from pass 4 to 8 where used for the experiments.
5.3.3 Static cell seeding
As a comparison to the perfusion seeding method, 300.000 rMSC cells per
scaffold suspended in 300 µl complete medium were injected with a syringe
(0.9 mm needle) into the composite material. After the injection, the samples
were incubated in complete medium for four hours to allow cell adhesion.
Five samples were washed with PBS and frozen in serum-reduced medium
and used for the determination of the cell number.
5.3.4 Perfusion cell seeding
For the cell seeding, the cell suspension was diluted to a density of 2 × 106
cells per 10 ml medium. Suspended cells were seeded according to the pro-
cedure used in the previous cell seeding experiments (see Chapter 4) using
the perfusion bioreactor system assembly as presented in Chapter 3. Ten
millilitre cell suspension were injected into the side valve of each perfusion
bioreactor channel with 106 cells per scaffold. The suspension was then os-
cillated through the scaffolds at 5 mm/s for 100 cycles. After completion of
the cell seeding cycles, the cell suspension was left four hours in the system
to allow cell adhesion and then extracted from the channel with a syringe.
5.3.5 Cell culture
As presented in Chapter 3, the assembly was changed after completed cell
seeding. Reservoirs with 100 ml advanced DMEM medium were put into the
channels as shown in Chapter 3 and exchanged weekly for the experiments of
two and three weeks period. The stimulation pattern was set to an oscillating
fluid flow velocity of 5 mm/s at 0.5 Hz for 30 minutes per day. The rest of the
day a steady flow of 0.1 mm/s was applied to exchange continually medium
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in the scaffolds. Cell culture was conducted for 1 day, 1 week, 2 weeks
and 3 weeks. The samples were analysed for cell distribution, proliferation
and differentiation. For the analysis of cell distribution, two samples were
used for each culture period, while for the analysis of cell proliferation and
differentiation four samples were used for each culture period (40 samples in
total) with up to 16 perfusion chambers used in parallel.
5.3.6 Cell distribution
Analogue to the sample treatment in the cell seeding experiments (see Chap-
ter 4) two samples were taken out of the perfusion chambers per culture pe-
riod after the cell culture period and were cut longitudinally with a scalpel.
The samples were stained with 10 µM solution of acridine orange (AO) and
ethidium bromide (EB) to visualize under a fluorescence stereoscope (Leica
MZ16F) living and apoptotic cells on interior and exterior of the scaffolds.
Images of the fluorescence were taken and stitched together to achieve a map
of cell distribution.
5.3.7 Cell proliferation
For the measurement of cell proliferation, samples were frozen three times to
lyse the cells. Using a LDH cytoxicity test as for the cell seeding presented
in Chapter 4, the cell number in the samples was determined. Complete ad-
vanced DMEM was used as control and high LDH concentrations in samples
were measured by diluting the corresponding sample in advanced medium
at dilutions of 1:3 and 1:9. The seeding efficiencies were compared using the
Student’s t-test to determine statistically significant differences.
5.3.8 Cell differentiation
The cell differentiation of the mesenchymal cells was determined by the gene
expression of collagen I, osteocalcin and Runx2. To extract the RNA of
the samples, they were taken out of the perfusion chambers and washed
in PBS. 350 µl RLT buffer of the RNeasy kit (Qiagen) was added to the
samples, which were then destroyed with a homogenizer (Polytron PT 1200
C, Tip: PT-DA 05/2 EC-C 84). The supernatant was then transferred with
the sample fragments to a QIAshredder tube (Qiagen) and centrifuged for
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two minutes at 13.2 × 103 rpm (Eppendorf Centrifuge 5415R). The lysate
of the collection tube was then treated with the RNeasy kit according to
the user manual. Per sample 30 µl of RNA suspended in ribonuclease-free
water were extracted. As control, rMSCs were trypsinized and put into six
well plates (500,000 cells/well) for 24 hours and treated with the RNeasy
kit according to the user manual. The concentration of RNA was measured
with the nanodrop spectrophotometer (Thermo Scientific) for every sample.
The RNA samples were then stored at -20 ◦C until the further treatment.
The extracted RNA was transcripted to cDNA, using the QuantiTect
reverse Transcription Kit (Qiagen) according to the user manual. 500 ng
RNA of every sample was used for the transcription. As quality controls one
sample was prepared containing all reactants except reverse transcriptase
(-RT) and one sample was prepared containing all reactants except the RNA
sample (NTC). The concentration of cDNA was measured with the nanodrop
spectrophotometer (Thermo Scientific). The gained cDNA was then stored
at -20 ◦C.
For the real time polymerase chain reaction (RT-PCR), the cDNA sam-
ples were prepared in an optical reaction 96-well plate. Using Quantitect
SYBR green (Qiagen) according to the user manual, a quantity of 75 ng
cDNA was analysed for every sample. Primers of collagen I, osteocalcin
and RunX-2 as well as β-actin as a comparison (housekeeping gene) were
used for the determination of osteoblastic differentiation. The well plate was
closed with adhesive film, agitated for 1 minute at 600 rpm and centrifuged
for 1 minute at 300 g. The DNA sequences were read out with the Abi
Prism 7700 sequence detector (Applied Biosystems). The Ct values for the
gene expressions were read out and normalized to the values of β-actin using
Equation 5.1, where Ct(sample) was the Ct value of the genes (collagen I,
osteocalcin or RunX-2) for cells cultured under perfusion, Ct(control) was the
Ct value of the genes (collagen I, osteocalcin or RunX-2) for cells cultured
in a well and Ct(β−actin) was the Ct value of the housekeeping gene β−actin
[36].
Norm. value = 2−∆∆Ct =
2−∆Ct(target)
2−∆Ct(norm)
=
2−(Ct(sample)−Ct(β−actin))
2−(Ct(control)−Ct(β−actin))
(5.1)
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The normalized value determine the up- or down-regulation of gene activity.
5.4 Results
5.4.1 Cell distribution
For the observation of cell distribution after 1 day, 1 week, 2 weeks and
3 weeks of culture, scaffolds were cut open longitudinally and cells were
stained with acridine orange (AO) and ethidium bromide (EB). The flu-
orescence images were treated analogous to the cell seeding presented in
Chapter 4. The images taken were stitched together to represent a map of
the cell distribution in the whole scaffolds (see Figure 5.2). The cell seed-
ing conducted before the culture provided a cell distribution throughout the
scaffolds, as suggested by the AO staining of the samples after 1 day. Up
to the longest period culture of 3 weeks, living cells were found on exterior
and interior of the scaffolds. The EB staining of the samples suggested an
increased part of apoptotic cells at 1 and 2 weeks culture on the interior
and it seemed that a maximum of apoptotic cells were found at 2 weeks of
culture. The exterior showed in all cases only few apoptotic cells.
Results 137


	



 	













	



 










Figure 5.2: Cell distribution after perfusion with daily stimulation for periods up
to three weeks. Acridine orange staining for living cells is shown as green areas,
ethidium bromide staining for apoptotic cells as red areas.
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5.4.2 Cell proliferation
The cell number in the scaffolds at different cell culture periods was assessed
by LDH measurement. The results of the measurements showed a low cell
number at the beginning of culture, which corresponded to a seeding effi-
ciency of 40.2 % ± 22.5 % (see Figure 5.3). The cells proliferated over the
first two weeks in an exponential manner (Ncells = 0.3 × e
0.2t), ending up
in a 13.5 fold amount of cells in the scaffolds compared to the start of cul-
ture. After two weeks, the cell number experienced a severe decrease, which
ended after three weeks in a cell number similar to the culture start. Stu-
dent’s t-test showed that the cell number measured after two weeks value
had a statistically significant difference the 1 day, 1 week and 3 week mea-
surement. The static seeding method provided a seeding efficiency of 32.1 %
± 14.0 %, followed by the 3 week culture period in which the cell number
did not change significantly as was confirmed by Student’s t-test.
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Cell number as percentage of initial cell number
1 day 1 week 2 weeks 3 weeks
static (n=5) 32.1±14.0 88.5±59.4 55.7±37.6 23.0±16.5
dynamic (n=4) 40.2±22.5 119.0±114.9 539.9±29.4 57.0±61.1
Figure 5.3: Cell proliferation under static conditions and perfusion with daily stim-
ulation after up to three weeks culture. The cell number showed an exponential
growth up to two weeks, whereas from week two to three the cell number severely
decreased. Student’s t-test showed that for the perfusion culture, the two weeks
value (*) had a statistically significant difference from the other perfusion culture
values (p<0.0005).
140 Cell Culture in the Perfusion Bioreactor System
5.4.3 Cell differentiation
Cell differentiation after 1 day, 1 week, 2 weeks and 3 weeks of cell cul-
ture under perfusion was measured by RT-PCR. For the measurement, the
highest concentrated RNA samples of every culture period was used. The
Ct values of osteocalcin, collagen I and Runx2 were normalized against the
control of rMSCs using β-actin as reference gene. No Runx2 and collagen I
expression was found in the samples for any culture period. For the osteo-
calcin expression, high values were found after 1 day (28-fold in comparison
to 24 h statistical cultured rMSCs), which decreased to a low level after
1-2 weeks. The upregulation of osteocalcin expression is depicted in Figure
5.4.
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Figure 5.4: Osteocalcin expression in rMSC after 1 day, 1 week, 2 weeks and 3
weeks perfusion culture in the perfusion bioreactor system.
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5.5 Discussion
The initial cell distribution throughout the scaffolds seen after the seeding
was corresponded to the findings of the previous cell seeding study (see
Chapter 4). The pattern used for perfusion culture in the range of similar
studies which yielded success in long term cultivation [4, 6, 26, 28]. Similar
to the calculation conducted in Chapter 4, the fluid flow shear stress on the
cells was estimated to be 150-390 mPa at 5 mm/s and 3-8 mPa at 0.1 mm/s,
which was considered well in the physiological range of bone cells [37, 38].
Throughout the long term experiments scaffolds maintained viable inside
of the scaffold, even though the imaging indicated an increase of apoptotic
cells in the scaffold interior over two weeks. Interestingly the cell viability
on the scaffold exterior did not seemed affected by the long term culture
under fluid flow perfusion. These results showed that the maintenance of
a viable environment in the perfusion bioreactor system was possible, even
though the cell mortality in the interior suggested that changes in the fluid
flow pattern may yield a better viability.
In the conducted long term cell culture study under medium perfusion
through porous scaffolds it was observed that after an initial exponential
proliferation of up to 2 weeks, the cell number decreased in the following
week. The decrease in cell number indicates a change in the viable environ-
ment, which decreased the cell survival in the scaffolds. Comparable studies
have shown that it is possible to culture cells in a fluid flow environment over
long terms of about two weeks [1, 8, 11, 20–24, 27, 28, 31, 33, 34, 39], but
most long term cultures showed similar cell number decreases after an initial
cell expansion phase [9–11, 13, 30, 40, 41]. The drop in cell number after an
initial proliferation stage was attributed to a prevention of DNA measure-
ment by entrapment of DNA in the ECM [9, 11], a loss of cells due to the loss
of scaffold material [13] or the influence of ECM maturation and the late-
stage differentiation of osteoblastic cells [10, 30, 40–42]. For the presented
study an entrapment of the measured LDH in ECM was excluded, because
cells were lysed and the scaffolds totally destroyed. It can be assumed that
only little LDH was left in the scaffold fragments after centrifugation in the
QIAshredder. It might be considered that cells were lost during culture by
material loss. A material loss of about 12.5 % during 3 weeks immersion in
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simulated body fluid (SBF) at 37 ◦C of porous PLA/glass composites under
static conditions was reported, showing that a considerable amount of cell
adhesion surface was lost during culture [43]. The drop in cell number expe-
rienced in this study was not attributed to the late-stage differentiation of
the MSCs, because this would rather result in a stabilisation of cell number
than a sudden drop in the population. The changes affecting might also
be attributed to the ‘overpopulation’ in the scaffolds after the exponential
growth. The amount of cells could have influenced proliferation by altering or
blockage of the fluid flow pathways or by elevated nutrient consumption and
waste generation. The proliferation of MSCs in the static method showed no
statistical significant changes over a long time with an apparent initial pro-
liferation phase up to 1 week, which indicated the limited nutrient supply in
the large scaffolds and hence supporting the beneficial influence of the perfu-
sion method on cell culture. One of the most important requirements of cell
survival is the availability of oxygen to the cells [2]. The presented set-up
did not allow a systemic monitoring of oxygen. Moreover the oxygen con-
sumption rate and the exposure of cells to oxygen is unknown. Nevertheless
it can be hypothesised that the growing cell population resulted in an up-
ward trend in oxygen consumption, which was not met with the continuous
medium exchange rate applied. Additionally not all cells in the growing cell
clusters might have had a direct exposure to the medium, impeding the up-
take of oxygen. Because oxygen and nutrient supply and waste removal are
crucial for a successful cell culture in large 3D scaffolds, it is for further re-
search of highest interest to incorporate monitoring and control mechanisms
for these parameters. This mechanisms should focus on the time-dependent
structural changes in the scaffold materials, because those changes can alter
the availability of oxygen and nutrients to the cells significantly.
The results of cell differentiation are inconclusive. While the osteocalcin
measurements indicate an early cell differentiation into the osteoblast cell
line, a lack of Runx2 and collagen I expression as early regulator of differen-
tiation [44–47] indicate the absence of osteoblastic differentiation. Because
the cells were cultured prior to the perfusion culture experiments, the cells
might have begun the differention. Because Runx2 (or Cbfa1) is early ex-
pressed in differentiation [48–50], it might have occured that the cells, when
inserted into the perfusion system, were already in the differentiation stage
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and Runx2 expression had ceased, which could explain the absence of Runx2
in the conducted measurements. In the case of an osteoblastic differentiation
the Runx2 expression continues into the late stage of osteoblast activity [51].
The absence of collagen I however indicates a failure in the measurement pro-
cedure, because collagen expression should be present during and beyond the
osteocalcin expression [52]. The shown pattern of gene expression leads to
the assumption that the primers for collagen I and Runx2 used for the RT-
PCR were faulty, while the primer for osteocalcin was able to give an image
of cell activity in the long term culture. The verification of these results
could not be conducted due to the length of every set of experiments. Tak-
ing these results in account, the measurements undertaken were not capable
to determine if the applied stimulus was sufficient to provoke the desired
reaction of the rMSC to differentiate into osteoblasts. This result has to
be deemed preliminar and further studies are required with a more detailed
analysis of cell activities before and after the long term perfusion culture.
In further studies a comparison experiment should be conducted, applying
only a steady flow to allow the distinction of the effect of the stimulation
phase on the cells.
The presented study has shown that the developed perfusion bioreactor
was capable to provide a viable environment for a long term cell culture
on large porous scaffolds. Further studies must be conducted to determine
the appropriate stimulus pattern for the osteoblastic differentiation of mes-
enchymal stem cells and to improve the cell viability.
5.6 Conclusion
• The developed perfusion bioreactor system provided a viable cell cul-
ture up to three weeks with cells throughout the large porous scaffolds.
Cell number increased exponentially over two weeks and decreased at
three weeks, which was attributed to the beginning cell differentiation
and the overpopulation of the scaffold.
• The fluorescence imaging of the scaffolds under perfusion culture con-
firmed the cell population dynamic. Additionally it was observed that
cells seemed to be under significantly more stress on the scaffold inte-
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rior than on the exterior.
• The cell differentiation analysis did not give a conclusive picture of the
differentiation of the rMSCs. Cell activity was indicated by osteocalcin
expression. It was concluded that the applied stimulation fluid flow
profile was not adequate to induce the desired differentiation. Further
detailed studies are necessary to observe the reaction of the cells on
the perfusion profile.
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Chapter 6
Development of an in vivo
Bone Chamber System
6.1 Introduction
One approach of tissue engineering to counter large bone defects consists
in the insertion of porous biomaterial into the defect to act as a support
and guidance for bone regeneration. The material used should promote the
ingrowth and formation of bone tissue and help to bear loads on the bone
to reduce recovery time. Prior to in vivo tests, biomaterials are thoroughly
tested in vitro to avoid adverse effects upon implantation. Even though those
tests are considerably extensive, they cannot reflect the complex environment
of a patient’s body, with fully developed tissue interacting with the material
and inflammatory and immune responses [1].
Bone chambers are useful tools for skeletal tissue engineering to gain
knowledge about the osteoconductive or osteoinductive properties of differ-
ent scaffold types [2, 3]. By placing a scaffold into the environment of a
living organism, the reaction on the implant material and structure can be
observed as well as the progress of tissue formation into the material over
time. This gives valuable insight into the applicability of a scaffold for its
intended purpose. The most common approach to bone chamber systems
is the implantation of a hollow metal cylinder into the region of interest
(see Figure 6.1). Scaffolds of different materials and fabrication can then
be inserted into this cylinder, where apertures allow the ingrowth of tissue
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(a) (b) (c)
Figure 6.1: Bone chamber designs for the study of bone ingrowth into allografts in
goats (a, b) [3, 4] and rats (c) [6].
into the scaffold. After extracting the scaffold or the entire bone chamber,
the developed tissue can be analysed histologically to determine the type
and amount of present tissue. Even though the application of bone cham-
ber systems is promising for the testing of different scaffold materials, most
studies focus on the bone ingrowth in allografts [3–7] or the bone ingrowth
into empty chambers [8–11]. Only few used synthetic scaffold material for
bone chamber studies [12].
Bone chambers used in animal experiments are either for single use only
or reusable for the repeated testing of different samples in the same chamber.
Chambers for single use have the advantage of a simpler surgical protocol,
but large numbers of samples require also large numbers of animals, which
implicates ethical and financial issues. Additionally inter-individual differ-
ences may have a severe influence on the measurement results. Reusable
bone chambers have the advantage of allowing the test of materials in as
few as possible animals and reduce the inter-individual variability [3, 9, 13].
Both bone chamber types can be used in different mammal species, from
small animals like rats [6] to big animals as goats [11, 14]. In regard to
different animal models and implantation methods it has been shown that
bone ingrowth is independent from species [11]. The space inside the bone
chambers for bone ingrowth ranges from cylinders of 2 mm in diameter and
7 mm length [6] up to internal diameter of 6 mm, and a length of 8.5 mm [15].
For clinical use however, large defects are of interest for experimentation.
Bone chambers can be constructed to allow application of certain stimuli
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(a) (b) (c) (d)
Figure 6.2: Bone chamber designs for the mechanical stimulation of bone forma-
tion.(a) Design for the manual compression of ingrowing bone in rabbits [9], (b)
hydraulic compression of ingrowing bone in dogs [8], (c) manual compression of
allografts in rats [7] and (d) in rabbit shear on titanium implant [13].
to the scaffold for accelerated bone ingrowth. By compression of the in-
growing bone tissue, tissue formation can be stimulated. Using compressive
stimulation on samples in bone chambers in rabbits showed the dependency
of tissue ingrowth on stimulation amplitude (see Figure 6.2a) [9]. Guldberg
et al. [10] developed a bone chamber which allowed a stimulation of a bone
graft with a hydraulic piston (see Figure 6.2b), showing an increase of tra-
becular bone surfaces after a few days of loading [5, 10]. The same hydraulic
bone chamber design showed in experiments that mechanical stimulation
controlled the pattern of bone cell activity and gene expression [8]. Using
another mechanical principle, Ta¨gil et al. [7] used a bone chamber implanted
and fully covered by skin, which was used to apply loads on ingrowing bone
tissue by pressing from the outside on the incorporated piston (see Figure
6.2c). This study showed dense trabecular bone in the treated bone grafts
after manually applying a compressive stimulus. Similar to those bone im-
plants Duyck et al. [13] developed a repeatable bone chamber which used
an electromechanical actuator (piezo) to move a titanium implant inside the
bone chamber producing shear stress on the adhering tissue to study the
effect of movement on osteointegration.
These studies showed the applicability of in vivo bone chamber systems.
For the study of larger bone defects and the testing of biomaterials with
and without compressive load it is necessary to develop a new reusable bone
chamber system for large scaffolds. The applicability for large scaffolds of
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different compositions constitutes a novelty in this field of application.
6.2 Objectives
The goal of the presented study was the development of a new reusable bone
chamber system for large scaffold dimensions (6 mm diameter and 12 mm
length) for implantation in the medial side of proximal dog tibia. The bone
chamber system was developed for the testing of the integration of different
porous biomaterials into a critical bone defect and investigating the role
of material properties for tissue ingrowth and development. Additionally a
compressive loading device was developed to compress the samples in situ
to investigate the influence of mechanical stimulation on tissue ingrowth
and differentiation. The scope of this work spanned the development of a
repeatable implanting system, including tools for implantation and sample
extraction and the development of a compression device, which allowed the
cyclic compression of the samples. The system was developed for the surgical
environment for the in vivo animal experiments. The large dimension of the
reusable bone chamber used primarily for the testing of synthetic porous
materials in vivo constitutes a novelty in the field. The results of these
studies will be a valuable input for further research in bone regeneration
modelling based on the scaffold tissue engineering approach, which was not
in the scope of this thesis project.
6.3 Material and methods
6.3.1 Experimental procedure
To develop a bone chamber system for the implantation of large porous scaf-
folds in vivo with the addition of compressive stimulations, the procedure for
the system had to be determined as a first step. A priori it was decided that
the bone chamber implant system should consist of an external self threading
chamber and an internal chamber to hold the implanted scaffold which could
be exchanged subsequently. After consulting the surgical team of the Rof
Codina foundation (Department of Veterinary Clinical Sciences, University
of Santiago de Compostela), the experimental procedure was broken down
Material and methods 157
into five phases. Consequently the design of the bone chamber system was
oriented on this general guideline.
The 5 phases were:
I Implantation of the external bone chamber.
In the first phase, a hole was drilled into the medial side of the proximal dog tibia.
The external chamber was then threaded into the bone. This required a special
focus on a suitable drill bit, a self-cutting thread and suitable tools for connection
of the external chamber to a handle or drill.
II Osteointegration of the external chamber.
In the second phase, the external bone chamber was left for three month to allow
the osteointegration of the chamber. During this time ideally the apertures, which
were later used for tissue ingrowth, were closed to prevent the filling of the external
chamber with tissue.
III Insertion of the scaffold and internal cage.
In the third phase, the scaffold was inserted into the external chamber using an
internal cage. The internal cage was needed to align the scaffold and to protect the
sample during the later extraction procedure.
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IV Stimulation and tissue ingrowth phase.
During the fourth phase, the scaffolds were left in the chambers for either 4 or
12 weeks. Part of the samples were compressed cyclically in weekly repetitions.
V Sample extraction and replacement.
The fifth phase was the extraction of the samples by cutting the ingrown tissue
between the internal and external chamber wall with a trepan. The intention was
to preserve samples and part of the ingrown tissue during the extraction procedure.
Directly after extraction, a new scaffold could be inserted into the external chamber.
The detailed design of the system for the determined phases is explained in the fol-
lowing section. The dimensional plans of the components are presented in Appendix
E.
6.3.2 Development of the bone chamber system
6.3.2.1 Implantation of the external bone chamber
The core diameter of the external chamber was determined to be 11 mm. To
thread in the chamber into bone, a hole of 11 mm diameter had to be drilled
beforehand. In a market research on orthopaedic bone drill burrs, no burr in this
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Figure 6.3: The shank of a commercial 11 mm HSS burr was modified to fit into a
surgical drill.
size could be found. As shown by a study by Natali et al. [16] it is possible to use
commercial available high speed steel (HSS) burrs in orthopaedic surgery. Based on
this finding, 11 mm commercial HSS burrs were purchased and modified for use in
the planned experiments. The dimensions of the burr shanks were copied from an
existing surgical bone drill, which was provided by the surgical team. Because the
composition of the burr material was unknown, the modified surfaces were tested on
corrosion by immersion in 5 % saline solution for 5 minutes and storage for 1 hour
at 37 ◦C. The concentration of saline solution was lent from standard ASTM B117
[17]. The surfaces were inspected before and after the corrosion test to determine
further anti-corrosive treatments.
For the insertion of the external chamber, an assembly was realized consisting
of an insertion tool (Material: Stainless steel AISI 01) fixated to the external bone
chamber (Material: Ti6Al4V) by two metric screws (Material: Ti6Al4V, M3x6)
and a PTFE spacer, which kept debris and ingrowing tissue out of the external
bone chamber interior (see Figure 6.4). The insertion tool featured the same shank
dimensions as the bone drill burr.
(a) (b)
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Figure 6.4: Assembly of the components for bone chamber insertion. (a) Explosion,
(b) assembly and (c) cross-section of the components.
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The external bone chamber had a thread for cortical bone, which was taken from
standard ASTM F543 [18] and four cutting flutes on the bottom for threading into
the bone. The thread was based on an 11 mm core diameter, which gave a wall
thickness of minimal 0.75 mm for the hollow bone chamber. For later tissue ingrowth
four apertures were provided in the external chamber wall with 6 mm length and
a width of 4 mm. In total the external chamber had a diameter of 22 mm and a
length of about 20 mm. The external bone chamber is depicted in Figure 6.5 with
the four different development stages.
The drilling of the hole and the threading of the external chamber was tested
in dog cadaver tibia at the veterinary hospital Rof Codina.
(a) (b) (c)
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Figure 6.5: The four different development versions of the external chamber. (a)
The first version, shown here with the insertion tool attached, proofed to be too
long. The second version (b) was shortened. In the third version (c) the apertures
were positioned further down. For the fourth and final version (d) the dimensions
of the head were minimized.
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6.3.2.2 Osteointegration of the external chamber
The insertion tool was taken off the bone chamber and the wound was closed over
the implant for the osteointegration of the external bone chamber. As pictured in
Figure 6.6 the external chamber was located in the tibia with the apertures on the
level of trabecular bone. The contained spacer had a metric thread on its top to
facilitate the extraction if needed.
(a) (b)
(c) (d)
Figure 6.6: The assembly and location of the external bone chamber in the dog
tibia during osteointegration. (a) The fabricated components, (b) explosion view,
(c) assembly of the components and (b) cross-sectional view.
6.3.2.3 Insertion of the scaffold and internal cage
For the insertion of scaffolds after the osteointegration phase, two different assem-
blies were developed, depending on whether compressive stimuli were to be applied
or not. For scaffolds which were not subjected to compression, the assembly con-
sisted of the internal cage, which contained the scaffold, and a cap to close the
scaffold compartment (see Figure 6.7).
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(a) (b)
(c)
Figure 6.7: Assembly of components for the insertion of scaffolds without compres-
sive stimulus. (a) The fabricated components, (b) explosion and (c) cross-sectional
view of the assembly.
Both cap and internal cage were fabricated from titanium (Ti6Al4V). The in-
ternal cage had a profile on the top, which was aligned with its counterpart in the
cap. The cap itself had notches on the top, so that aligning the notches of the cap
with the threaded holes on top of the external chamber aligned the apertures of
the internal cage with the apertures of the external chamber (see Figure 6.8). The
internal cage had an internal diameter of 6.2 mm, a wall thickness of 0.4 mm and
apertures matching the dimensions of the external chamber. The total opening was
giving access to about 36 % of the lateral surface of the scaffold. The distance of
scaffold surface to core diameter of the external chamber thread was about 2.5 mm,
a gap that had to be bridged by ingrowing tissue. This assembly was left covered
by skin tissue for the 4 or 12 weeks of planned tissue ingrowth.
The assembly for the compression of scaffolds in vivo contained the same in-
ternal cage as previously described. Instead of the cap, a connector (Material:
Ti6Al4V) was fixated with two metric titanium screws to the external chamber.
The connector aligned the apertures of the internal cage in the same manner as the
previously described cap. Additionally the connector incorporated a piston consist-
ing of a pole (Material: Ti6Al4V) screwed to a PTFE head or a titanium piston
head for compression of stiff materials. The piston could be held in position with
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(a) (b) (c) (d)
Figure 6.8: Alignment of the apertures for tissue ingrowth. The internal cage (a)
had a profile on its top which corresponded to the profile in the cap (b). The cap
and internal cage (c) was then inserted into the external cage. The cap notches
aligned with the holes did ensure the alignment of the apertures (d).
a plastic clip (1.5 mm rings of FEP tubing, cut open on one side). The connector
penetrated the skin tissue for the connection of a compression device. The connec-
tor could be closed off for the periods of no stimulation with a protective cap, where
the cap was secured with a headless screw (see Figure 6.9).
6.3.2.4 Stimulation and tissue ingrowth phase
After the insertion of the scaffolds into the bone chamber, it was intended to leave
them for 4 or 12 weeks. In the case of compression of the scaffolds, a compresion de-
vice was coupled to the bone chamber weekly. The development of the compression
device is broken down in Sections 6.3.3 and 6.3.5, to explain in depth the function
of its electronics, hardware and software.
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(c)
Figure 6.9: Assembly of the components for scaffolds intended for compressive
stimulation. (a) Fabricated components, (b) explosion and (c) cross-sectional view
of the assembly.
Material and methods 165
6.3.2.5 Sample extraction and replacement
After the desired period of tissue ingrowth, the skin over the implant was opened
and the cap or connector taken off. With a dental trepan (Art.Nr. 227B.204.090
from Komet Dental, internal height 12 mm, internal diameter 7.9 mm, external
diameter of 9 mm) it was possible to cut between internal and external chamber
to extract the sample (see Figure 6.10). After trepanation a new internal cage
containing a scaffold could be inserted.
(a) (b)
Figure 6.10: Trepanation of the sample for the extraction and insertion of a new
scaffold.(a) The gap between internal cage and external chamber was used to insert
a dental trepan. (b) The trepan cut with a depth of 12 mm down to the bottom of
the gap.
6.3.3 Electronics and hardware development
The in vivo compression system for the bone chamber consisted of the compression
device, a metal casing containing electronic control and measurement components
and a laptop computer running custom developed software. The software on the
laptop was controlling the movement of the linear stepper motor by giving out
digital signals over a data I/O interface to the motor controller board. The dis-
placement resulted in a compression which was measured with a force sensor. The
resulting force signal was then amplified and read out by the data I/O interface. All
components implicated in these processes are depicted in Figure 6.11. The function
of the components are explained in the subsequent sections.
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Figure 6.11: Block diagram of the electronics components. A laptop controls over
the digital output (Dout) and analogue input (Ain) of a data interface the linear
stepper motor and force measurement.
6.3.3.1 Control and measurement electronics
All electronic components were contained in a metal casing, shielding the measure-
ment equipment against external noise and protecting the user against electrical
damages. The exterior of the box is depicted in Figure 6.12a. The user had access
from the exterior to a 4-pin connector to connect the force sensor, a 6-pin connector
for the stepper motor, a switch to turn on or off the power source and a connector
for the main power. An air inlet at the top allowed to move air through the box to
the air outlet on the side to cool off the electronic components. The box contained
a signal amplifier for the force sensor signal, a voltage source for all components,
a voltage converter for the force sensor and amplifier, a motor controller board for
the driving of a stepper motor, a relay for switching on and off motor and controller
board, an USB digital analogue interface and a cooling fan. The location of the
components is indicated in Figure 6.12b.
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(a) External view of the electronics box, holding control and measure-
ment components.
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(b) View of the internals of the electronics box. The location of the individual
electronic components is indicated.
Figure 6.12: Metal casing containing electronic components to control motor move-
ment and measure force signals.
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Stepper motor controller board The stepper motor controller board (RSSM2,
RS-online, Art. No.: 240-7920) used was appropriate to drive an unipolar stepper
motor with four phases. The board was supplied with 12 VDC and was able to drive
up to 2 A through the motor windings. The connections of the controller board are
listed in Table 6.1.
Pin Description Connected to:
Control panel
+5V 5V output (logic high) Not connected
ENB Enables the CKl input DO3 on USB interface
H/F Half or full step GND
DIR Direction DO2 on USB interface
WAV Wave mode GND
DIS Disables the CKl input GND
CK0 Clock output Not connected
CKl Step rate input DO0 on USB interface
Motor panel
0VL Ground of the motor GND
+VL Controller power supply +12V of the power supply
PHD Motor winding ‘D’ Phase Q2 on motor
PHB Motor winding ‘B’ Phase Q4 on motor
PHC Motor winding ‘C’ Phase Q1 on motor
PHA Motor winding ‘A’ Phase Q3 on motor
+VM Motor voltage VM on motor
0VM Logic low Not connected
Table 6.1: Connections of the motor controller board.
Relay It was observed that the stepper motor run hot, when it was left in stand-
by. By using a relay (T-5, Cebek Electronics Circuits) it was possible to turn off the
power supply of the motor and the motor controller board. The relay was powered
by the 12 VDC source and the signal for switching was taken from the DO1 port of
the data I/O interface. The connections of the relay are depicted in Figure 6.13.
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Figure 6.13: The connections of the power supply relay. Schematic modified from
the user manual of the relay board.
Data I/O interface For controlling the actuator movements and measuring
voltages, an interface (Meilhaus RedLab 1008) was chosen which was connected
to the designated laptop using a USB connection. With a resolution of 11 bits
in differential mode, a voltage resolution of 0.48 mV ( 1V
211
) could be achieved by
the analogue input of the interface. The analogue input was used to control the
function of the 12 VDC source and the 10 VDC converter and to measure the
output of the amplified force sensor signal. The digital output was used to set the
logic levels on the relay and motor controller board. The connections of the Redlab
data I/O interface are listed in Table 6.2. LabView drivers were provided by the
manufacturer, which facilitated the later software development. For the correct
function of the interface, the Meilhaus software InstaCal (Version 5.7.2) had to be
installed on the laptop.
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Pin Connected to: Description
Differential analogue inputs
CH0-CH1 Signal amplifier Measures the voltage output of
the force signal amplifier.
CH2-CH3 10VDC converter Measures the correct function of
the 10VDC output.
CH4-CH5 12VDC power supply Measures the correct function of
the power supply.
Digital outputs
DO0 Motor controller board ‘CKl’ Step rate of the motor.
DO1 Relay Switching motor power supply.
DO2 Motor controller board ‘DIR’ Direction of the motor move-
ment.
DO3 Motor controller board ‘ENB’ Enables the step rate input.
Table 6.2: Connections of the data I/O interface.
12 VDC power supply The motor and motor controller board were supplied
by a 12 VDC source. Because the motor had a specified current per winding of
0.42 A, which sums up to 1.7 A when windings are active, the power supply had
to provide more than 20 W power (P = 1.7 A × 12 V = 20.2 W). For this reason
a 50 W supply was purchased (ZWS50-12, Coutant Lambda). The connection to
the mains connector was secured by two fuses (Schurter, 5A). A flip switch was
inserted into the circuitry to turn the power supply on and off (see Figure 6.14).
The power supply was covered with a metal casing, which was connected to common
ground, to prevent influence on other electronic components. The metal casing of
the electronics was connected to the common ground as a security measure.
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Figure 6.14: Connection of the 12 VDC power supply to the mains connector. The
connection was secured by two fuses.
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Voltage converter To achieve a stable 10 V direct current source for the force
sensor and signal amplifier a voltage converter was built. The converter was based
on a LM2940 regulator (National Semiconductor) which could drive up to 1 A.
The input voltage was 12 VDC directly connected from the power supply. The
10 VDC output was stabilized with a 22 µF capacitor as suggested in the regulator
manual. The LM2940 chip was equipped with a cooling sink (Aavid Thermalloy
PF720, 28.9 K/W), to protect it from overheating. The voltage converter circuitry
is depicted in Figure 6.15. The voltage converter was tested by connecting the
12 VDC power supply to the input and measuring the voltage on the output with
a multimeter (Noru, NR-908-140).
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Figure 6.15: Voltage converter for the stable regulation of 10 VDC from a 12 VDC
source. (a) Wire diagram of the voltage converter. (b) Connections of the voltage
converter board.
Cooling fan To move air over the electronic components for cooling, a fan (ebm-
pabst, 612FH) was installed. The fan was connected directly to the 12 VDC power
supply taking up a power of 1.4 W. The fan run whenever the power supply was
switched on. The fan sucked in air from the top of the electronics box which exited
through the side. The air inlet and outlet were placed in a manner which guided
the airflow over the power supply, voltage converter, motor controller board and the
relay board. These components were suspected to generate the most heat inside
the electronics box.
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Signal amplifier The force sensor used in the compression device had a signal
output of 0 mV - 100 mV corresponding to applied forces of 0 N to 100 N. To
improve the signal for the later conversion from analogue voltage to a digital value,
a signal amplifier was used. It was intended to amplify the sensor signal to up to
1 V. The advantage of this was the use of the whole measurement range of ±1 V
of the USB data I/O device, which allowed a voltage resolution of 0.48 mV. Higher
amplifications would force the use of the next higher measurement range of ±10 V,
which would result in a lower resolution of 4.8 mV. A basic inverting amplifier was
implemented using an 8-pin TL071 operational amplifier (Texas Instruments) (see
Figure 6.16). The amplifier was connected to 10 VDC as a power source which was
stabilized on the same circuitry board by a 220 µF capacitor. This amplifier had
an amplification factor of -10 (Equation 6.1) [19].
G = −
R2
R1
= −
100kΩ
10kΩ
= −10 (6.1)
The signal amplifier was tested by applying a direct current voltage at the input
with a 1.5 V battery connected to a potentiometer. The input and output voltage
was measured with a multimeter (Noru, NR-908-140).
Material and methods 173




	





 








  






Figure 6.16: Signal amplifier realized for the amplification of the force sensor signal
voltage. (a) Circuit diagram of the signal amplifier based on the TL071 operational
amplifier with an amplification of -10. (b) Actual build of the amplifier on proto-
typing board. (c) Indication of the connections of the circuit and the situation of
the electronic parts. The resistors are on the backside.
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6.3.3.2 Device for in vivo compression of scaffolds
For the compression of the implanted scaffolds in the bone chamber, a device was
developed which was coupled weekly to the implant. The device consisted of a
handle, which was fixated on the bone chamber and a moving axis, which was
fixated on the piston of the assembly. The device contained a linear stepper motor
for movement of the piston and a force sensor for the measurement of the occurring
forces .
Linear actuator A stepper motor was chosen as linear actuator, allowing a
large displacement at high forces. The stepper motor (Danaher motions, 42DBL10C2U-
L12) was a unipolar motor with four windings (see Figure 6.17) which could move
a force of 100 N at a step rate or 300 steps per second. The displacement of every
step was 25.4 µm. The power consumption of the motor was specified with 10 W
at 12 VDC supply. According to its datasheet, the motor had an axial backlash of
150 µm.
 
Figure 6.17: The stepper motor used for linear displacement. A picture of the
stepper motor (a) taken from the manufacturers datasheet. The wire diagram (b)
shows the four windings of the motor and the connection of the six wires.
Material and methods 175
Force sensor The force sensor of the device (XFTC310, FPG Sensors and In-
strumentations) was appropriate for a maximal force measurement of 100 N. The
output signal of the sensor ranged from 0 mV to 100 mV, depending on the applied
force. The sensor worked as a Wheatstone bridge (see Figure 6.18), where force and
output voltage had a linear relation. The sensor needed a stabilized voltage source
of 10 VDC to function correctly.
 
Figure 6.18: Miniature force sensor XFTC310 used in the compression device. (a)
Picture of the force sensor from the manufacturer datasheet. (b) Representation of
the sensor as Wheatstone bridge with the four connections.
Compression device The device used for the in vivo compression of scaffolds
incorporated the linear stepper motor and force sensor described beforehand. The
linear stepper motor pushed down its threaded axis, which was connected to the
force sensor. The axis was prevented from turning around the length axis by tight-
ening a fixation nut which pushed against the force sensor. The force sensor itself
was threaded into a stainless steel (ASTM A176 [20]) block, mounted on a preci-
sion linear slide (IKO Nippon Thompson, BSR1540SL). A fixation nut secured the
threading of the force sensor to the block. The block provided on the opposed end
a bolt thread for threading of a miniature drill chuck, which by turning could be
closed or opened. To minimize the backlash of the stepper motor, a spring loaded
tension system was implemented on the top of the motor (see Figure 6.19). A com-
pression spring (Springmasters, D12030, free length 56 mm, 0.81 N/mm) hidden
in an aluminium casing was pulling the motor axis upwards, so that no backlash
occurred when the motor changed directions. By tightening the axis fixation nuts
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on top of the mechanism the pull up force could be adjusted.
The aluminium handle, which held the components, was used to fixate the
stepper motor and the linear guide. The handle was used by the user to hold the
device while fixating it to the bone chamber implant. Additionally the handle did
serve as a heat sink for the stepper motor which did dissipate heat during activation.
At the tip of the handle a hole was provided for the fixation for the bone chamber
implant. The handle was slid over the implant connector. A threaded ‘L’-shaped
fixation screw was then used to press the cleft end of the handle together against
the cylindrical connector.
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Figure 6.19: Working principle of the mechanism for the reduction of axial backlash
of the linear stepper motor. A spring pushes the thread of the motor axis against the
thread of the rotating part of the motor. (Not all components of the compression
device design are shown here.)
The parts of the compression device are depicted schematically in cross-section
in Figure 6.20a. The connection to the implanted bone chamber is shown in Figure
6.20b. Figure 6.21 shows the assembled compression device.
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(a) Schematic cross-section through the compression device,
connected to the bone chamber implant.
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(b) Close-up of the fixation of the bone chamber implant to the
compression device.
Figure 6.20: Schematic cross-section of the compression device, depicting its com-
ponents.
178 Development of an in vivo Bone Chamber System
	 
	
 


 

 
 
 

 
 
 
 

	
(a) The assembled compression device with indication of the components.
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(b) Close-up of the cleft end of the handle and the linear guide in a partial
assembled device.
Figure 6.21: Photographs of the compression device used to compress scaffolds in
vivo.
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6.3.4 Validation of the compression device
6.3.4.1 Minimal time step
One critical parameter for the compression device was the minimum time needed
for one step, where one step included the output of two digital signals (a ‘1’ followed
by a ‘0’ to activate the step) and the input of the analogue force signal. LabView
programs were written to measure the time needed for digital output and analogue
input. Both programs measured 100 times the time needed for the respective func-
tions. The programs are depicted in Figure 6.22.
(a) LabView program used to determine the time for digital output.
(b) LabView program used to determine the time for analogue input.
Figure 6.22: LabView programs to measure 100 times the time needed for digital
output or analogue input.
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6.3.4.2 Calibration of the force measurement
To calibrate the force measurement of the force sensor, the resulting voltage was
measured at different loadings. For the measurements the force sensor was mounted
in a test rig (see Figure 6.23). The rig consisted of an acrylic base plate (1.5 mm
thick) on which the force sensor was mounted vertically with a stainless steel screw.
Guided by four rods, a movable stage was rested on the force sensor. On top of the
movable stage, weights could be positioned to apply loads to the sensor.
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Figure 6.23: The test rig used to test the force measurement consisted of a movable
stage guided by 4 rods and resting in a right angle on the force sensor. Weights
were placed on the movable stage to apply force on the sensor. The force sensor
was mounted on a base plate and a movable stage rested on top of the force sensor.
The motor and force sensor were connected to the electronics, which was connected
via USB to the laptop computer. A LabView program was written, using the
algorithm for reading the analogue data from the data I/O. The software read out
the analogous signals on three ports every 50 ms and displayed them on screen (see
Figure 6.24). The first port was connected to the signal amplifier and its range was
set to ±1 V. The setup of the force measurement included all electronics used in the
final device. This ensured that the measurements were made in the configuration
of later use.
For the application of loading on the force cells, weights were purchased (2×0.5 kg,
5×1 kg and 2×2 kg). The exact weight was determined by weighing on a scale (Mea-
sure Tech MB-2610). The weights were then placed on the movable stage of the test
rig in approximately 10 N steps. The resulting voltage measurements were read of
the display. Measurements were conducted in triplication.
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Figure 6.24: Software for the measurement of voltages for different forces applied
to the test rig.
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6.3.4.3 Displacement validation
To verify the software control of the piston movement, the displacement was mea-
sured as a function of the step number controlled by the software. A software was
written in LabView to displace the piston (see Figure 6.25). The user had the pos-
sibility to enter the number of steps for displacement and select the direction. A
displacement of 5 to 25 steps was measured with a micrometer (NSK, resolution
0.01 mm), displacements of 25 to 250 steps were measured with a caliper (TESA
Shopcal, resolution 0.01 mm). All measurements were done in triplicate.
6.3.4.4 Motor temperature
One of the concerns of the developed compression device was the heat dissipation of
the used linear stepper motor. To measure developing temperatures, a temperature
sensor was applied to the metal motor casing. The sensor was a K-type thermocou-
ple connected to a thermometer (RS1313). For the measurement, the compression
device was used for 10 minutes of linear compression of 508 µm at 0.5 Hz. After
the compression the system was left five minutes to allow the cooling of the motor.
This procedure was repeated four times, while the temperature was measured every
minute.
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Figure 6.25: Software for the evaluation of the displacement in dependency of the
step numbers.
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6.3.4.5 Compression of different scaffold materials
For the validation of the compression device, different compression tests were con-
ducted to ensure the function of the device with the porous materials intended to
implant. For this purpose the device was used to measure forces under compression
with no sample, PLA/glass composite, glass ceramic and nickel-titanium in the in-
ternal chamber. The fabrication of the materials is explained in further detail in
Chapter 7.
Interference in force measurement during compressive movement
To measure the effect of friction on the measurements with materials, a measurement
was conducted without materials. A bone chamber was mounted with internal
chamber and compression device connector including the piston. The compression
device was then fixated on the connector and the piston. Three tests were conducted
with different assemblies of piston, internal cage and connector. Ten cycles were
completed of 508 µm compression at 0.5 Hz. Force measurements at every step
were obtained.
PLA/glass composites Three samples of the PLA/glass composites were
tested under cyclic compression. The sample dimensions were measured with a
calliper (TESA Shopcal) before, directly after, 3 hours after and 24 hours after
compression to determine if the samples experienced a permanent deformation. The
samples were compressed 609.6 µm for 450 cycles at 0.5 Hz. Force measurements
were documented at every step.
Glass ceramics To measure the elastic modulus and the maximal stress of
the glass ceramics, eight samples were tested on a commercial mechanical testing
equipment (Adamel Lhomargy, DY-34) with a 10 kN force cell and a compression
velocity of 1 mm/min. To test the developed compression device, five glass ceramics
samples were compressed 127 µm in 450 cycles at 0.5 Hz with a titanium piston
head. The sample length and diameter was determined before and after compression
with a calliper (TESA Shopcal). Of these compressive tests, the elastic modulus
was determined and compared to the previously determined modulus.
Nickel-titanium Of the porous nickel-titanium scaffolds supplied, only one was
available for testing the developed compression device for the cyclic compression.
The piston head used was fabricated of titanium. The sample dimension was mea-
sured with a calliper (TESA Shopcal) and compressed three times for 10 cycles at
0.5 Hz with compressions of 25.4 µm, 50.8 µm, 76.6 µm, 101.6 µm and, 127 µm.
Material and methods 185
The resulting maximum and minimum forces were used to calculate the compressive
modulus.
6.3.5 Software development
For the compression device a software was developed for control the linear stepper
motor movement and the measurement of occurring forces, using LabView (Version
8.0). The software provided a graphical user interface to give easy access to the
functions of the device to the surgical team, which was meant to use the compression
device without supervision after an introductory training. The software showed the
compression parameters, the state of the system for the compression procedure, a
real-time graph with the displacement and the measured force and the software
generated a file with all measurements.
Compression procedure The function of the software was integrated in the
procedure for the in vivo sample compression:
1. To start, the laptop was turned on.
2. The electronics box was connected to the mains and via USB to the computer.
3. The software was started.
4. The electronics box was turned on, after connecting motor and sensor of the
compression device.
5. In the software settings, the material type to be compressed was selected.
6. The protective cap was removed from the implanted bone chamber.
7. The piston fixation was opened.
8. The compression device was connected to the implanted bone chamber by
use of the clamping mechanism.
9. The piston fixation was driven down to the piston by the software.
10. The piston fixation was closed.
11. The compression was started by the software.
12. The measured forces were saved in a ‘.txt’ file.
13. After the compression procedure, the piston fixation and handle clamp was
opened and the compression device taken off the implant.
14. When all compressions were finished, the software was closed.
15. Finally the electronics box was turned off and the computer shut down.
186 Development of an in vivo Bone Chamber System
While the software had to comply to the selected procedure of application, it also
had to ensure the safety of user and the equipment itself. Therefore during the
manual positioning of the linear actuator and the automatic compression the soft-
ware protected the device from overloading. During movement of the linear stepper
motor, the occurring force was monitored and, when a force larger than a set limit
was detected, the motor moved two steps (50.8 µm) in the opposite direction of
the actual movement and finally stopped. The software also monitored the correct
function of the 12 VDC source and the 10 VDC converter by measuring the volt-
ages. If an unexpected failure occurred during the automatic compression phase,
the user had the possibility to cancel the compression. Whenever the linear stepper
motor was not used, the software turned the voltage source for the linear stepper
motor off, to protect the motor and controlling electronics from electric surge and
to let the motor cool off.
Compression movement The movement of the piston for the compression
was broken down into different phases to guarantee the same positions and off-
set measurements for different bone chamber assemblies. When the compression
was started, the piston was in the position in which the piston was fixated to the
compression device. In this position the offset force was measured. The piston
was then moved upwards to the mechanical limit. This was considered the defined
start position for all compression sessions. The piston was then moved down to the
surface of the scaffold either by sensing the resistive force of the scaffold or by a
fixed displacement. When the scaffold was reached, the cyclic compression was ini-
tiated according to the compression protocol. After completing the compressions,
the piston was moved up to the initial position, in which the piston was fixated. A
schematic of the piston movement is depicted in Figure 6.26.
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Figure 6.26: Movement of the compression device piston realized by the developed
software.
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Parameters of the compression To have the possibility of adjusting param-
eters for the compression after compilation of the executable software, a settings.ini
file was provided containing the following content:
#maxforce:100;[N]
#uplimit:3;[N]
#stepsize:25.4;[um]
’Calibration Values of Sensor + Amplifier
#slope:14.4;[mV/N]
#maxwayup:200;[steps]
#maxwaydown:200;[steps]
Additionally parameters for the different compressed materials were provided in
their respective protocol files, which are presented in Table 6.3.
Scaffold materials
Parameters Nickel- PLA/glass Glass- Unit
titanium composite ceramics
File name niti.txt pla.txt glass.txt -
#Waveform triangle triangle triangle -
#Frequency 0.5 0.5 0.5 Hz
#Cycle number 450 450 450 -
#Compression 127 508 127 µm
#touchforce 5 999⋆ 5 N
#waytogo 2 2 2 mm
Table 6.3: Protocol files for the different material-dependent compressions. ⋆ When
the touchforce parameter was over 50 N, the piston was moved towards the sample
with a discrete displacement instead of depending on the measured force.
These parameters had the following significance in the compression procedure.
When the compression device was fixated to the implant and the compression was
started, the piston was pulled up until a force bigger then the specified parameter
‘#uplimit’ from the ‘settings.ini’ file was reached. At this point the piston was
at the upper mechanical limit, which was considered the start position for every
compression. If the force was not detected until step number ‘#maxwayup’, a
warning was shown and the procedure cancelled, because it was considered that the
piston was not fixated on the linear actuator.
Depending on the protocol selected previously, the piston moved then down
for a fixed displacement (‘#waytogo’ from the protocol file), or the piston was
moved down until a certain force (‘#touchforce’ from the protocol file) was detected,
indicating the touching of the sample. If the force was not detected until step
number ‘#maxwaydown’, a warning was shown and the procedure cancelled, to
protect the compression device.
When the piston was touching the sample, the compression cycles began, with
a cycle number defined as ‘#Cycle number’ in the protocol file with a displacement
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of ‘#Compression’ at a frequency of ‘#Frequency’. The waveform was chosen by
the ‘#Waveform’ parameter. The developed software supported triangular and
sinusoidal waveforms. When the cycle number was completed or the compression
cancelled, the piston was moved up to its start position.
During the compression and the manual positioning of the compression, the
device was protected from overloading. During movements of the linear stepper
motor, the occurring force was monitored and, when a force larger than ‘#maxforce’
from the ‘settings.ini’ file was detected, the motor was moved two steps into the
opposite direction of the actual movement.
Software structure The software was organized into routines which are listed
with a short description in Table 6.4. For the comprehension of the detailed func-
tion, screenshots of all subroutines are provided in Appendix F as well as flowcharts
showing the logical operation and dependencies of the subroutines in Appendix G.
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main.vi: Main application; Windows of the GUI.
Input: - Output: -
2stepsback.vi: Drives the actuator two steps upwards.
Input: - Output: -
2stepsdown.vi: Drives the actuator two steps downwards.
Input: - Output: -
calcsinus.vi: Generates a sinus value at a given timepoint for the displacement.
Input: - Displacement l
- Max. displacement lmax
- Frequency f
Output: Time t
choose protocol.vi: GUI menu for choosing a protocol and input animal ID.
Input: - Output: - Protocol name
- Protocol path
- Patient ID
- Touch force [N]
- Frequency [Hz]
- Cycle number
- Compression [µm]
- Waveform
control10V.vi: Tests if the voltage source of 10V is within a range of ± 0.25 V.
Input: - Output: - “Voltage in range?” (T/F)
control12V.vi: Tests if the voltage source of 12V is within a range of ± 0.25 V.
Input: - Output: - “Voltage in range?” (T/F)
controltmin.vi: Measures 25 times the time needed to set DO twice and read
AI once and gives out the average.
Input: - Output: - Smallest timestep tmin
convert mV to N.vi: Converts the measured voltage to force, taking in ac-
count the offset and slope of the calibration.
Input: - Analog input signal [V]
- Offset [mV]
- From settings.ini: #slope
Output: - Force [N]
generate dt.vi: Converts a consecutive time array into differential time.
Input: - Time Array [s] (1D) Output: - dt Array [s] (1D)
generatesinus.vi: Generates a time point for every displacement step (uses
calcsinus.vi for calculation) for a wave.
Input: - Compression [µm]
- Frequency [Hz]
Output: - Time array [s] (1D)
- Step array [µm] (1D)
generatetotalwave.vi: Generates the overall waveform for all cycles (uses gen-
eratesinus.vi and generatetriangle.vi).
Input: - Compression [µm]
- Frequency [Hz]
- Number of Cycles
- Waveform
Output: - Total time array [s] (1D)
- Total step array [µm] (1D)
continued on next page
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continued from previous page
generatetriangle.vi: Generates a time point for every displacement step for a
triangle wave.
Input: - Compression [µm]
- Frequency [Hz]
Output: - Time array [s] (1D)
- Step array [µm] (1D)
get analog.vi: Reads the analog input voltage, converts it to force (using
convert mV to N.vi).
Input: - Offset [mV]
- Voltage range
Output: - Voltage [V]
- Force [N]
- Error Message
getoffset.vi: Measures 10 times the momentary force signal and calculates the
average.
Input: - Analogue measurement range Output: - Offset [mV]
- Offset [V]
limitsensoric.vi: Moves piston up, until the piston head hits its upper limit or
a certain number of steps have been exceeded.
Input: - #maxforce from settings.ini
- #uplimit from settings.ini
- #maxwayup from settings.ini
- Offset [mV]
- Analogue measurement range
Output: - “Overload?” (T/F)
- Number of done steps
pistontosample.vi: Moves the piston downwards for a certain number of steps.
Input: - #maxforce from settings.ini
- #waytogo from settings.ini
- Offset [mV]
- Analogue measurement range
Output: - “Overload?” (T/F)
- Number of done steps
pistonup.vi: Drives the piston up to its start position.
Input: - Number of steps
- Offset [mV]
- Voltage range
Output: - “Piston is at start position?”
(T/F)
timearray.vi: Takes a 1D array of half-wave time points and completes it to a
full-wave time point array.
Input: - First half time array [s] (1D) Output: - Time array for one cycle [s] (1D)
touchsensoric.vi: Moves the piston downwards, until the sample is touched or
a certain number of steps have been exceeded.
Input: - Offset [mV]
- Voltage range
Output: - Number of steps
- “Touching sample?” (T/F)
- “Overload ?” (T/F)
up down.vi: GUI: Allows user to drive the piston up and down manually.
Input: - Offset [mV]
- Voltage range
Output: - “Overload ?” (T/F)
Table 6.4: List of software subroutines, their function, input and output.
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Use of the software The software was provided to the user as an executable
file with the ‘settings.ini’ file in the same directory, the protocol files in a ‘protocols’
folder and a ’results’ folder containing the saved measurements. For the easy use,
links were provided on the desktop to the application and the ‘results’ folder. Exe-
cuting the compression device control software prompted to the user the main panel,
which included the display of protocol parameters, actual phase of the compression
procedure and a graph of displacement and measured force. The control buttons at
the bottom of the screen allowed the user to access the settings panel, the manual
displacement control, start the compression procedure and exit the software (see
Figure 6.27a). When the ‘Change Settings’ button was pressed, the settings panel
opened up (see Figure 6.27b). This panel allowed to choose the protocol used for
the compression (which depended on the scaffold material) and to enter the patient
identifier. The panel was closed by pushing the ‘OK’ button. When the ‘Manual
Actuator Control’ button was pressed on the main panel, a control panel appeared
which gave control over the movement of the linear actuator (see Figure 6.27c).
By holding the ‘UP’ button pressed, the actuator moved upwards, when ‘DOWN’
was held pressed, the actuator moved downwards. The control panel was closed
by pushing the ‘OK’ button. When the ‘Compress’ button on the main panel was
pushed, the compression procedure started. The actual phase of the procedure as
well as the compression and force were indicated in the main panel. After com-
pleting or cancelling by pushing the ‘Cancel’ button of the compression procedure,
the measured forces were saved in a file. The location of the file was displayed
for the user (see Figure 6.27d). When the ‘EXIT’ button of the main panel was
pushed, a reminder was shown that the electronics box had to be turned off before
disconnecting the motor and sensor (see Figure 6.27e). By pressing ‘OK’ the soft-
ware was then closed. The generated result file from the force measurement was
structured as presented in Table 6.5. Beneath the experiment date, the protocol
used and the Patient ID, four columns contained the time of every displacement
and the displacement value, as well as the time of force measurement and the force
value. The file name itself consisted of the start date and time of the compression
and the patient ID (e.g. 090310-13 24 43-Dummy.txt was created on March 10th
2009 at 13:24:43 for the patient ‘Dummy’).
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(a) Main screen of the software. Top left: Parameters of the chosen pro-
tocol and patient ID. Top right: Indicator of the phase of the compression
procedure. Middle: Indications of the compression and measured force
over time. Bottom: Control buttons.
(b) The settings panel allowed to select the proto-
col, displayed the protocol parameters and allowed
to insert the patient ID.
(c) Manual control
over linear actuator
movement.
(d) The notification of the di-
rectory of the saved result file.
(e) Reminder appearing before
exiting the program.
Figure 6.27: Screenshots of the developed software for control of the compression
device.
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10/03/2009 13:24
Protocol Name:PLA/Glass composites
Patient ID:Dummy
Step Time [ms] Displacement [µm] Force Time [ms] Force [N]
50 25.4 61 7.8566
100 50.8 117 8.8399
150 76.2 165 8.5686
... ... ... ...
Table 6.5: The result file generated after the compression contained information
about the date, patient ID and protocol used.
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6.4 Results
6.4.1 Implantation of the bone chamber
Surgical drill burr To provide a 11 mm burr for the bone chamber implanta-
tion, a commercial HSS burr was modified. It was found that the modified surfaces
tended to corrode heavily after immersion for 5 min in 5 % saline solution and 1 hour
at 37 ◦C (see Figure 6.28). To counter corrosion, newly modified burrs were treated
with physical vapour deposition with Chrome Nitrate at the modified surface prior
to sterilization and use.
(a) Surface of the modified drill
shank.
(b) Surface after corrosion test.
(c) Drill treated with chrome nitrate by PVD.
Figure 6.28: Modified drill burr without surface treatment. (a) shows the surface
before, (b) shows the surface after the corrosion treatment. Even after a short
period of 1 hour after wetting with 5% saline solution corrosion is observable. (c)
shows the burr shank treated by physical vapour deposition.
Use of the bone chamber system in the surgical environment The
implantation tools for the developed bone chamber systems were tested successfully
in dog cadaver tibia before the implantation of the chamber in the animal experi-
ments. Finally the function of the system was verified by implantation in dogs. The
protocol for the animal experiments is explained in detail in Chapter 7. The bone
chamber was implanted as shown in Figure 6.29. Before drilling the appropriate
hole for the bone chamber, a small diameter hole was drilled into the tibia. The
modified HSS drill was used to expand the hole and the bone chamber was threaded
in using the insertion tool. After taking off the tool, the wound was closed over the
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implant for the osteointegration phase.
After osteointegration, the implantation site was opened up, a scaffold was
inserted into an internal chamber, the protective cap was assembled on the internal
cage and the assembly inserted into the bone chamber (see Figure 6.30). The
wound was then closed over the chamber. When inserting the samples for later
compression, the actuator connector was assembled instead of the protective cap
(see Figure 6.9). This connector was protruding from the wound, which allowed the
compression device to be connected to the implant and the piston (see Figure 6.31).
When the sample was implanted for the intended period, the wound was opened
up again and the protective cap or actuator connector taken off. Cutting between
internal cage and external chamber with a trepan, the sample was taken out, leaving
the empty chamber ready for a new sample (see Figure 6.32).
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Figure 6.29: Implantation of the bone chamber. (a) Preparation of the dog leg for the implantation. (b) A small hole is drill for guidance in
the tibia. (c)+(d) The hole for the threading of the bone chamber was produced with the modified HSS drill. (e) The bone chamber with
the attached insertion tool was inserted in the hole and (f) threaded into the bone. The insertion tool was detached. (g) The skin was closed
over the implant. (h)+(i) Location of the implanted chamber in the medial side of the proximal tibia.
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Figure 6.30: For the insertion of the scaffolds, the implantation site was opened
(a) and the Teflon spacer taken out (b). The sample compartment was held free
of ingrowing tissue (c). The scaffold was inserted into the internal cage (d), the
protective cap assembled (e). The assembly was inserted into the bone chamber
and the wound closed (f). For the experiments with compressive load, the actuator
connector and piston was assembled instead of the protective cap.
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Figure 6.31: For the in vivo compression of implanted scaffolds, the developed
compression device was connected to the piston from the exterior.
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Figure 6.32: After the experiments, the samples were extracted from the bone
chambers. (a) The protective cap or actuator connector was taken off. (b) Between
internal cage and external chamber a gap was provided to (c)+(d) cut the samples
with a trepan out. The sample was then prepared for the histology.
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6.4.2 Electronics and hardware development
6.4.2.1 Signal amplifier
The signal amplifier realised for the amplification of the force sensor was tested
by application of constant voltages to its input. The resulting output voltage was
measured and is depicted in Figure 6.33. After application of a linear regression, an
amplification of -10.01 was observed. This was practically identical to the theoretic
amplification of -10 of the circuitry.
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Figure 6.33: Amplification measurement of the implemented inverting amplifier
circuitry.
6.4.3 Validation of the compression device
After development of the software for the compression device, several tests were
conducted with the device.
6.4.3.1 Minimal time step
Using the described method the time needed for setting the digital port and reading
out the analogue input was averaged over 100 measurements. It was determined
that the setting of the digital port needed 8 ms in average and the reading of
the analogue port needed 16 ms. For the compression device in every step, the
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step signal had to be set two times and the analogue input had to be read one
time, summing the time for one step up to 32 ms. The fixed minimal displacement
velocitiy (25.4 µm per 32 ms) was significantly limiting the possible frequencies
and amount of compression (see Figure 6.34). The frequency was calculated as
a function of the step number Nsteps, which depends on the linear displacement
scompression (see Equation 6.2).
f =
1
Nsteps × 32ms
;Nsteps = 2×
scompression
25.4µm
(6.2)
In the final software for the compression device, the smallest possible time step
was measured for every protocol to validate the applicability of the frequency and
compression parameters.
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Figure 6.34: The possible compression depth and frequency with a fixed minimum
time step of 32 ms and steps of 25.4 µm.
6.4.3.2 Calibration of the force measurement
The voltage resulting from the application of different forces on the force sensor was
measured for the calibration of the signal chain of force sensor, signal amplifier and
USB data I/O interface. The applied weight and the resulting voltage is listed in
Table 6.6.
The resulting voltage was related linear to the applied force (see Figure 6.35). The
sensitivity of of the force measurement system was determined with 0.0144 V/N.
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Weight [g] Force [N] Voltage [V]
0 0 -0.0822 ± .001
1030.2 10.1 0.0498 ± .006
1998.5 19.6 0.215 ± 0.025
3003.3 29.5 0.351 ± 0.014
3934.0 38.6 0.508 ± 0.050
4938.8 48.4 0.636 ± 0.047
5981.5 58.7 0.787 ± 0.044
6964.2 68.3 0.921 ± 0.024
7981.4 78.3 1.05 ± 0.02
9017.7 88.5 1.18 ± 0.01
10047.9 98.6 1.35 ± 0.04
Table 6.6: List of weights applied to the force sensor and the corresponding voltage
readings (n=3).
Taking into account the voltage measurement resolution of 0.48 mV, this implied a
force measurement resolution of 0.03 N ( 0.48mV
14.4mV/N ).
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Figure 6.35: Voltage resulting from the loading of the force sensor after amplification
(n=3). The slope of the regression line shows a sensitivity of 0.0144 V/N for the
measurement.
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6.4.3.3 Displacement validation
The displacement of the linear stepper motor at increasing step numbers was mea-
sured between 5 and 250 steps. The correlation between step number and dis-
placement can be seen in Figure 6.36. The measured displacement was determined
to be 25.0 µm/step. This was 1.5 % smaller than the theoretical displacement of
25.4 µm/step.
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Figure 6.36: The measured displacement showed a linear correlation to the steps
proceeded with the stepper motor.
6.4.3.4 Motor temperature
The motor temperature was measured over one hour, with the motor being active
for 10 minutes and cooling off for 5 minutes repeatedly. As can be seen from the
measurements (see Figure 6.37), the motor temperature rose steeply from room tem-
perature when the motor was activated for the first time. When the motor stopped,
the temperature dropped exponentially. By repeating the motor movements and
cooling phases, the maximum temperature of every activity was stabilizing at about
55 ◦C.
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Figure 6.37: The temperature measured directly on the motor casing measured over
one hour. The motor was active for 10 minutes and left for cooling for 5 minutes.
6.4.3.5 Compression of different scaffold materials
Interference in force measurement during compressive movement
Measurements of the occurring forces at compressive movements at 0.5 Hz frequency
and 508 µm displacement without scaffolds showed an interference signal. The force
signal was alternating synchronously with the piston movement and had a range of
about 5 N peak to peak (see Figure 6.38). The force wave form depended on the
different component assemblies which indicated that friction was the cause of the
signal.
PLA/glass composite After compression of the PLA/glass composites (at
0.5 Hz, 609.6 µm compression and 450 cycles) the force measurements were plotted
and compared to pure offset measurements (see Figure 6.39). The forces occurring
during compression of the composites could not be distinguished from the signal
of the measurement without sample. The expected force value at a compression of
0.6 mm (equaling 5 %) with a elastic modulus of the material of 130 kPa [21] was
0.2 N, too small to be determined reliably with the developed compression device.
Diameter and length of the PLA/glass composite scaffolds were measured be-
fore, directly after, 3 hours after and 24 hours after the compression cycles. The
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Figure 6.38: Three cycles of three measurements with different piston assembly
without a sample in the internal cage. The force signal is alternating with the
piston movement of 0.5 Hz frequency and 508 µm displacement.
three samples had a length of 11.6 mm ± 0.1 mm and diameter 5.9 mm ± 0.1 mm
before the compression. The dimensions were normalized to the initial values and
depicted in Table 6.7. Directly after compression, the samples were deformed about
1 %, but regained their length after 3 hours of rest. The diameter of the scaffolds
did not change significantly during compression.
Time after compression
0h 3h 24h
length 99.0 % ± 0.6 % 99.7 % ± 0.2 % 99.7 % ± 0.2 %
diameter 99.7 % ± 0.8 % 100.6 % ± 0.8 % 100.3 % ± 1.3 %
Table 6.7: PLA/glass composite scaffold length and diameter measured after cyclic
compression. Values are normalized to the dimensions before compression (n=3).
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Figure 6.39: Force measurements of three PLA/glass composites under compression
of 609.6 µm at 0.5 Hz in comparison to compression of an empty internal cage.
Only three of 450 cycles are shown. The resulting force measurements cannot be
distinguished from the interference signal in force measurement.
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Glass ceramics Eight samples of the porous glass ceramics were tested with
the Adamel test equipment. The samples had a diameter of 7.7 mm ± 0.5 mm
and a length of 12.5 mm ± 1.2 mm. The compressive modulus derived from the
stress-strain curves was 273.0 MPa ± 156.2 MPa, showing a wide range of moduli.
The yield stress was determined to be 6.3 MPa ± 1.4 MPa.
Five porous glass ceramic samples were compressed in the developed compres-
sion device (at 0.5 Hz, 127 µm compression and 450 cycles) and the resulting forces
were determined (see Figure 6.40a). Using the force measurements for every sample
at compressions of 76.2 µm, 101.6 µm and 127 µm of the first 10 cycles, it was
possible to calculate the compressive modulus for every sample. The stress-strain
curves of all samples are depicted in Figure 6.40b. From those curves a modulus of
244.9 MPa ± 42.8 MPa could be determined, which was about 10 % smaller that
the previous measured modulus. This result showed that the developed compression
device reproduced reliably the measurements of the commercial test equipment.
It was observed that over the course of 450 compression cycles the measured
force decreased (see Figure 6.41). The decrease of force is possibly caused by de-
struction of the micro-structure of the samples, even though it was ensured that
the compression of 127 µm kept the theoretic strain of the sample under the yield
point of 6.3 MPa with a maximal strain of 2.9 MPa (see Equation 6.3).
σ = E × ε = 273MPa×
0.127mm
12mm
= 2.9MPa (6.3)
The partial destruction of the samples was confirmed by the measurements of the
scaffold dimensions before and after cyclic compression. Table 6.8 shows the de-
crease in sample length about 1.7 %. The diameter of the samples was the same
after compression compared to the value before compression.
before compression after compression
length [mm] diameter[mm] length [mm] diameter[mm]
Sample 1 9.98 5.37 9.77 5.35
Sample 2 10.40 5.31 10.30 5.34
Sample 3 10.42 4.96 10.06 4.86
Sample 4 10.15 5.32 9.98 5.47
Sample 5 10.22 5.96 10.19 5.83
Mean 10.23 5.38 10.06 5.37
SD 0.18 0.36 0.20 0.35
Table 6.8: Length and diameter of the glass ceramics samples measured before and
after 450 compression cycles.
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(a) The average of force measurement for the first 10 of 450 compression cycles of 5 glass
ceramic samples.
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(b) Stress-strain diagram for the three largest compressions (up to 127 µm) for 5 samples
compressed in the developed device (n=10).
Figure 6.40: Force measurements and stress-strain curves resulting from the cyclic
compression of glass ceramics scaffolds.
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Figure 6.41: Graph of the average maximum forces achieved in every cycle of the
compression of glass ceramics samples (n=5). The maximum force decreased over
time.
Nickel titanium scaffolds One nickel titanium sample (11.8 mm length,
5.9 mm diameter) was compressed cyclically for 10 cycles with compressions of up to
127 µm. These compressions were repeated three times (see Figure 6.42a). The low
standard deviations showed the high repeatability of force measurements with the
same component assembly. From the force measurements stress-strain curves were
calculated and the compressive modulus was determined with 370.7 MPa (see Fig-
ure 6.42b). This value was only a third of the literature value of 1.2 GPa ± 0.4 GPa
given by the provider of the material [22].
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(a) Average force signals of sample compressions with nickel titanium (n=3). The mea-
surements showed a high repeatability at different compression displacements. Five cycles
of ten are shown.
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(b) Stress-strain curve for the compressions of nickel titanium scaffold (n=3).
Figure 6.42: Compression of nickel titanium scaffold.
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6.5 Discussion
In the presented study, a bone chamber system for repeatable implantation of large
scaffolds and additional mechanical stimulation was developed. The implantation of
the bone chamber system in the dog tibia showed feasible with the developed tools
and the selected procedure. The design took in consideration that the bone ingrowth
apertures were as big as possible to enhance the mass of ingrowing tissue as has
been shown in similar bone chamber design studies [15]. One limiting dimension of
the bone chamber design was the gap between internal cage and external chamber
which caused a distance of tissue to scaffold of 2.5 mm. In the subsequent study
(see Chapter 7) it has to be shown that tissue has the ability to cross this distance
and grow into the scaffold.
The bone chamber system was made as a portable device, which was an ad-
vantage for the use and manipulation in the operating theatre. The system was
equipped with a compression device with a displacement resolution of 25.4 µm, a
velocity of 0.79 mm/s, a maximal force of 100 N and a force measurement resolu-
tion of 0.03 N. The compression pattern applied with the device was programmable
and hence presented a high flexibility of the system, adapting the protocol to the
material properties of the used samples. Additionally, the software for the device
provided a graphical user interface, which made the use of the system easy for the
user. The system design allowed the easy transport and setup in the operating the-
atre. It had been shown, that the custom made circuitry was functioning correctly.
The signal amplifier was considered a crucial component, because it was treating
the force sensor signal before measurement and hence had to amplify reliably the
signal.
The testing device was tested to determine functionality and limitations. It was
found that the time needed for one step of the motor and the measurement of the
resulting force was limited to 32 ms. This limited the frequencies of compression
depending inversely on the maximum compression. The compression device could
compress samples up to 762 µm at 0.5 Hz, equalling 6.4 % of the 12 mm scaffolds.
The force of compression was limited to 100 N by the stepper motor. Hence the
compression displacement has to be adjusted to the stiffness of the scaffold materi-
als. The comparison of the range of compression with previous studies is difficult,
because the used systems applied rather forces than displacement on the implants
[5, 7, 8, 10].
The force measurement resolution of 0.03 N was deemed to be sufficient for
the measurement of occuring forces of the materials intended for the implantation
(PLA/glass composites, glass ceramics and nickel titanium). The testing with the
materials however had shown that the force measurement was limited by inter-
ferences during cyclic compression, which was attributed to friction during piston
212 Development of an in vivo Bone Chamber System
movement. The signal impeded the measurement of small force values, which were
expected for the PLA/glass composite materials. For the much stiffer glass ceramics
and nickel titanium the interference was negligible in comparison to the resulting
high force signals even at small compressions. In the case of the composite scaffolds,
it was suggested to use the force measurement to detect the ingrowing tissue, which
would constitute a higher resistance to compression.
After cyclic compression the composite scaffolds showed a deformation about
1 %, which disappeared within three hours. This showed that the material behaved
viscoelastic, whereas the deformation was small in comparison to the compression
(5 %).
The test measurements with the glass ceramics material have shown that the
developed system measured forces comparable to a commercial material testing
equipment. The cyclic compression showed a permanent deformation of the sam-
ples in the range of the overall compression, which might have been caused by
damage of the microstructure. The measured force during the cyclic compression
was decreasing with preceding cycles, which indicated that the destruction of the
sample appeared as fatigue. The forces at the last cycles indicated that the samples
were still compressed.
The measurements with nickel titanium have shown the reproducibility of the
force measurements. An elastic modulus of 370 MPa was determined which was
a third of the value given by the provider [22]. The specified value of 1.2 GPa
± 0.4 GPa for the Young’s modulus was in the range of similar porous titanium
materials [23–25]. It was suggested that the material properties were altered due to
the machining required to obtain scaffolds in the desired dimensions. The material
was not cooled during the treatment in the turning lathe, to prevent contamination
with the coolant. The generated heat might have influenced the mechanical prop-
erties of the nickel-titanium. It was excluded that other parts of the bone chamber
experienced larger deformation during compression than the sample and hence par-
tially prevent the compression of the sample. It was suggested that the weakest
part of the chamber was the area of the apertures, where four flat struts connect
the bottom of the top of the implant. The deformation in this region was estimated
to be two magnitudes smaller than in the sample assuming the specified Young’s
modulus for the materials. Because only one sample was available for testing, no
conclusion can be drawn about the material properties.
The developed bone chamber system has shown to be reliable and functional.
The application of large scaffold dimensions and the overall design constitute a
novelty in the field of bone chamber systems.
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6.6 Conclusions
• A reusable bone chamber system for the testing of large porous scaffolds in
large bone defects in dog tibia was developed. The bone chamber system
proved to be applicable for the implantations.
• For the in vivo loading of implanted scaffolds a programmable compression
device with force measurement was developed and validated.
• The functionality of the system must be validated subsequently in vivo ex-
periments.
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Chapter 7
In vivo Application of the
developed Bone Chamber
System
7.1 Introduction
Biomaterials for bone tissue engineering must be examined thoroughly in vitro and
in vivo concerning their biocompatibiliy and their capacity of osteoinduction or
osteoconduction before they can be used in the clinical field. As described in the
previous chapter, bone chamber systems are useful tools for the study of in vivo
performance of biomaterials. Besides the technical development of the bone cham-
ber system, it is important to test the system in vivo, because the implantation
procedure and the reaction of the tissue to the implant cannot be anticipated en-
tirely beforehand. For the success of the implantation, the period of implantation
is crucial as well as the protocol for the compressive stimulation. In previous stud-
ies, bone chambers were implanted for compressive stimulation of bone growth in
different animal models (see Table 7.1). In those studies, the bone chambers were
left for up to four weeks before beginning the cyclic compression [1–5]. After this
period, compressions of up to 20 N were applied cyclically to the ingrown tissue.
The cycle number of the compressive stimulation ranged from 10 to 3600 cycles per
session [1–8] and the frequencies applied were in a range of 0.1 Hz to 1 Hz. The
compressions were repeated in intervals of twice per week up to daily [1–8]. In these
studies the compressions were applied by force rather than displacement [1–8]. In
general strains in bone in vivo are considered smaller than 0.2 % [9–11]. In vitro
studies have shown to require strains of a magnitude higher than in vivo to achieve
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the adequate intracellular biochemical response [12–14]. The duration of cyclical
loadings were up to 12 weeks until sample extraction [3–8], whereas some studies
allowed an additional tissue growth time after the loading up to 12 weeks [1, 2].
The dog model is used frequently in the field of bone tissue engineering, because
of the similar bone mineral density compared to humans [15, 16]. Dogs withstand
stress situations and anaesthesia which is important for the daily treatment [17].
Studies have shown that results of the dog model in bone tissue engineering can be
extrapolated to humans, which validates the selection of the model for this study of
histocompatibility [18]. The tibia was chosen as implantation site, because surgery
and later treatment of the chambers were easy to achieve. The medial side of
the proximal tibia lies subcutaneous, so no important functional tissue (muscles,
nerves, large blood vessels) was put at risk in the implantation process. Overall the
tibia is considered as an adequate implantation site because of the high amount of
trabecular bone in its interior [17].
Based on the promising results of in vivo bone chamber studies, it was intended
in the presented study to use the developed bone chamber system (see Chapter 6)
for the implantation of large porous scaffolds into dog tibia.
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Table 7.1: Compression patterns of in vivo experiments with systems similar to the
developed bone chamber system.
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7.2 Objectives
The objective of the conducted in vivo experiments was to study the tissue re-
sponse to the implanted bone chamber previously developed. The bone cham-
ber was filled with scaffolds consisting of PLA/glass composite, glass ceramics and
nickel-titanium, to study the osteoconductivity or osteoinductivity of the materials.
Scaffolds of PLA/glass composites and glass ceramics were compressed to stimu-
late the development of ingrowing tissue. The integration of the chambers and
the tissue ingrowth into scaffolds was evaluated by analysis of histological cuts and
radiographies.
7.3 Materials and methods
7.3.1 Scaffold materials
The scaffold materials for the implantation in the bone chamber were porous cylin-
ders of PLA/glass composites, glass ceramics and nickel-titanium (see Figure 7.1)
with dimensions of 6 mm diameter and 12 mm length.
(a) PLA/glass compos-
ite
(b) Nickel-titanium (c) Glass ceramic
Figure 7.1: Examples of porous material cylinders used as scaffolds in the in vivo
implantation experiments.
PLA/glass composites were fabricated as described in Chapter 2. The compos-
ite scaffolds were sterilized by gamma radiation (8 kGy) prior to the implantations.
Glass ceramic scaffolds were produced by foaming glass particles (0.1 µm - 100 µm,
Na2O-CaO-P2O5-TiO2) with egg white and sintering with a resulting porosity of
about 30 % [19]. The glass ceramics scaffolds were sterilized by gamma radiation
(8 kGy). Cylinders of porous nickel-titanium were produced by self-propagating
high-temperature synthesis (SHS) as described by Barrabe´s et al. [20] with porosi-
ties of 62 - 65 %. Because the cylinders provided were too big, they were mech-
anized on a lathe to match the dimension requirements. The titanium scaffolds
were cleaned in ultrasonic bath in acetone, ethanol and distilled water for 5 min-
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utes each and sterilized by autoclave. The dimensions of the different scaffolds were
measured with a calliper (see Table 7.2). As can be observed in Figure 7.1, the
cylindrical form of the scaffolds could be obtained in composite and nickel-titanium
scaffolds, whereas the glass ceramic scaffolds showed irregularities in form duie to
the manufacturing process.
Scaffold Type n Diameter [mm] Length [mm]
PLA/glass composite 6 6.2 ± 0.1 12.5 ± 0.2
Nickel-titanium 8 6.0 ± 0.1 12.0 ± 0.1
Glass ceramic 12 5.7 ± 0.2 10.2 ± 0.7
Table 7.2: Dimensions of the scaffolds fabricated for the in vivo experiments.
7.3.2 In vivo experiments
The described surgical interventions and histological analysis were conducted by
the surgical unit of the University Veterinary Hospital Rof Codina in Lugo (Spain).
7.3.2.1 Experiment animals
Six female Beagle dogs (canis familiaris) were enrolled for the bone chamber study.
The dogs were three years old, had an average weight of 15 kg and were treated
in conformity with the ’Directive for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes (86/609/EEC)’ of the European Union.
The in vivo study protocol was approved by the Regional Ethics Committee for
Animal Research.
7.3.2.2 Surgical procedure
For the implantation of the bone chambers, the dogs were prepared for anaesthe-
sia with acepromazine (Calmo Neosan, 0.01 mg/kg intramuscular) and morphine
(0.5 mg/kg intramuscular). Anaesthesia was induced with propofol (Propovet,
2-4 mg/kg intravenous). Dogs were intubated to maintain the anaesthesia dur-
ing the operation with isoflurane (2.5 %) and oxygen (100 %). After making an
incision and spreading the the skin and subcutaneous tissue on the medial side of
the proximal tibia, a hole of 11 mm diameter was drilled through both cortical sur-
faces. To prevent fracture of the bone, smaller diameter holes were drilled before
using the 11 mm drill. The bone chamber was then threaded manually into the
hole, using the insertion tool developed for this purpose. The Teflon spacer was in-
serted and the wound closed over the implant. To ensure the correct implantation,
the implantation sites were x-rayed in the latero-lateral and posteroanterior projec-
tion. After the operations, the dogs were kept under close observation in individual
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cages. They received antibiotics (cefovecin sodium), analgesics, anti-inflammatories
(Meloxicam) and gastric protection (Omeprazole) as post-operative treatment.
After three month of osteointegration, the dogs received a general anaesthesia
for the insertion of the scaffolds. The skin over the implant was opened, the Teflon
spacer extracted and the scaffold in the internal cage inserted. To minimize the
development of scar tissue by repeated opening of the tissue over the bone chamber,
incisions were made parallel, moving the skin over the chamber for access. A total
of 56 samples were used for implantation in the bone chambers, with 24 PLA/glass
composites, 24 glass ceramic and 8 nickel-titanium (see Table 7.3).
Sample number
Implantation period
Scaffold Type 4 weeks 12 weeks Total
Without mechanical stimulation
PLA/glass composite 6 6 12
Glass ceramic 6 6 12
Nickel-titanium 6 2 8
Mechanical stimulation
PLA/glass composite 6 6 12
Glass ceramic 6 6 12
Table 7.3: Number of different scaffold types used in implantations with and without
compressive stimulation.
The samples were extracted after 4 or 12 weeks implantation, which required
the general anaesthesia of the dogs. The protective cap of the implant was taken
off and the sample cut out with a dental trepan burr connected to a dental drill.
The samples were immediately immersed in 10 % formaldehyde for the further
histological preparation.
When cyclic compressions were applied to the scaffolds weekly, the medication
of the dogs had to be augmented with antibiotics of the lincosamid group to prevent
infections. The wounds were cleaned with physiological serum and povidone-iodine
three times daily. When the compressions were applied, the dogs were sedated with
medetomidine and medicated with butorphanol as analgesic. The applied cyclic
compressions consisted of 450 cycles of linear compression (triangular waveform)
of 508 µm for the PLA/glass composites and 127 µm for the glass ceramics. The
detection of the samples by force was only applied for the glass ceramics samples
with a sensor force of 5 N. After the compression, the dogs were medicated with
atipamezole to eliminate the effects of the anaesthetic.
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7.3.2.3 Euthanasia
The sacrifice of the animals after the experiments was conducted by an intravenous
injection of sodium pentobarbital. This substance suppresses the central nervous
system and causes death in a few seconds. This method is commonly used and does
not imply suffering of the animal [21].
7.3.3 Sample preparation
The extracted samples were included in glycol methacrylate as described by Donath
[22]. The samples were fixated by immediate immersion in 10 % formaldehyde
after extraction for two weeks. After fixation the samples were dehydrated by
immersion in increasing ethanol concentrations of 70 % to 100 % for three days
for each concentration. The samples were then infiltrated with glycol methacrylate
(Technovit 7200) and benzoyl peroxide diluted with ethanol. For three days each,
the samples were immersed in benzoyl peroxide dilutions of 30 % to 100 %. The
last immersion was done in vacuum to ensure the correct intrusion of the polymer.
The samples were then included in a block of Technovit 7200. Sections of 200 µm
of the block were cut with a band saw and the cuts were polished down to 70 µm
thickness. The samples were stained with Levai-Laczko stain and examined under
light microscope (Olympus CH30) and loupe (Olympus SZX9). The samples were
analysed for tissue and cells based on standard ISO 10993-6 [23].
7.3.3.1 Microscopic evaluation
The quantitative histology was performed for an average of 15 histological sections
per sample. After determining the tissue types present in the samples, the bone-
implant contact and new bone volume for all sections was calculated. The bone-
implant contact (BIC) (%) was the ratio of histological sections displaying bone-
implant contact with respect to the total number of sections (see Figure 7.2a).
The amount of BIC representing the fraction of mineralized bone tissue in direct
contact with the implant could not be determined, because a very low value for this
parameter was observed in the histological sections. The new bone volume (NBV)
(%) was the percentage of new bone tissue in the sample. The values were calculated
using MicroImage 1.0, where new bone matrix was coloured violet (stereoscopic
microscope)(see Figure 7.2b).
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(a) The measurement of bone-implant contact
(BIC) includes the detection of bone-material
interfaces. Bone is stained purple with Levai-
Laczko stain.
(b) New bone volume (NBV) was
measured by the amount of purple
stain inside the internal cage (red
circle).
Figure 7.2: Illustration of the histomorphometrical measurement of BIC and NBV.
7.3.3.2 Statistical analysis
The histomorphometrical data was analysed statistically using SPSS 15.0 software.
The two-way analysis of variance was chosen, followed by the Tukey’s post hoc test.
A p-value <0.05 was considered statistically significant.
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7.4 Results
7.4.1 Surgical procedure
The surgical procedures were conducted as planned in the development of the bone
chamber system. The animals did not show any alteration after the operations and
no problems in anaesthesia and surgical practice were experienced. After the appli-
cation of the compressions, the dogs showed signs of pain in the treated extremities.
The pain was classified using the Melbourne scale for pain in dogs [24–26]. The dogs
scored 6 out of 24 of the scale, which was considered a slight pain, relieved with the
administration of meloxicam.
7.4.1.1 Complications
Delayed wound healing and fractures Directly after implantation of the
bone chambers two types of complications were observed, insufficient wound healing
and bone fractures. In 14 of 37 incisions the wound did not close properly imme-
diately after operation. In most cases this was caused by dogs licking the wound.
The wound healing was also delayed by the appearance of fibrous tissue due to the
repeated opening of the implantation site. The first implant, which was realized
with a bone chamber version previous to the final version provoked severe wound
healing problems. The cause of the problem was most likely the large dimensions of
the implant head of this version and the large Teflon area presented by the spacer.
The wound healing was finally accomplished after taking out the Teflon spacer.
Two of the six dogs enrolled in this study experienced fractures around one
implant after implantation, which caused the loss of two chambers. The fractures
were fixated to save the dogs from early euthanasia, because both still presented
working implants in the opposite tibia (see Figure 7.3).
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(a) First case of fracture (left: fixation after fraction; middle and right:
fracture fully healed around the implant).
(b) Second case of fracture (left: fixation after fraction; middle: the bone
chamber fell out of the tibia ; right: fracture healed after fixation).
Figure 7.3: Two cases of bone fractures of dog tibia after the bone chamber im-
plantation.
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Infections One of the bone chambers with application of cyclic loading showed
a severe loosening associated with suppuration and pain. A radiography of the
bone chamber showed no bone remodelling around the implant (see Figure 7.4). To
exclude microfractures, which might have been overseen in the radiography after im-
plantation, a Computer Assisted Tomography scan of the chamber was conducted.
The extracted chamber was examined bacteriologically, which showed an infection
with Pseudomona spp.
Figure 7.4: Radiographs of the bone chamber affected by infection showed no bone
remodelling around the external chamber.
Implant loosening After loosening and loss of one bone chamber in the com-
pression experiments, all bone chambers were examined on loosening. It was found
that 5 of the 10 bone chambers showed a slight loosening at some point, which was
confirmed by radiolucent areas around the implants in radiographies, similar to the
lost bone chamber.
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7.4.2 Histological findings
Out of 56 samples used in this study, 32 were extracted and examined histologically.
The implantation of samples with cyclical loading was not conducted further, be-
cause it was suspected that the further use might lead to an implant loosening. All
samples presented ingrown tissue, whereas directly at the extraction of the samples
it was observed that the tissue resembled soft tissue rather than bone. Even though
tissue was found in all samples, it was observed that three of 12 glass ceramic sam-
ples had pores too small to allow tissue ingrowth, resulting in areas lacking any
tissue.
In 16.1 % of the histological sections, signs of infection were observed. These
sections were excluded from data analysis, because of the influence on tissue for-
mation in the bone chamber lumen. After both implantation periods, most of the
samples presented newly formed tissue consisting of a mixture of newly formed
bone, bone marrow and fibrous tissue (see Figures 7.5a, 7.5c and 7.5e).
The results of the histomorphometry are presented in Table 7.4. No statisti-
cally significant differences were found between samples regarding NBV and BIC.
There were no statistically significant differences between different periods of time.
However all materials showed an increasing trend of BIC and NBV over time.
Scaffold type n BIC [%] NBV [%]
4 weeks 12 weeks 4 weeks 12 weeks
PLA/glass composite 12 2.5±0.2 4.2±0.7 7.3±1.1 11.4±3.1
Nickel titanium 8 3.2±0.6 4.4±0.9 6.6±2.1 11.0±2.8
Glass ceramics 12 2.1±0.4 4.0±0.8 6.0±1.3 12.0±3.1
Table 7.4: Results of histomorphometric measurements. Values represent the mean
percentage (± SD).
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(a) Histological section of PLA/glass
composite samples after 4 weeks of im-
plantation. The material was partly ab-
sorbed and the chamber filled with fibrous
tissue.
(b) Histological section of PLA/glass
composite samples after 12 weeks of im-
plantation.
(c) Histological section of nickel-titanium
sample after 4 weeks implantation.
(d) Histological section of nickel-titanium
sample after 4 weeks implantation. Be-
ginning ossification in the internal cage
aperture was observed, whereas the scaf-
fold was surrounded and intruded by fi-
brous tissue.
(e) Histological section of glass-ceramic
sample after 12 weeks of implantation.
Bone tissue can be seen on the exterior
of the scaffold, which is covered in a layer
of fibrous tissue.
(f) Histological section of glass-ceramic
sample after 12 weeks of implantation.
Figure 7.5: Histological sections of extracted samples after Levai-Laczko staining.
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PLA/glass composite scaffolds were more absorbed than glass ceramic scaffolds,
while the nickel-titanium scaffolds showed no signs of resorption (as expected). Bone
marrow found in the samples was well organized and contained large numbers of
adipocytes and blood vessels (see Figure 7.6a). Between the graft and the newly
formed bone and between the bone chamber and the newly formed bone a fibrous
layer was present, which consisted of a mixture of mineralized bone and immature
woven bone in a fibrovascular stroma (see Figure 7.6b). Histology suggested that
new bone originated from bone outside of the bone chamber. In the newly formed
bone, trabeculae were lined with osteoblasts and osteocytes, extending up to the
implant (see Figure 7.6b). Less bone trabeculae were observed at the implant
surface for the 4 week experiments.
(a) Bone marrow found in the samples
contained large numbers of adipocytes
(Ad) and blood vessels (←)(x100 magni-
fication).
(b) Illustration of mineralized bone (MB)
and immature woven bone (NB) in a fi-
brovascular stroma (F). Trabeculae were
lined with osteoblasts (◦) and osteocytes
() were found within the newly formed
bone tissue and extended up to the im-
plant (x100 magnification).
Figure 7.6: Histological sections of newly formed tissue, found in implanted samples.
7.5 Discussion
With this study it was intended to experimentally prove the function of the devel-
oped bone chamber system and to test the osteointegration of materials deemed
suitable for the application in bone tissue regeneration in a repeatable in vivo en-
vironment. For this, bone chambers were implanted into the medial side of the
proximal tibia in dogs.
The compression pattern chosen for the developed bone chamber system was
in the range of comparable studies, which yielded successful enhancement of bone
growth and tissue mineralization [1–8]. A weekly stimulation of 0.5 Hz and 450 cy-
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cles was selected with compressions of 1 % and 5 % for glass ceramics and PLA/glass
composites respectively. However, the compressed samples were not analysed at the
time of this writing. The compression experiments was delayed to the end of the
study when the described implant mobility was observed to prevent an influence on
the implantations without compression.
The design of the bone chamber, which was based on the 6 mm diameter and
12 mm long scaffolds, made it inevitable to choose a species of appropriate pro-
portions for the implantation in the tibia. The chosen dog animal model made it
difficult to compare the study with other bone chamber studies, because of different
implantation sites or different species of the experiment animal and different exper-
imental protocols. Because the bone chamber system developed for the studies was
never used before, no direct comparison to other studies could be drawn.
The surgical procedure for the bone chamber system used in this study appeared
to be appropriate, showing no complications during surgery and anaesthesia. The
bone chamber system needed an 11 mm diameter hole for implantation, which was
considered to be a critical size defect (CSD). Comparable studies in rabbit [6] with
10 mm diameter defects were conducted successfully, which was the basis for the
assumption of the possible success of this study.
One of the experienced post-surgery complications was the delayed or insuffi-
cient wound healing after implantation of the bone chambers. This was caused by
the dogs licking the wounds, the repeated opening of the wound and the exposure
of PTFE surfaces. It has been shown that PTFE implants can cause pronounced,
persistent inflammations [27], which might have cause the severe adverse reaction.
The exposition of the skin flap to the PTFE spacer over a long time period was an
inadequate design choice and has to be revised in further designs to avoid the prob-
lems in wound healing. In this sense, the bone chamber might be left empty during
the osteointegration phase, which then has to be freed of ingrown tissue before the
insertion of the first scaffold.
Another complication of the experiments were the occurrence of fractures due
to the large defects created in the tibia. The remaining bone left by the large
dimensions of the bone chamber was in two cases not enough to support the weight
of the dogs. The diameter of the bone chamber was determined by the scaffold
dimensions and the trepan available for the sample extraction. Exchanging the
trepan for a thin walled cutting device could make the bone chamber diameter
smaller and hence safer.
The third complication encountered were infections on the implant site. The
most frequent symptom for an infection in traumatologic implants is the loss of the
implant [28]. In the occurring case, the lost bone chamber was examined for bacte-
ria and Pseudomona spp was identified as source of the infection. Pseudomona spp
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is a resistant gram negative bacteria, which is considered to be highly pathogenic
and can be found amongst others in the hospital environment and is resistant to
antibiotics and antiseptics. Even a thorough medication and cleaning of the implan-
tation site cannot guarantee a prevention of an infection. It can be excluded that
the infection found was caused by the implantation or the implant itself, because
symptoms arouse for the first time after the application of the cyclic compressions.
It was suggested that the space between actuator connector and piston was open
to allow influx of air, which might have been the way of infection. For a further
design of the compression device and the chamber, it would be desirable to have a
implantable chamber, totally closed off to the surrounding. Without any doubt, a
severe change in the design might lead to a limitation in types of scaffolds usable
and the programmability of the device. Such limitations call for a very well defined
catalogue of design requirements for the device before development which cannot
be changed easily in the subsequent realisation of the system.
At the beginning of the compression phase of the experiments the observed im-
plant loosening occurred. It was suggested that the loosening was effected by the
mechanical stress of the compression, because the bone chambers were mechanically
fixed in the implantation site, rather then really integrated in the bone. The mo-
bility of the implanted bone chambers indicated that the chambers were integrated
by fibrous integration or fibro-osteointegration [29, 30] rather than by osteointe-
gration. The non-bony integration of the bone chamber might be caused by the
size of the bone defect produced, letting the defect fill up with fibrous tissue be-
cause of the limited amount of cells for bone regeneration in the surrounding area.
The bone chamber integration might also have been affected by the compression
device or by the compression itself. The weight of the device could have caused
microfracture during the connection, which led finally to the loosening. The com-
pression device was not fixated sufficiently to assure a stress-free application against
the dog’s leg. When moving the piston, the stepper motor imposed an impulse to
the whole device, which certainly was transmitted to the connected bone chamber.
Even though the amplitude of the impulses is not known, the amount of impulses
per cyclic compression session is suspected to be sufficient to provoke an implant
loosening by step-by-step fraction of the bone-implant connection. In the case of
PLA/glass composites, the bone chamber received 18.000 impulses per session, the
glass ceramics received 4.500 impulses.
Without any doubt, a series of studies could be undertaken, trying to optimize
the bone chamber surface for the osteointegration. It has been reported that nickel-
titanium materials can be bioinert, causing a delayed healing time until reaching
osteointegration and formation of a fibrous capsule around the implant [31–33]. A
treatment of the titanium surface by coating with hydroxyapatite or collagen can
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enhance the integration in bone significantly [34, 35]. Even though such a treatment
has to be tested in in vivo experiments to ensure the suitability for the used animal
model, a surface treatment should be considered for a further bone chamber re-
design.
The materials chosen for the bone chamber and scaffolds were deemed applica-
ble for the implantation, based on the in vivo behaviour of comparable materials
(nickel-titanium [36, 37] and calcium phosphate glass ceramics [38]) and their in
vitro biocompatibility (PLA/glass composite [39–42]). Additionally the total du-
ration of 12 weeks for implantations with and without compressive loading should
have permitted a sufficient amount of newly formed bone. The histology of the
extracted samples showed tissue ingrowth into the bone chambers. The tissue was
a combination of newly formed bone, bone marrow and fibrous tissue. There was
no significant difference in new bone volume and bone-implant contact found be-
tween different materials and implantation times. The found tissue indicated that
new bone formation in the scaffolds was beginning, but the presence of not absorbed
PLA/glass composite and glass ceramic material, as well as the nickel-titanium scaf-
folds, affected the velocity and structure of ingrowing tissue and bone formation.
Analogue to the experienced problems in wound healing caused by the present
PTFE surface, it can be considered that the apertures of the bone chamber were
closed by fibrous tissue as an initial reaction to the spacer. The fibrous tissue was
hence the first tissue to intrude the scaffolds and delayed the appearance of bone
tissue.
As has been shown by the results, the bone chamber system did not work suffi-
ciently to allow conclusions about the osteoinductive or osteoconductive properties
of the implanted scaffolds. Further revision of the design is necessary to achieve a
better integration of the external chamber and ingrowth of bone tissue.
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7.6 Conclusions
• The evaluation of the reusable bone chamber system in beagle dog tibia has
been conducted. Several complications were encountered including problems
in wound healing, fractures, infections and implant loosening.
• Histological analysis of the implanted samples without loading after 4 and
12 weeks showed tissue ingrowth, composed of newly formed bone, bone mar-
row and fibrous tissue into the bone chambers. The new bone volume (NBV)
and bone-implant contact (BIC) were not significantly different between the
different scaffold materials and implantation times. The present tissue indi-
cated a favourable environment for bone formation, but the bone formation
seemed to be delayed by material left in the chambers.
• In the current configuration the compression device of the bone chamber
system cannot be used for the in vivo loading of scaffolds. As suggested by
the experimental data, the application of the device might cause loosening of
the bone chambers by impacts of the stepper motor moving or infection of
the bone chambers due to the design of the actuator connector assembly.
• The implantation of the bone chambers did cause unpredictable complications
and could not provide the desired results reliably. Nevertheless did the study
provide an insight into the problems of the current bone chamber design. A
redesign of the bone chamber system and the surgical protocol are crucial for
further experiments, to ensure better clinical results.
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Chapter 8
Conclusions
• For the cell seeding and culture on large porous scaffolds for bone tissue en-
gineering, an in vitro perfusion bioreactor system was developed. Studies for
the determination of appropriate cell seeding parameters were conducted, as
well as long term cell culture experiments under steady fluid flow with stim-
ulation by oscillating fluid flow. The studies have shown that it was possible
to seed cells throughout large porous scaffolds, which is deemed a crucial step
for the further cell culture. The results with osteoblast-like cells suggested
that an increasing fluid flow velocity improved cell distribution on the in-
terior of the scaffolds, while an increase in cycle number of the oscillatory
perfusion enhanced the uniformity between samples. The bioreactor system
provided a viable environment for long term cell culture of mesenchymal stem
cells. Cells proliferated up to two weeks in an exponential manner, followed
by a severe decrease at three weeks, which was attributed to the beginning
of cell differentiation and limitation of cell population size by the nutrient
transport. The cell differentiation analysis conducted showed cell activity,
but the differentiation into the osteoblast cell line could not be observed due
to inconclusive test results. Further detailed studies are necessary to observe
the reaction of the cells on the perfusion profile. For future experiments,
the developed perfusion bioreactor system can be used with different scaf-
fold materials, to provide different structures for cell culture. Additionally
different stimulation patterns can be applied to find the ideal parameters for
cell differentiation into bone forming cells. Further development of the sys-
tem, including application of sensors, might give a more detailed view on cell
activity in real-time.
• For the testing of large porous scaffolds in vivo, a bone chamber system was
developed. The system allowed the repeated implantation of large porous
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scaffolds of different material compositions in a large bone defect in dog tibia.
The ingrowing tissue was observed to allow conclusions about the osteocon-
ductive or osteinductive properties of the scaffold materials. Additionally a
compression device was developed to apply cyclic loading on the scaffolds
in vivo to study the effect of mechanical stimulation on tissue development.
The functionality of the bone chamber system was evaluated by implantation.
Histology showed that the chambers were integrated into the bone by fibro-
osteointegration, causing the loosening of the chambers during the application
of loads. This made the in vivo mechanical compressive stimulation of the
samples impossible. After 4 and 12 weeks newly found tissue was found in all
samples, indicating an ongoing formation of bone. A delay of bone ingrowth
was attriuted to the created bone defect size and the formation of a predomi-
nantly fibrous layer.Even though the experienced complications did not allow
final conclusions about scaffold material properties, the study provided input
for further development of the device and clinical protocol.
• The presented studies constituted a novelty in the field of bone tissue engi-
neering, regarding the creation of bioreactors for the study of large porous
scaffolds in vitro and in vivo. The developed systems established the basis
for further studies in mechanobiology of cells and tissues, including the use of
scaffolds produced by Rapid Prototyping. The results of the cell culture on
well-defined structures can be complemented by numerical simulation, which
constitutes an promising approach in modern tissue engineering.
• For the future more long term cell culture experiments have to be conducted
in the perfusion bioreactor system under a range of perfusion profiles to deter-
mine the ideal culture conditions. A focus has to be laid on cell differentiation
and restructuring of the engineered tissue. Furthermore it would be interest-
ing to establish conditions under which the engineered tissue becomes stable
over a long term, representing an in vitro model of bone tissue, which can be
used for e.g. drug testing. For the developed in vivo bone chamber system a
redesign must be conducted to minimise the caused defect in the experiment
animal bone. The compression device has to be changed to incorporate a cou-
pling system, which minimises the risk of infection during loading. With only
a few changes the compression device might be used for in vitro mechanical
stimulation of cells in scaffolds or for measurement of mechanical properties
of engineered tissue.
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Appendix B
Source Code for Volume
Transport Validation
CLS
PRINT
PRINT "*************************************************"
PRINT "* *"
PRINT "* 2.25 ml Volume Transport Control *"
PRINT "* *"
PRINT "*************************************************"
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT
PRINT " Press:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
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’************************* Constants *************************
vol = 2.25 ’moved Volume in ml
pi = ATN(1) * 4
’************************* Input values **********************
200
CLS
GOSUB header
PRINT
PRINT "Please calibrate the pump before going on..."
PRINT
PRINT
PRINT "Set pump to Flow pressing <MODE> and push the <^> button to maximum."
INPUT "max. Fluid flow of the pump [ml/min]*: ", Qmax
’input of max. Flow [ml/min]
PRINT
INPUT "...Fluid Flow Velocity [mm/s]: ", v
IF Qmax = 0 THEN GOTO 200
IF v = 0 THEN GOTO 200
PRINT
A = pi * 3 ^ 2 ’scaffold area [mm^2]
Q = A * v ’Flow [mm^3/s]
Q = 60 * Q / 1000 ’Flow [ml/min]
Qproz = Q / Qmax * 100 ’ input of max. Flow [%]
t = vol / Q * 60 ’time half-cycle [s]
t1 = INT(t * 100 + .5) ’rounded time
t = t1 / 100
PRINT
PRINT "Calculating..."
’************************* convert Q to IPC signal *********
y! = INT(Qproz * 10 ^ 1 + .5)
speed$ = STR$(y!)
’conversion to Pump signals (i.e. 1S00100 for 10%)
speed$ = LTRIM$(speed$)
IF y! < 10 THEN GOTO 111
IF y! < 100 THEN GOTO 112
IF y! < 1000 THEN GOTO 113
IF y! < 10000 THEN GOTO 114
111
speed$ = "1S0000" + speed$
GOTO 115
112
speed$ = "1S000" + speed$
GOTO 115
113
speed$ = "1S00" + speed$
GOTO 115
114
speed$ = "1S0" + speed$
GOTO 115
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115
PRINT "Done!"
PRINT
300
PRINT
PRINT "SUMMARY"
PRINT "-------"
PRINT "Fluid Flow velocity [mm/s]: "; v
PRINT
PRINT "Fluid Flow [ml/min]: "; Q
PRINT
PRINT "Flow [%]: "; Qproz
PRINT
PRINT "IPC signal: "; speed$
PRINT
PRINT "Duration [s]: "; t
PRINT
PRINT
PRINT "OPTIONS:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to start pump."
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************ Initiation *************************
OPEN "COM2:9600,n,8,1,CS,DS,RS" FOR RANDOM AS #1
’************************* WARNING *************************
CLS
GOSUB header
PRINT
PRINT
PRINT "Writing to IPC"
PRINT
TIMER ON
Start = TIMER
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set Pump to 0 ***"
PRINT #1, "1S00000"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
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PRINT TIME$, TIMER, "*** Set pump counter-clockwise ***"
PRINT #1, "1K"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Start Pump ***"
PRINT #1, "1H"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set Pump to "; Qproz; "% ***"
PRINT #1, speed$
PRINT TIME$, TIMER, "*** Wait "; t; "s ***"
Start = Start + t
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Stop Pump ***"
PRINT #1, "1I"
TIMER OFF
CLOSE #1
PRINT
PRINT "DONE!"
PRINT
PRINT "OPTIONS:"
PRINT , "<a> Enter new velocity."
PRINT , "<b> Same velocity."
PRINT , "<x> End program."
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
CASE "a"
GOTO 200
CASE "b"
GOTO 300
END SELECT
END
’*** Header Graphic ***
header:
PRINT "*************************************************"
PRINT "* *"
PRINT "* 2.25 ml Volume Transport Control *"
PRINT "* *"
PRINT "*************************************************"
253
RETURN
’*********** day changes ********
tmchg:
Start = Start - 86399.99
DO
LOOP UNTIL TIMER <= 10
RETURN
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Appendix C
Source Code for Cell Seeding
in the Perfusion Bioreactor
System
CLS
PRINT
PRINT
PRINT
PRINT
PRINT " _/_/_/ _/ _/ "
PRINT " _/_/_/ _/_/_/ _/ _/_/ _/ _/_/ _/ _/ "
PRINT " _/_/ _/ _/ _/_/ _/ _/_/_/_/ _/ _/ "
PRINT " _/_/ _/ _/ _/ _/ _/ _/ _/ "
PRINT " _/_/_/ _/_/_/ _/ _/ _/_/_/ _/_/_/ _/ _/ "
PRINT " _/ "
PRINT " _/ "
PRINT
PRINT
PRINT " _/_/_/ _/ _/ "
PRINT " _/ _/_/ _/_/ _/_/_/ _/_/_/ _/_/_/ "
PRINT " _/_/ _/_/_/_/ _/_/_/_/ _/ _/ _/ _/ _/ _/ _/ "
PRINT " _/ _/ _/ _/ _/ _/ _/ _/ _/ _/ "
PRINT " _/_/_/ _/_/_/ _/_/_/ _/_/_/ _/ _/ _/ _/_/_/ "
PRINT " _/ "
PRINT " _/_/ "
PRINT " Square wave generator for ISMATEC IPC pump"
PRINT
PRINT " Press:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
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DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************* Constants *************************
vol = 2.25 ’moved Volume in ml
pi = ATN(1) * 4
’************************* Input values **********************
CLS
GOSUB header
PRINT
PRINT
PRINT "Input values"
PRINT "------------"
PRINT "Set pump to Flow pressing <MODE> and push the <^> button to maximum."
INPUT "max. Fluid flow of the pump [ml/min]: ", Qmax ’input of max. Flow
PRINT
INPUT "Please type in your name: ", name$
PRINT
PRINT "Fluid Flow "
PRINT "-------------"
INPUT "Fluid Flow Velocity [mm/s]: ", v
INPUT "Number of Cycles [-]: ", c
PRINT
A = pi * 3 ^ 2 ’scaffold area [mm^2]
Q = A * v ’Flow [mm^3/s]
Q = 60 * Q / 1000 ’Flow [ml/min]
Qproz = Q / Qmax * 100 ’ input of max. Flow [%]
t = vol / Q * 60 ’time half-cycle [s]
t1 = INT(t * 100 + .5) ’rounded time
t = t1 / 100
’************************* convert Q to IPC signal *********
y! = INT(Qproz * 10 ^ 1 + .5)
speed$ = STR$(y!)
’conversion to Pump signals (i.e. 1S00100 for 10%)
speed$ = LTRIM$(speed$)
IF y! < 10 THEN GOTO 111
IF y! < 100 THEN GOTO 112
IF y! < 1000 THEN GOTO 113
IF y! < 10000 THEN GOTO 114
111
speed$ = "1S0000" + speed$
GOTO 115
112
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speed$ = "1S000" + speed$
GOTO 115
113
speed$ = "1S00" + speed$
GOTO 115
114
speed$ = "1S0" + speed$
GOTO 115
115
PRINT
PRINT "OPTIONS:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
PRINT
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************* Print Summary ********************
OPEN "Seedlog.txt" FOR OUTPUT AS #2
CLS
PRINT #2, "Name: "; name$
PRINT #2, "Date [m/d/y]: "; DATE$
PRINT #2, "Time [h:m:s]: "; TIME$
PRINT #2, "Fluid Flow velocity [mm/s]: "; v
PRINT #2, "max. Fluid Flow [ml/min]: "; Q
PRINT #2, "max. Flow [%]: "; Qproz
PRINT #2, "IPC signal: "; speed$
PRINT #2, "cycle duration [s]: "; 2 * t
PRINT #2, "Number of cycles: "; c
PRINT #2,
GOSUB header
PRINT
PRINT
PRINT "SUMMARY"
PRINT "-------"
PRINT "Name: "; name$
PRINT "Date [m/d/y]: "; DATE$
PRINT "Time [h:m:s]: "; TIME$
PRINT "Fluid Flow velocity [mm/s]: "; v
PRINT "max. Fluid Flow [ml/min]: "; Q
PRINT "max. Flow [%]: "; Qproz
PRINT "IPC signal: "; speed$
PRINT "cycle duration [s]: "; 2 * t
PRINT "Number of cycles: "; c
PRINT
PRINT
PRINT "OPTIONS:"
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PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************ Initiation *************************
OPEN "COM2:9600,n,8,1,CS,DS,RS" FOR RANDOM AS #1
’************************* WARNING *************************
200
CLS
GOSUB header
PRINT
PRINT
PRINT "CAUTION!"
PRINT "--------"
PRINT " "
PRINT "This will start the pump process which will durate "; 2 * t * c;
" second(s)"
PRINT "Be sure that:"
PRINT
PRINT "- The pump is connected at COM2 of the computer"
PRINT "- Power supply is guaranteed over the duration of the experiment"
PRINT
PRINT "- Be sure to have two equal medium levels in the U-Tube
(at least 3,5cm over Perfusion Chambers!)"
PRINT
PRINT
PRINT "OPTIONS:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’********************* write to IPC ************************
CLS
GOSUB header
PRINT
PRINT
PRINT "Writing to IPC"
PRINT
TIMER ON
Start = TIMER
PRINT "Time [h:m:s]", "Time [s]", "Q [%]", "Q [ml/min]", "IPC Comand"
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PRINT #2, "Time [h:m:s]", "Time [s]", "Q [%]", "Q [ml/min]", "IPC Comand"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set Pump to 0 ***"
PRINT #1, "1S00000"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set pump counter-clockwise ***"
PRINT #1, "1K"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Start Pump ***"
’PRINT #2, TIME$, TIMER, "*** Start Pump ***"
PRINT #1, "1H"
PRINT TIME$, TIMER, "*** Wait .5s ***"
’PRINT #2, TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set Pump to "; Qproz; "% ***"
PRINT #1, speed$
PRINT "Driving medium levels to start position"
’gets the levels in "start position"
PRINT TIME$, TIMER, "*** Wait "; t / 2; "s ***"
PRINT TIME$, TIMER, "-"; Qproz, "-"; Q, speed$
PRINT #2, TIME$, TIMER, "-"; Qproz, "-"; Q, speed$
Start = Start + t / 2
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
FOR k = 1 TO c
char$ = INKEY$
IF char$ = "x" THEN END
PRINT "Cycle "; k; " of "; c
PRINT #2, "Cycle "; k; " of "; c
PRINT TIME$, TIMER, "*** Set pump clockwise ***"
PRINT TIME$, TIMER, Qproz, Q, speed$
PRINT #2, TIME$, TIMER, Qproz, Q, speed$
PRINT #1, "1J"
PRINT TIME$, TIMER, "*** Wait "; t; "s ***"
Start = Start + t
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IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set pump to counter-clockwise ***"
PRINT TIME$, TIMER, "-"; Qproz, "-"; Q, speed$
PRINT #2, TIME$, TIMER, "-"; Qproz, "-"; Q, speed$
PRINT #1, "1K"
PRINT TIME$, TIMER, "*** Wait "; t; "s ***"
Start = Start + t
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
NEXT k
PRINT TIME$, TIMER, "*** Wait .1s ***"
Start = Start + .1
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Stop Pump ***"
PRINT #2, TIME$, TIMER, "*** Stop Pump ***"
PRINT #1, "1I"
TIMER OFF
SOUND 440, 5
PRINT #2, "Pump cycle complete."
CLOSE #1
CLOSE #2
PRINT
PRINT
PRINT "Pump cycle complete."
PRINT
PRINT "A log file <Seedlog.txt> has been created."
PRINT
PRINT
PRINT
PRINT "Press <any key> to end program"
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
END
’*** Header Graphic ***
header:
PRINT "*************************************************"
PRINT "* Cell Seeding *"
PRINT "*-----------------------------------------------*"
PRINT "* *"
PRINT "* Square wave generator for ISMATEC IPC pump *"
PRINT "* *"
PRINT "*************************************************"
RETURN
’*********** day changes ********
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tmchg:
Start = Start - 86399.99
DO
LOOP UNTIL TIMER <= 10
RETURN
262
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Appendix D
Source Code for Cell Culture
in the Perfusion Bioreactor
System
CLS
PRINT
PRINT
PRINT
PRINT
PRINT " _/_/_/ _/ _/ "
PRINT " _/ _/_/ _/ _/ "
PRINT " _/ _/_/_/_/ _/ _/ "
PRINT " _/ _/ _/ _/ "
PRINT " _/_/_/ _/_/_/ _/ _/ "
PRINT
PRINT
PRINT " _/_/_/ _/ _/ "
PRINT " _/ _/ _/ _/ _/_/_/_/ _/ _/ _/ _/_/ _/_/ "
PRINT " _/ _/ _/ _/ _/ _/ _/ _/_/ _/_/_/_/ "
PRINT " _/ _/ _/ _/ _/ _/ _/ _/ _/ "
PRINT " _/_/_/ _/_/_/ _/ _/_/ _/_/_/ _/ _/_/_/ "
PRINT
PRINT " Culture pattern generator for ISMATEC IPC pump"
PRINT
PRINT
PRINT " Press:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
DO
char$ = INKEY$
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LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************* Constants *************************
’When changing the type of pump tube you have to change
’parameters dtube and Qmax here!
dtube = 2.79 ’pump tube diameter [mm]
pi = ATN(1) * 4
’************************* Input values **********************
CLS
GOSUB header
PRINT "This program is for use with 2.79 mm pump tubing!"
PRINT
PRINT "Input values"
PRINT "============"
PRINT
PRINT "Set pump to Flow pressing <MODE> and push the <^> button to maximum."
INPUT "max. Fluid flow of the pump [ml/min]: ", Qmax ’input of max. Flow
PRINT
INPUT "Please type in your name: ", name$
CLS
GOSUB header
PRINT
PRINT "Fluid Flow Pattern"
PRINT
PRINT " v1|--- --- ---"
PRINT " | | | | | |"
PRINT " v2| | | | -------------------------- |"
PRINT " |___|___|___|___|______________________________|____"
PRINT " | | | | | ’ |"
PRINT " | | | | | 24h |"
PRINT " | | | | | | "
PRINT "-v1| --- --- ---"
PRINT
PRINT " <-t->"
PRINT " <----Period 1---><--------Period 2--------->"
PRINT
PRINT
PRINT "Period 1 - Alternating fluid flow"
PRINT "---------------------------------"
PRINT
INPUT "Fluid Flow Velocity v1 [mm/s]: ", v1
INPUT "Time for every direction t [s]: ", tdir
INPUT "Total time for alternating flow [min]: ", taf
PRINT
PRINT "Period 2 - Continuous fluid flow"
PRINT "--------------------------------"
PRINT
INPUT "Fluid Flow Velocity v2 [mm/s]: ", v2
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PRINT
’*************** Calculating Values *******************
A = pi * 3 ^ 2 ’scaffold area [mm^2]
Q1 = A * v1 ’Flow Period 1 [mm^3/s]
Q2 = A * v2 ’Flow Period 2 [mm^3/s]
Q1 = 60 * Q1 / 1000 ’Flow Period 1 [ml/min]
Q2 = 60 * Q2 / 1000 ’Flow Period 2 [ml/min]
Q1proz = Q1 / Qmax * 100 ’ input of max. Flow Period 1 [%]
Q2proz = Q2 / Qmax * 100 ’ input of max. Flow Period 2 [%]
taf = taf * 60 ’Total time for alternating flow [s]
c = taf / tdir ’Get the number of cycles
c! = INT(c / 2) * 2 ’Round the number of cycles
taf = c! * tdir
c = c! / 2
rday = 86400 - taf ’rest of day [s]
dday = rday / 2 ’break down rest of day into 2s pieces
’************************* convert Q1 and Q2 to IPC signal *********
y! = INT(Q1proz * 10 ^ 1 + .5)
speed1$ = STR$(y!) ’conversion to Pump signals for 1st period
speed1$ = LTRIM$(speed1$)
IF y! < 10 THEN GOTO 111
IF y! < 100 THEN GOTO 112
IF y! < 1000 THEN GOTO 113
IF y! < 10000 THEN GOTO 114
111
speed1$ = "1S0000" + speed1$
GOTO 115
112
speed1$ = "1S000" + speed1$
GOTO 115
113
speed1$ = "1S00" + speed1$
GOTO 115
114
speed1$ = "1S0" + speed1$
GOTO 115
115
y! = INT(Q2proz * 10 ^ 1 + .5)
speed2$ = STR$(y!) ’conversion to Pump signal for 2nd period
speed2$ = LTRIM$(speed2$)
IF y! < 10 THEN GOTO 211
IF y! < 100 THEN GOTO 212
IF y! < 1000 THEN GOTO 213
IF y! < 10000 THEN GOTO 214
211
speed2$ = "1S0000" + speed2$
GOTO 215
212
speed2$ = "1S000" + speed2$
GOTO 215
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213
speed2$ = "1S00" + speed2$
GOTO 215
214
speed2$ = "1S0" + speed2$
GOTO 215
215
PRINT
PRINT "OPTIONS:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
PRINT
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************* Print Summary ********************
OPEN "Cultlog.txt" FOR OUTPUT AS #2
CLS
PRINT #2, "Name: "; name$
PRINT #2, "Date [m/d/y]: "; DATE$
PRINT #2, "Time [h:m:s]: "; TIME$
PRINT #2,
PRINT #2, "Period 1 - Alternating fluid flow"
PRINT #2, "---------------------------------"
PRINT #2, "Fluid Flow Velocity [mm/s]: "; v1
PRINT #2, "IPC signal: "; speed1$
PRINT #2, "Time for every direction [s]: "; tdir
PRINT #2, "Number of cycles: "; c
PRINT #2, "Duration [min]: "; taf / 60
PRINT #2,
PRINT #2, "Period 2 - Continuous fluid flow"
PRINT #2, "--------------------------------"
PRINT #2, "Fluid Flow Velocity [mm/s]: "; v2
PRINT #2, "IPC signal: "; speed2$
PRINT #2, "Duration [h]: "; rday / 3600
PRINT #2,
PRINT #2, "------------------------------------------"
PRINT #2,
GOSUB header
PRINT
PRINT "SUMMARY"
PRINT "-------"
PRINT "Name: "; name$
PRINT "Date [m/d/y]: "; DATE$
PRINT "Time [h:m:s]: "; TIME$
PRINT
PRINT "Period 1 - Alternating fluid flow"
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PRINT "---------------------------------"
PRINT "Fluid Flow Velocity [mm/s]: "; v1
PRINT "IPC signal: "; speed1$
PRINT "Time for every direction [s]: "; tdir
PRINT "Number of cycles: "; c
PRINT "Duration [min]: "; taf / 60;
PRINT
PRINT "Period 2 - Continuous fluid flow"
PRINT "--------------------------------"
PRINT "Fluid Flow Velocity [mm/s]: "; v2
PRINT "IPC signal: "; speed2$
PRINT "Duration [h]: "; rday / 3600
PRINT
PRINT "OPTIONS:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************* WARNING *************************
CLS
GOSUB header
PRINT
PRINT "We will begin the perfusion now. Please assure that:"
PRINT "- The pump is connected at COM2 of the computer"
PRINT "- Power supply is guaranteed over the duration of the experiment"
PRINT
PRINT "While running you can CANCEL the operation with the <x> key."
PRINT "The software stops after the time for one direction in period 1
or after 2s in period 2."
PRINT "PAUSE with the <p> key!"
PRINT
PRINT "Do not close the lid of the laptop, it may cause the program to go
to sleep!"
PRINT
PRINT
PRINT "OPTIONS:"
PRINT , "<x> to cancel or"
PRINT , "<any key> to proceed..."
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
SELECT CASE char$
CASE "x"
END
END SELECT
’************************ Initiation *************************
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OPEN "COM2:9600,n,8,1,CS,DS,RS" FOR RANDOM AS #1
’********************* write to IPC ************************
CLS
char$ = ""
GOSUB header
PRINT
PRINT
PRINT "Writing to IPC"
PRINT
’Initiate Pump
TIMER ON
Start = TIMER
PRINT "Time [h:m:s]", "Time [s]", "Q [%]", "Q [ml/min]", "IPC Comand"
PRINT #2, "Time [h:m:s]", "Time [s]", "Q [%]", "Q [ml/min]", "IPC Comand"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set Pump to 0 ***"
PRINT #1, "1S00000"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Set pump clockwise ***"
PRINT #1, "1J"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT TIME$, TIMER, "*** Start Pump ***"
PRINT #1, "1H"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
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PRINT "Beginning perfusion period 1."
FOR k = 1 TO c
PRINT "Cycle Number "; k; "of"; c
PRINT TIME$, TIMER, Q1proz, Q1, speed1$
PRINT #2, TIME$, TIMER, Q1proz, Q1, speed1$
PRINT #1, "1J"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
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LOOP UNTIL TIMER >= Start
PRINT #1, speed1$
PRINT TIME$, TIMER, "*** Wait "; tdir-0.5; "s ***"
FOR n = 1 TO 10
char$ = INKEY$
SELECT CASE char$
CASE "x"
GOTO 999
CASE "p"
GOSUB pause
END SELECT
Start = Start + ((tdir-0.5) / 10)
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
NEXT n
char$ = INKEY$
SELECT CASE char$
CASE "x"
GOTO 999
END SELECT
PRINT TIME$, TIMER, "-"; Q1proz, "-"; Q1, speed1$
PRINT #2, TIME$, TIMER, "-"; Q1proz, "-"; Q1, speed1$
PRINT #1, "1K"
PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
PRINT #1, speed1$
PRINT TIME$, TIMER, "*** Wait "; tdir-0.5; "s ***"
FOR n = 1 TO 10
char$ = INKEY$
SELECT CASE char$
CASE "x"
GOTO 999
CASE "p"
GOSUB pause
END SELECT
Start = Start + ((tdir-0.5) / 10)
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
NEXT n
NEXT k
PRINT "Beginning perfusion period 2."
PRINT TIME$, TIMER, "*** Set pump to clockwise ***"
PRINT TIME$, TIMER, Q2proz, Q2, speed2$
PRINT #2, TIME$, TIMER, Q2proz, Q2, speed2$
PRINT #1, "1J"
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PRINT TIME$, TIMER, "*** Wait .5s ***"
Start = Start + .5
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
FOR k = 1 TO dday
PRINT #1, speed2$
PRINT ".";
Start = Start + 2
IF Start >= 86399.99 THEN GOSUB tmchg
DO
LOOP UNTIL TIMER >= Start
char$ = INKEY$
SELECT CASE char$
CASE "x"
GOTO 999
CASE "p"
GOSUB pause
END SELECT
NEXT k
GOTO 888
999
PRINT TIME$, TIMER, "*** Stop Pump ***"
PRINT #2, TIME$, TIMER, "*** Stop Pump ***"
PRINT #1, "1I"
TIMER OFF
CLOSE #1
CLOSE #2
PRINT
PRINT
PRINT "Software stopped."
PRINT
PRINT "A log file <Cultlog.txt> has been created."
PRINT
PRINT
PRINT
PRINT "Press <any key> to end program"
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
END
’******************* SUBROUTINES ***********************
’*** Header Graphic ***
header:
PRINT "*************************************************"
PRINT "* Cell Culture *"
PRINT "* Pattern generator for ISMATEC IPC pump *"
PRINT "*************************************************"
RETURN
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’*********** day changes ********
tmchg:
Start = Start - 86399.99
DO
LOOP UNTIL TIMER <= 10
RETURN
’********** pause **************
pause:
PRINT #1, "1I" ’stop perfusion
PRINT
pt = Start - TIMER
PRINT "You are in pause mode!"
PRINT #2, TIME$, TIMER, "*** Perfusion paused ***"
PRINT
PRINT "Hit any key to proceed!"
DO
char$ = INKEY$
LOOP UNTIL char$ <> ""
Start = TIMER + pt
PRINT "Returned from Pause mode..."
PRINT #2, TIME$, TIMER, "*** Returned from pause ***"
PRINT #1, "1K" ’start perfusion again
RETURN
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Figure F.1: Main.vi program of the bone chamber system. Continued in Figure
F.2.
289
Figure F.2: Main.vi program of the bone chamber system. Continuation of Figure
F.1, continued in Figure F.3.
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Figure F.3: Main.vi program of the bone chamber system. Continuation of Figure
F.2, continued in Figure F.4.
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Figure F.4: Main.vi program of the bone chamber system. Continuation of Figure
F.3, continued in Figure F.5.
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Figure F.5: Main.vi program of the bone chamber system. Continuation of Figure
F.4, continued in Figure F.6.
293
Figure F.6: Main.vi program of the bone chamber system. Continuation of Figure
F.5, continued in Figure F.7.
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Figure F.7: Main.vi program of the bone chamber system. Continuation of Figure
F.6.
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Figure F.8: Subroutine driving the actuator two steps upwards (2stepsback).
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Figure F.9: Subroutine driving the actuator two steps downwards (2stepsdown).
297
Figure F.10: Subroutine generating a sinus value at a given timepoint for the dis-
placement (calcsinus).
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Figure F.11: GUI menu for choosing a protocol and input animal ID
(choose protocol).
299
Figure F.12: Subroutine testing if the voltage source of 10 VDC is working (con-
trol10V).
Figure F.13: Subroutine testing if the voltage source of 12 VDC is working (con-
trol12V).
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Figure F.14: Subroutine measuring the average time needed to set the digital output
twice and read the analogue input once (controltmin).
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Figure F.15: Subroutine converting the measured voltage to force, taking in ac-
count the offset and slope of the calibration (convert mV to N).
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Figure F.16: Subroutine converting a consecutive time array into differential
time.(generate dt).
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Figure F.17: Subroutine generating a time point for every displacement step for a
sinus wave (generatesinus).
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Figure F.18: Subroutine generating the overall waveform for all cycles (generateto-
talwave).
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Figure F.19: Subroutine generating a time point for every displacement step for a
triangle wave (generatetriangle).
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Figure F.20: Subroutine reading the analogue input voltage, converting it to force
(get analog).
Figure F.21: Subroutine measuring the average momentary force signal (getoffset).
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Figure F.22: Subroutine moving piston up, until the piston head hits the upper
limit or a certain number of steps have been exceeded (limitsensoric).
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Figure F.23: Subroutine moving the piston downwards for a certain number of
steps.(pistontosample).
309
Figure F.24: Subroutine driving the piston up to its start position (pistonup).
310 LabView Software for the Bone Chamber System
Figure F.25: Subroutine completing a 1D array of half-wave time points to a full-
wave time point array (timearray).
311
Figure F.26: Subroutine moving the piston downwards, until the sample is touched
or a certain number of steps have been exceeded (touchsensoric).
312 LabView Software for the Bone Chamber System
Figure F.27: GUI allowing the user to drive the piston up and down manually
(up down).
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Figure G.1: Flowchart of the compression device control software for the bone
chamber experiments (1 of 8).
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Figure G.2: Flowchart of the compression device control software for the bone
chamber experiments (2 of 8).
316 Bone Chamber Control Software Flowcharts
	

	 


	  






  
  
  
! 
"


 #" 

$	 	#"  ! 
%&
" 
   !!
  #
'
  	(
) 


	#
  *+
  *,
 
 #" 

$	 	#"  ! 
%&
" 
   !!
  #
'
  	
) 


	#
  **
  *
 
' &	

	

Figure G.3: Flowchart of the compression device control software for the bone
chamber experiments (3 of 8).
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Figure G.4: Flowchart of the compression device control software for the bone
chamber experiments (4 of 8).
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Figure G.5: Flowchart of the compression device control software for the bone
chamber experiments (5 of 8).
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Figure G.6: Flowchart of the compression device control software for the bone
chamber experiments (6 of 8).
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Figure G.7: Flowchart of the compression device control software for the bone
chamber experiments (7 of 8).
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Figure G.8: Flowchart of the compression device control software for the bone
chamber experiments (8 of 8).
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